



A systematic review of threshold values of pollen concentrations for symptoms of allergy

Nadine Steckling-Muschack · Hanna Mertes · Isabella Mittermeier ·
Paul Schutzmeier · Jana Becker · Karl-Christian Bergmann · Stephan Böse-O'Reilly ·
Jeroen Buters · Athanasios Damialis · Joachim Heinrich · Michael Kabesch ·
Dennis Nowak · Sandra Walser-Reichenbach · Alisa Weinberger ·
Mihai Zamfir · Caroline Herr · Susanne Kutzora · Stefanie Heinze

Received: 2 November 2020 / Accepted: 28 April 2021
© The Author(s), under exclusive licence to Springer Nature B.V. 2021

Abstract Pollen threshold values used in public warning systems are intended to inform people of the risk of developing allergy symptoms. However, there is no consensus about which pollen concentrations provoke allergy symptoms. The aim of this systematic review was the evaluation of studies investigating the relationship between pollen concentrations (alder, ash, birch, hazel, mugwort and ragweed) and the number of cases in which participants visited a doctor, drug consumption and allergy symptoms. This systematic

literature review is registered in PROSPERO (CRD42019112369). A PubMed search was applied and enriched by consultation with experts and a snowball strategy. The included studies were checked for risk of bias (RoB), and extensive data were extracted and compared. Of 511 studies, 22 were eligible according to the previously established inclusion criteria, and 17 from these showed a low RoB. The strongest evidence was reported for ash (*Fraxinus*) pollen, where an increase of number of doctor's visits at an interquartile range (IQR) of 18–28 grains/m³ was detected by three studies. Five studies about birch (*Betula*) pollen showed a threshold value of 45 grains/m³ for increased drug consumption. The evidence of a threshold value was limited for alder (*Alnus*), hazel (*Corylus*), mugwort (*Artemisia*) and ragweed (*Ambrosia*) pollen. The inconsistent results

Nadine Steckling-Muschack and Hanna Mertes should be considered as joint first author. Susanne Kutzora and Stefanie Heinze should be considered as joint senior author.

Supplementary Information The online version of this article (<https://doi.org/10.1007/s10453-021-09709-4>) contains supplementary material, which is available to authorized users.

N. Steckling-Muschack · H. Mertes ·
P. Schutzmeier · J. Becker · S. Böse-O'Reilly ·
J. Heinrich · D. Nowak · C. Herr · S. Heinze
Institute and Clinic for Occupational, Social and
Environmental Medicine, University Hospital, LMU
Munich, Ziemssenstr. 1, 80336 Munich, Germany

N. Steckling-Muschack · S. Böse-O'Reilly
Institute of Public Health, Medical Decision Making and
Health Technology Assessment, Department of Public
Health, Health Services Research and Health Technology
Assessment, UMIT-Private University for Health
Sciences, Medical Informatics and Technology, Eduard
Wallnoefer Center I, 6060 Hall in Tyrol, Austria

I. Mittermeier (✉) · S. Walser-Reichenbach ·
A. Weinberger · M. Zamfir · C. Herr ·
S. Kutzora · S. Heinze
Department for Occupational and Environmental
Medicine, Bavarian State Office for Health and Food
Safety, Pfarrstr. 3, 80538 Munich, Germany
e-mail: Isabella.Mittermeier@lgl.bayern.de

J. Becker
Institute of Health Economics and Health Care
Management, Helmholtz Zentrum München GmbH,
German Research Center for Environmental Health,
Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

concerning all types of pollen, except ash pollen, can be the result of multiple factors, e.g., age, gender, allergen content of pollen and individual sensitivity. These influencing factors should be investigated more closely in future research.

Keywords Aeroallergens · Conjunctivitis · Pollen · Rhinitis · Systematic review · Pollen thresholds

1 Introduction

Pollen is one of the most common aeroallergens causing allergic diseases (Navarro et al., 2009). Allergens from pollen induce the production of immunoglobulin E (IgE) antibodies, which circulate in blood but more importantly are then linked to the surface of mast cells. These mast cells reside in the mucosal membranes. Upon renewed exposure, the allergen is bound to the IgE from the mast cells and triggers the release of inflammatory mediators. Further information on the development of allergic reactions can be found in Janeway et al. (2001). This results in symptoms typical of an allergic reaction (Janeway et al., 2001). IgE antibodies in serum indicate allergic sensitization and are the minimal precondition for the

clinical manifestation of allergic diseases (Schoefer et al., 2008).

A genetic predisposition for the development of sensitization to allergens has been confirmed (Bousquet et al., 2001). However, in the last decades, a rising prevalence of allergic diseases that cannot be explained by changes in the genetics of the population was observed (Bergmann et al., 2016; Pawankar et al., 2020; Bousquet et al., 2001). Besides individual predispositions, studies have identified environmental factors promoting the development of allergic reactions, among which is climate change (Pawankar et al., 2020).

In addition, Buters et al. (2012, 2015), found that the sensitivity of population depends on the local flora (and pollen). They concluded if a plant species is widespread in a geographical area, the population can tolerate a higher concentration of this pollen before symptoms occur.

Allergic rhinitis (AR) is the most prevalent allergic disease (Pawankar et al., 2020). AR is an inflammation of the nasal mucosa and frequently associated with ocular symptoms, which is expressed in the term rhinoconjunctivitis (Pawankar et al., 2020). People suffering from AR have a lower quality of life in comparison with the general population (Navarro et al., 2009).

K.-C. Bergmann
Allergy-Center Charité, Charité – Universitätsmedizin
Berlin, Freie Universität Berlin, Humboldt-Universität zu
Berlin, Berlin Institute of Health, Luisenstr. 2,
10117 Berlin, Germany

K.-C. Bergmann
German Pollen Information Foundation, Robert-Koch-
Platz 7, 10115 Berlin, Germany

S. Böse-O'Reilly · M. Kabesch
University Children's Hospital Regensburg (KUNO-
Clinics), University of Regensburg, Clinic St. Hedwig,
Steinmetzstr. 1-3, 93049 Regensburg, Germany

J. Buters
ZAUM, Center of Allergy & Environment, German
Center for Lung Research (DZL), Helmholtz Center
Munich/Technische Universität München, Biedersteiner
Str. 29, 80802 Munich, Germany

A. Damialis
Chair and Institute of Environmental Medicine, UNIKA-
T, Technical University of Munich and Helmholtz
Zentrum München, Neusässer Str. 47, 86156 Augsburg,
Germany

J. Heinrich · D. Nowak
Comprehensive Pneumology Center (CPC) Munich,
Member DZL, German Center for Lung Research, Max-
Lebsche-Platz 31, 81377 Munich, Germany

J. Heinrich
Allergy and Lung Health Unit, Melbourne School of
Population and Global Health, The University of
Melbourne, 07 Bouverie Street, Carlton, Melbourne,
VIC 3053, Australia

M. Kabesch
Research and Development Campus Regensburg
(WECARE) at the Hospital St. Hedwig of the Order of St.
John, University of Regensburg, Prüfeningerstr. 21,
93049 Regensburg, Germany

The first attempts to establish threshold pollen concentrations values for informing the people of potential allergy symptoms date back to 1970s in Sweden. From clinical experience, Swedish physicians had defined the risk of pollen-induced symptoms to be low between 0 and 10 pollen grains/m³, middle—between 10 and 30, high—between 30 and 100 and very high—for more than 100 grains/m³. Later on, the neighboring country Denmark adopted the British threshold values, defining a low risk between 0 and 30, middle between 30 and 50, high between 50 and 150 and very high for more than 150 grains/m³ (summarized by Kiotseridis et al. (2013)). Meanwhile, the European Academy of Allergy and Clinical Immunology (EAACI) determined the so-called high pollen days and further characteristics defining pollen season for five different pollen types (Pfaar et al., 2017) based on a narrative review of threshold values for pollen-induced symptoms (De Weger et al., 2013). A high ragweed pollen day, for example, was defined with at least 50 pollen/m³, respectively, and a high birch pollen day with 100 pollen/m³. However, these values had been disputed, as more recent studies highlighted that threshold values may strongly depend on regional conditions such as vegetation and climate and on individual conditions (De Weger et al., 2013).

The aim of this study was to perform a systematic review of studies investigating the relationship between pollen concentrations (alder, ash, birch, hazel, mugwort, ragweed) and the number of doctor's visits, drug use and allergy symptoms.

2 Methods

This systematic literature review is registered in PROSPERO (registration number: CRD42019112369) since January 24, 2019. The Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) (Moher et al., 2009) were considered (Electronic Supplementary Material 1). The reviewer team included two researchers, one main and one second reviewer, and was supported by an expert team (co-authors), contributing as advisors.

2.1 Article sources

A complex search string including terms related to the categories: exposure, allergy symptoms and

association (Table 1), was used by the reviewer team in the database PubMed (Electronic Supplementary Material 2). The search was conducted on August 14, 2018. The date of publication was not restricted and included literature published in English and German. In addition, on May 28, 2020, the authors performed an update of the systematic literature search for the period 2018–2020. Additionally, the expert team was consulted to include further relevant literature.

The authors found many studies dealing with threshold values of grass pollen. Therefore, the results concerning grass pollen were excluded from this paper and will be presented in detail in a following paper (LUPO2).

2.2 Review process

Two reviewers independently performed the title, abstract and full-text screening. The main reviewer extracted the data of the included studies. Both reviewers were involved in the derivation and application of the rules for RoB assessments. Finally, a snowball strategy was applied meaning the reference lists of all identified literature were screened for further important references. EndNote X8 was used to process the literature references.

In addition to the PubMed search, sources for relevant studies were expert consultations, screenings of reference lists and the systematic screening of the book Allergenic Pollen (Sofiev and Bergmann, 2013). This book deals with the production, distribution in the atmosphere, release of allergens from pollen and health effects as well as monitoring and forecast of different pollen types. At the time, it was the only book that summarized studies examining pollen thresholds. These studies were not systematically researched.

2.3 Eligibility criteria for included studies

Eligibility of studies was assessed according to the inclusion and exclusion criteria listed in Table 2 by abstract and full-text screening. The search results were summarized according to the PRISMA flow diagram (Moher et al., 2009) (Fig. 1). Reasons for exclusion were listed with the name of the category of criteria for inclusion and exclusion (Table 2). If several analyses (e.g., additionally stratified by age) were presented, the non-stratified results were extracted and are included in the tables.

Table 1 Search term

	Search term	August 14, 2018	May 28, 2020
Original search term	Pollen [tiab] AND ragweed OR Ambrosia OR “Ambrosia artemisiifolia” OR mugwort OR Artemisia OR “Artemisia vulgaris” OR birch OR Betula OR alder OR Alnus OR ash OR Fraxinus OR grass OR Poaceae OR hazel OR Corylus OR rye OR Secale AND “pollen threshold” OR “pollen thresholds” OR “pollen level” OR “pollen levels” OR “pollen load” OR “pollen count” OR “pollen counts” OR “pollen quantification” OR “pollen quantifications” OR “pollen concentration” OR “pollen concentrations” OR “aeroallergen concentration” OR “aeroallergen concentrations” OR “aeroallergen level” OR “aeroallergen levels” OR “atmospheric pollen counts” OR “symptom load index” OR “pollen symptom score” OR “pollen symptoms score” AND (“pollen induced allergy” OR “pollen-associated allergic risk” OR allergy OR allergies OR “pollen allergy” OR “pollen allergies” OR “seasonal allergy” OR asthma OR “allergic asthma” OR “asthma exacerbation” OR “asthma exacerbations” OR rhinitis OR “allergic rhinitis” OR rhinoconjunctivitis OR “allergic rhinoconjunctivitis” OR conjunctivitis OR “allergic conjunctivitis” OR “conjunctival symptoms” OR “seasonal conjunctivitis” OR hayfever OR “hay fever” OR pollinosis OR rhinitis OR “seasonal rhinitis” OR “pollen-induced rhinitis” OR “allergic rhinitis” OR “seasonal allergic rhinitis” OR “allergic reaction” OR “allergic reactions” OR “allergic symptoms” OR “allergic symptoms” OR “allergic response” OR “allergic responses” OR “clinical response” OR “clinical symptoms” OR “clinical symptom” OR wheeze OR “hospital admission” OR “hospital admissions” OR “emergency department” OR “learning ability” OR “working ability” OR “working capacity” OR “allergy symptoms” OR “initiation of symptoms” OR “conjunctival symptoms” OR “nasal symptoms” OR “bronchial symptoms” OR “ocular symptoms” OR “respiratory symptoms” OR “itchy eyes” OR “itchy-watery eyes” OR “blocked nose” OR “runny blocked nose” OR “itchy nose” OR sneezing OR “itchy skin” OR wheeze OR wheezing OR “whistling in the chest” OR “shortness of breath” OR “chest tightness” OR “persistent cough” OR cough OR asthma OR “allergic symptoms” OR “atopic eczema” OR “asthma medication” OR “allergy medicines” OR “rescue medication” OR antihistamine) AND association OR associated OR relationship OR related OR relation OR significant OR significance OR correlation OR correlated NOT Animals NOT Placebo Filters: english[la] OR german [la] OR french[la] OR spanish[la]	511 hits	68 hits

Table 1 continued

	Search term	August 14, 2018	May 28, 2020
Later addition to the search term	Pollen [tiab] AND ragweed OR Ambrosia OR “Ambrosia artemisiifolia” OR mugwort OR Artemisia OR “Artemisia vulgaris” OR birch OR Betula OR alder OR Alnus OR ash OR Fraxinus OR grass OR Poaceae OR hazel OR Corylus OR rye OR Secale AND “pollen threshold” OR “pollen thresholds” OR “pollen level” OR “pollen levels” OR “pollen load” OR “pollen count” OR “pollen counts” OR “pollen quantification” OR “pollen quantifications” OR “pollen concentration” OR “pollen concentrations” OR “aeroallergen concentration” OR “aeroallergen concentrations” OR “aeroallergen level” OR “aeroallergen levels” OR “atmospheric pollen counts” OR “symptom load index” OR “pollen symptom score” OR “pollen symptoms score” AND (“drug consumption”) AND association OR associated OR relationship OR related OR relation OR significant OR significance OR correlation OR correlated NOT Animals NOT Placebo Filters: english[la] OR german [la] OR french[la] OR spanish[la]		

2.4 Assessment of the risk of bias

The risk of bias (RoB) of each included study was assessed to evaluate their internal validity. The assessment was done on the study level and—if more than one outcome was investigated—on the outcome level (Moher et al., 2009). The RoB tool of the Office of Health Assessment and Translation (OHAT), National Toxicology Program of the US Department of Health and Human Services designed for cohort, case–control and cross-sectional studies was selected as the starting point, supplemented and adapted to the needs of the review. As done previously (Zhao et al., 2018), the tool was also used for time-series and case-crossover studies.

The available instructions for the ratings of the OHAT criteria were considered (OHAT, 2015a; b), but adapted to the topic in agreement with the expert

team to formulate precise rules for the RoB assessment. An extensive catalogue of rules for the RoB assessment was developed (Table 3) and used for an objective and replicable study assessment (Table 4, Electronic Supplementary Material 3). The same answer possibilities as applied by OHAT were used, and these are “definitely low RoB (+ +),” “probably low RoB (+),” “probably high RoB (-),” “definitely high RoB (- -)” and “not applicable (NA).”

Studies with a high or probably high RoB in any category except one (category: conflict of interest, CoI) were omitted from results synthesis and consequently not described in “Result” section. Studies with no information about CoI were included, but the corresponding probably high RoB due to CoI was mentioned explicitly in “Results” section.

Table 2 Criteria for inclusion and exclusion

Criteria		Inclusion	Exclusion
PECO/ PICOS <i>Exposure</i>	Population	General human population showing pollen-related allergy symptoms, any gender, age, nationality	Population never showing pollen-related allergy symptoms
	Pollen type	Alder, ash, birch, hazel, mugwort, ragweed or rye	Other pollen than the included, e.g., grass (Cyperaceae and Poaceae); a mixture of the included pollen grass (Cyperaceae and Poaceae) was initially included and was part of the search term, and however, finally it was excluded and moved to a separate paper)
	Pathway	Airborne	Any other than airborne
	Origin	Natural exposure	Allergen challenge, pollen chamber
	Unit	Pollen concentrations (grains/m ³)	Exposure estimated without pollen concentration measurement; pollen concentrations are not reported
	Time reference	Data of Exposure was assessed with periodicity, which not exceeded 1 week	Exposure data from more than one week was summarized (e.g., monthly or yearly)
	Interventions	No interventions	Any interventions
	Comparison	Different humans exposed to different concentrations of pollen or equal humans exposed to different concentrations of pollen at various points in time	Other comparisons than the included
	Main outcomes	Pollen-related acute allergy symptoms, bronchial (e.g., allergic asthma), nasal (e.g., seasonal allergic rhinitis, SAR) and ocular (e.g., rhinoconjunctivitis)	Not pollen-related allergy symptoms, e.g., perennial allergic rhinitis (PAR), other related health outcomes like eosinophilic esophagitis (EOE), mortality, health indicators like quality of life scores, lung/pulmonary function, medical interventions, tests of sensitization (e.g., IgE value or skin prick test);
	Additional outcome	Pollen-related hospital admissions, emergency department visits, visits to physician, drug consumption, reimbursement of anti-allergenic drugs	
Outcome	Measurement	Diagnosed, self-reported, reported by someone else (e.g., mother), measured by symptoms scores indicating the start of symptoms or indicating in which range of pollen counts symptoms occur	Health outcomes not measured, measured by symptoms scores indicating a change of the score but not a range of pollen counts with symptoms occurring
	Time reference	Daily or weekly (including averaged values and lag days)	Values summarized per month, year, etc.
	Design	Epidemiological observational studies, control groups of intervention studies	Epidemiological experimental studies, basic research studies regarding new technologies or applications, clinical research studies, study protocols, case studies, case series, reviews, meta-analysis, intervention groups of intervention studies
	Association	Association between pollen concentration and occurrence of the health outcomes	Pollen concentration and frequency of the health outcomes were described separately; the association was not analyzed. Pollen concentration in relation to health symptoms was not quantified
Study design*	Effect measures	Relative risk, odds ratio, threshold values, percent change, results are presented numerically and not only graphically	Correlation coefficient, results are presented graphically and not numerically
Others			
	Language	English, German	All other languages
	Publication year	All publication years	No exclusion

Table 2 continued

Criteria	Reference place	Inclusion All places/countries	Exclusion No exclusion
----------	-----------------	-----------------------------------	---------------------------

*See Röhrig et al., (2009) for the applied categorization of study designs

EOE Eosinophilic esophagitis, *IgE* immunoglobulin E, *SAR* Seasonal allergic rhinitis, *PAR* Perennial allergic rhinitis, *PECO/PICO* Population, Exposure/Intervention, Comparison, Outcome

2.5 Data synthesis

Data synthesis was done in a qualitative way, arranged according to pollen type and health outcome. The reported increases of pollen concentrations always assumed a baseline of 0 grains/m³. All following pollen threshold values are based on daily averages.

3 Results

The literature search in PubMed yielded 454 hits. Additionally, 57 studies were identified by the expert team or the snowball strategy, resulting in 511 indicated studies. From these, 22 studies met the inclusion criteria (Table 2 and Fig. 1). Five of them had to be excluded due to high or probably high RoB (Table 4, Electronic Supplementary Material 3). Thus, the data of final 17 studies were synthesized.

The update of the literature search retrieved 68 hits. The vast majority of them (66 references) were excluded in title and abstract screening due to exclusion criteria. After full-text screening of the two remaining references, both were excluded due to the exclusion criteria (Table 2 and Fig. 1).

Table 5 summarizes key aspects of the final 17 studies (pollen type, country and health outcome), and Table 6 gives more detailed characteristics. Ash ($n = 9$) and ragweed ($n = 8$) were the mainly examined pollen types. Ten studies focused on the number of doctor's visits (either on hospital admissions or emergency department or visits to physician) in association with pollen concentrations. Six studies analyzed drug consumption (for details see in Electronic Supplementary Material 4) and two the occurrence of symptoms in connection with pollen concentrations. The time period for data collection started in 1993 in the oldest case and ended in 2014 in the most recent study. The following subgroups were

analyzed: only children ($n = 4$ studies), only adults ($n = 3$), only individuals being 65 years or older ($n = 1$), all individuals except infants ($n = 4$) and all individuals without restrictions regarding age ($n = 5$) (for details see Tables 6 and 7). All studies included male and female subjects. The sample size was a lot larger in the studies focusing on the number of doctor's visits ($n = 502$ up to $n = 60,066$) or drug sale data ($n = 6,780$ up to $n = 118,723$) and rather small in studies focusing on symptoms ($n = 30$ and 61) (Table 6 and Table 7). From all the 17 pollen outcome analyses included in this review, eight were published with a CoI statement and nine without (Table 6).

Table 7 shows the study results and corresponding necessary information. The results were subsequently described per pollen type. An overview of pollen types, kind of health outcome, studies and significance is provided in Fig. 2.

3.1 Studies on alder pollen

Four studies analyzed the association between *alder* and the occurrence of health outcomes (Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Guilbert et al., 2018; Guilbert et al., 2016). Guilbert et al. (2018) observed the number of doctor's visits due to asthma and three other studies reported drug consumption for allergic rhinoconjunctivitis (D. M. Caillaud et al., 2015; Zeghnoun et al., 2005; Guilbert et al., 2016). Only Zeghnoun et al. (2005) found statistically significant results for a population aged 65 years and older, for which an interquartile range (IQR) increase of 19 grains/m³ resulted in an increase of prescriptions for an oral antihistamine on the same day ($RR = 1.14$) (Zeghnoun et al., 2005). For all other age groups (Zeghnoun et al., 2005) and for the other three studies such as Caillaud et al. (2015) (IQR = 35.5 grains/m³), Guilbert et al., (2018) (IQR = 9 grains/m³) and




Fig. 1 PRISMA flowchart (adapted from (Moher et al., 2009)).

*The first obvious reason for exclusion was listed, while multiple reasons are possible. The reasons listed correspond to the criteria for inclusion (Table 1). For example, the reason

“association/effect measure” means that the study does not match with one or more of the criteria for inclusion in these categories (e.g., no reporting of odds ratios but reporting of correlation coefficients)

Guilbert et al. (2016) (IQR = 18.25 grains/m³), no statistically significant results were shown.

3.2 Studies on ash pollen

Nine studies analyzed *ash* pollen (Ito et al., 2015; Motreff et al., 2014; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Fuhrman et al., 2007; Guilbert et al., 2018; Osborne et al., 2017; Dales et al., 2008; Guilbert et al., 2016). Four studies analyzed the number of doctor’s visits due to asthma (Guilbert et al., 2018; Osborne et al., 2017; Dales et al., 2008; Ito et al., 2015). Guilbert et al., (2018) observed a 4 grains/m³ increase of ash pollen with no statistically significant effects. Osborne et al. (2017) and Dales et al. (2008) reported threshold values between 18 and 20 grains/m³ with low statistically significant percentage increases. Ito et al. (2015) mentioned a statistically significant cumulative rate ratio of 1.7 (95% CI 1.5–1.9) for an increase of 223 grains/m³. Six studies observed drug consumption due to increasing

pollen concentrations (Ito et al., 2015; Motreff et al., 2014; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Fuhrman et al., 2007; Guilbert et al., 2016). Guilbert et al. (2016) showed that an IQR of 24.5 grains/m³ yielded statistically significantly increased medication sales in the 19–39 and 40–64 age groups. An increase of 28 to 223 grains/m³ showed significant results in non-age restricted populations (D. M. Caillaud et al., 2015; Fuhrman et al., 2007; Ito et al., 2015; Motreff et al., 2014; Zeghnoun et al., 2005). Zeghnoun et al., (2005) reported a statistically significant cumulative relative risk of 1.22 (95% CI 1.13–1.31) for a change in pollen concentration of 28 grains/m³. Fuhrman et al., (2007) observed a statistically significant increase of 7.3% for drug consumption for an increasing IQR of 33 grains/m³ (95% CI 4.6–10.1). Caillaud et al., (2015) found a statistically significant increased risk of drug consumption associated with an IQR of 41 grains/m³ (RR = 1.019, 95% CI 1.004–1.033). Motreff et al., (2014) observed a statistically significant RR in one of two project areas

Table 3 Rules for the risk-of-bias (RoB) assessment

Criteria	Question	Assessment possibilities*	Rules for the assessment (topic-related rules were established by the authors based on the general rules defined by OHAT (2015b, a) and Lam et al., (2016)
Confounding bias	Did the study design or analysis account for important confounding and modifying variables?	+ +	If the following five confounders, defined as most important by the authors of the systematic review “LUPO,” were at least considered: nitrogen dioxide (NO ₂), ozone (O ₃), particulate matter (PM), relative humidity/precipitation, wind speed
		+	If three or four of the most important confounders were considered
			If three or four confounders were considered but not all included in the final model
		–	Information should be available but is missing
			If one or two of the most important confounders were considered
			If none of the most important confounders but other relevant confounders were considered
Detection bias: exposure characterization	Can we be confident in the exposure characterization?	– –	No consideration of confounder
			The authors assume or even declare the bias
		+ +	Daily exposure characterization AND There is direct evidence that exposure characterization is adequate for the study population (e.g., residence and pollen trap in same city)
		+	More than weekly but not daily exposure characterization AND/OR There is no direct evidence that exposure characterization is adequate for the study population
		–	Weekly or less frequent exposure characterization AND/OR Information should be available but is missing
		– –	Exposure was inappropriately assessed (e.g., unserious source of exposure assessment) AND/OR The authors assume or even declare the bias
Detection bias: outcome assessment	Can we be confident in the outcome assessment?	+ +	Self-reported symptom(s)/symptom diary, diagnosed by a doctor, emergency visits, hospitalizations, intake or prescriptions or sales of medication, AND Daily assessment of the outcome AND ICD code of outcome was reported and used
		+	Outcome was not self-reported or reported by a doctor but by a third person (e.g., mother) AND/OR Outcome was assessed not daily but several times a week AND/OR ICD code of outcome was not used/reported
		–	Information should be available but is missing AND/OR Outcome was assessed once a week or less often AND/OR Outcome definition was inappropriate (e.g., a mixture of several outcomes), but outcome was appropriately measured AND/OR
			Content of symptom scores was not described
		– –	Outcome (appropriate or inappropriate definition) was inappropriately measured (e.g., inconsistent definition or data collection) AND/OR The authors assume or even declare the bias

Table 3 continued

Criteria	Question	Assessment possibilities*	Rules for the assessment (topic-related rules were established by the authors based on the general rules defined by OHAT (2015b, a) and Lam et al., (2016)
Attrition bias	Were outcome data complete without attrition or exclusion from analysis?	+ +	There was no or a low attrition or exclusion (<10%) (Genaidy et al., 2007; OHAT 2015b) AND Reasons were documented, when subjects were removed from the study or excluded from analysis
		+	There was no or a low attrition or exclusion (<10%) (Genaidy et al., 2007; OHAT 2015b) AND Reasons were not documented, when subjects were removed from the study or excluded from analysis AND/OR There was an acceptable attrition or exclusion (between 10 and 20% (Genaidy et al., 2007; OHAT 2015b)) AND Reasons were documented, when subjects were removed from the study or excluded from analysis
		–	Information should be available but is missing (to be distinguished from NA) AND/OR There was an acceptable attrition or exclusion (between 10 and 20% (Genaidy et al., 2007; OHAT 2015b)) AND Reasons were not documented, when subjects were removed from the study or excluded from analysis AND/OR There was an unacceptable large attrition or exclusion (>20% (Genaidy et al., 2007; OHAT 2015b)) AND Reasons were documented, when subjects were removed from the study or excluded from analysis
		– –	There was unacceptable large attrition or exclusion (>20%) AND Reasons were not documented, when subjects were removed from the study or excluded from analysis The attrition/exclusion rate is unknown The authors assume or even declare the bias
		NA	Not applicable: If secondary data (e.g., insurance or hospital data) are analyzed, every case is considered separately what prevents information about attrition. If specific cases of secondary data were excluded by the authors (e.g., specific age groups), then the attrition bias should be assessed.
Selective reporting bias	Were all measured outcomes reported?	+ +	All measured outcomes (summarized scores as well as all components, as described in “Method” section) are reported (in “Results” section)
		+	It seems that all measured outcomes (summarized scores as well as all components, as described in “Method” section) are reported (in “Results” section) OR A summarized outcome (e.g., a score) is reported and all previously described components were included but were not presented separately
		–	Information should be available but is missing OR It is not understandable, if all measured outcomes were presented OR It is not understandable, how the results were derived.
		– –	Results of important measured outcomes were not reported AND/OR Some of the outcomes were summarized in a score, while others were excluded from the score without reasonable explanation. AND/OR Only significant or a selection of the best findings was reported

Table 3 continued

Criteria	Question	Assessment possibilities*	Rules for the assessment (topic-related rules were established by the authors based on the general rules defined by OHAT (2015b, a) and Lam et al., (2016)
Conflict of interest	Do the authors declare no conflict of interest?	+ +	“Study authors make a claim denying conflicts of interest.” “The study did not receive support from a company, study author, or other entity having a financial interest in the outcome of the study” (Lam et al., 2016)
		+	“There is insufficient information to permit a judgment of low risk of bias, but there is indirect evidence that suggests” no conflict of interest (Lam et al., 2016)
		–	Information should be available but is missing AND/OR “There is insufficient information to permit a judgment of high risk of bias, but there is indirect evidence that suggests” a conflict of interest. (Lam et al., 2016)
		– –	“The study received support from a company, study author or other entity having a financial interest in the outcome of the study” (Lam et al., 2016)

*Assessment possibilities: + + definitely low RoB, + probably low RoB, – probably high RoB, – – definitely high RoB, NA not applicable

ICD International Statistical Classification of Diseases and Related Health Problems NA not applicable, NO₂ nitrogen dioxide; O₃ ozone; OHAT Oral Health Assessment Tool, PM particulate matter

when a 60 grains/m³ pollen increase was detected (RR = 1.02, 95% CI 1.01–1.03). Ito et al., (2015) reported a statistically significant cumulative rate ratio of 1.9 (95% CI 1.7–2.1) for a change of 223 grains/m³.

3.3 Studies on birch pollen

Eight studies (Ito et al., 2015; Fuhrman et al., 2007; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; D. Caillaud et al., 2014a; Osborne et al., 2017; Guilbert et al., 2016; Guilbert et al., 2018) analyzed *birch* pollen in association with different health outcomes. Three studies investigated the number of doctor’s visits following asthma (Ito et al., 2015; Osborne et al., 2017; Guilbert et al., 2018) symptoms. No statistically significant results were reported by Osborne et al. (2017) for a percentile increase of 195 grains/m³. Guilbert et al. (2018) found a statistically significant increase in the number of doctor’s visits for a change of 3.2% (95% CI 1.1, 5.3) with an interquartile range increase of 40 grains/m³. Ito et al. (2015) showed a cumulative rate ratio of 1.3 (95% CI 1.19–1.48) for 98th percentile increase of 1680.3 grains/m³. Regarding drug consumption, five studies (Ito et al., 2015; Fuhrman et al., 2007; Zeghnoun et al., 2005; Caillaud et al., 2015; Guilbert et al., 2016) were included, while all show positive statistically significant results at least

in some subgroups. Zeghnoun et al., (2005) observed that an IQR increase of 45 grains/m³ resulted in an increase of drug consumption (RR = 1.22, 95% CI 1.11–1.35). Caillaud et al. (2015) showed an increasing risk of drug consumption (RR=1.030, 95% CI 1.005–1.055) with an IQR of 58 grains/m³. Ito et al., (2015) reported a cumulative rate ratio of 2.0 (95% CI 1.8–2.2) per 0–98th percentile increase of 1680.3 grains/m³. Fuhrman et al. (2007) found a statistically significant increase of 7% (95% CI 3.8–10.4) with an IQR increase of 45 grains/m³. Guilbert et al. (2016) showed statistically significant results in age subgroups for a threshold value of 85 grains/m³. They observed the highest increase in risk of drug consumption (RR = 1.05, 95% CI 1.04–1.06) for birch pollen among the 19–39-year-old men. The smallest increase of risk (RR = 1.02, 95% CI 1.01–1.04) was found among the 13–18-year-old girls and the 6–12-year-old boys. Nasal, ocular and bronchial symptoms were analyzed in one study (D. Caillaud et al., 2014a) in association with an increase in pollen concentration of 10 grains/m³. Odds ratios were statistically significant, when the increase was below but not above a certain concentration (110 grains/m³ for nasal symptoms, 70 grains/m³ for ocular and bronchial each).

3.4 Studies on hazel pollen

Exposure to *hazel* pollen was investigated in five studies (Fuhrman et al., 2007; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Guilbert et al., 2018; Guilbert et al., 2016). The study of Guilbert et al. (2018) on the number of doctor's visits due to hazel pollen exposure yielded no statistically significant results (IQR=4 grains/m³). Drug consumption in association with hazel pollen exposure was analyzed in four studies (Fuhrman et al., 2007; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Guilbert et al., 2016). Fuhrman et al. (2007) reported a statistically significant increase of 2.3% (95% CI 0.4–4.3) with an IQR increase of 23 grains/m³. Zeghnoun et al. (2005) showed statistically significant risk (RR = 1.08, 95% CI 1.00–1.15) with an IQR of 15 grains/m³ among the over 65 years old. Caillaud et al. (2015) (IQR = 31 grains/m³) and Guilbert et al. (2016) (IQR = 9 grains/m³) found no statistically significant effects.

3.5 Studies on mugwort pollen

Five studies analyzed *mugwort* pollen (Motreff et al., 2014; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Guilbert et al., 2018; Tobias et al., 2003). Guilbert et al. (2018) (IQR = 1 grain/m³) and Tobias et al. (2003) (IQR = 2.1 grains/m³) focused on the number of doctor's visits (Guilbert et al., 2018; Tobias et al., 2003) and yielded no statistically significant results. Drug consumption was surveyed in three studies (Motreff et al., 2014; Zeghnoun et al., 2005; D. M. Caillaud et al., 2015). Motreff et al. (2014) observed a statistically significant RR in one of two project areas when a pollen increase of 3 grains/m³ was analyzed (RR = 1.09, CI 1.05–1.13). Zeghnoun et al. (2005) (IQR = 7 grains/m³) and Caillaud et al. (2015) (IQR = 6.5 grains/m³) reported no statistically significant results.

3.6 Studies on ragweed pollen

Ragweed pollen were investigated in eight studies (Gleason et al., 2014; Heguy et al., 2008; Villeneuve et al., 2006; Zhong et al., 2006; Cakmak et al., 2002; D. Caillaud et al., 2014b; Motreff et al., 2014; D. M. Caillaud et al., 2015). The increased number of doctor's visits are the outcome in five ragweed studies focusing on asthma (Gleason et al., 2014; Heguy et al.,

2008; Zhong et al., 2006) or allergic rhinitis (Villeneuve et al., 2006), rhinitis or sinusitis (Cakmak et al., 2002) and conjunctivitis (Cakmak et al., 2002). Cakmak et al., (2002) found a statistically significant positive association between an increase of 72 grains/m³ and an increase of 11.4% (95% CI 3.36–19.43) for frequency of doctor's visits due to sinusitis and conjunctivitis. Villeneuve et al., (2006) investigated an interquartile increase of 22.6 grains/m³ and ten days average of the number of doctor's visits for allergic rhinitis and found a statistically significant increase of 6.4%. Regarding asthma, the results are very diverse: Zhong et al., (2006) observed a statistically significant risk of an increase in the frequency of doctor's visits at pollen concentrations above 100 grains/m³ (RR = 1.54, 95% CI 1.02–2.33). In contrast, Gleason et al. (2014), who investigated children, reported a protective effect, where asthma-related emergency department visits were observed in combination with a tenfold pollen increase the same day (Gleason et al., 2014). Heguy et al., (2008) found no statistically significant effect for visits to physician due to higher ragweed pollen concentrations (Heguy et al., 2008). Regarding drug consumption, the studies of Caillaud et al., (2015) (IQR=5 grains/m³) and Motreff et al., (2014) (IQR = 5 grains/m³) were included, but both studies did not find significant results. Caillaud et al., (2014b) investigated the relation of nasal, ocular and respiratory symptoms with pollen season and found mostly positive associations (up to RR = 1.33) if an increase of 10 pollen grains/m³ was observed.

3.7 Sub-analyses by age

For alder, the only statistically significant result regarding drug consumption was found for people aged 65 years and older (Zeghnoun et al., 2005). In contrast, Guilbert et al. (2018) observed lower hospitalization effects in the oldest age groups in comparison with young people for mugwort and in a lower degree for birch. Guilbert et al. (2016) (alder, ash, birch, hazel), Fuhrman et al. (2007) (ash, birch, hazel) and Zeghnoun et al. (2005) (ash, birch) identified adults as most affected. Zeghnoun et al. (2005) found other age patterns for other pollen types (not investigated here). Ito et al. (2015) found highest associations between medication sales and tree pollen concentration for children (5–17 years) and weak

Table 4 Heat map of the risk-of-bias (RoB) assessment

Nb.	Authors (year)		key criteria			other criteria			
			Confounding bias	Detection bias: exposure char-acterization	Detection bias: Outcome assessment	Attrition bias	Selective reporting bias	Conflict of interest	In- or exclusion from data syn-thesis
1	Caillaud et al. (2014a)		+	++	+	+	++	—	inclusion
2	Caillaud et al. (2014b)		+	++	+	++	+	++	inclusion
3	Caillaud et al. (2015)		+	++	+	NA	++	++	inclusion
4	Cakmak et al. (2002)		+	++	+	++	++	++	inclusion
5	Dales et al. (2008)		+	++	++	NA	++	—	inclusion
6	Darrow et al. (2012)		—	+	++	NA	++	—	exclusion
7	Fuhrman et al. (2007)		+	++	+	++	++	++	inclusion
8	Gleason et al. (2014)		+	+	++	NA	++	++	inclusion
9	Guilbert et al. (2018)		+	++	++	NA	++	++	inclusion
10	Guilbert et al. (2016)		++	++	+	NA	++	++	inclusion
11	Héguy et al. (2008)		+	++	++	NA	++	—	inclusion
12	Hofman et al. (1996)		—	+	—	NA	—	—	exclusion
13	Huynh et al. (2010)		+	—	—	—	++	++	exclusion
14	Ito et al. (2015)	medication sale	+	+	++	NA	++	++	inclusion
		ED visits	+	+	++	NA	++	++	inclusion
15	Lewis et al. (2000)		—	++	++	NA	—	—	exclusion
16	Motreff et al. (2014)		+	++	+	NA	++	—	inclusion
17	Osborne et al. (2017)		+	++	++	NA	++	—	inclusion
18	Ross et al. (2002)	asthma medication use	—	++	+	—	—	—	exclusion
		symptom score	—	++	—	—	—	—	
19	Tobías et al. (2003)		+	++	++	NA	++	++	inclusion
20	Villeneuve et al. (2006)		+	++	++	NA	++	—	inclusion
21	Zeghnoun et al. (2005)		+	++	+	NA	++	—	inclusion
22	Zhong et al. (2006)		+	++	++	NA	++	—	Inclusion
Legend:									
Nb. = number; ED = emergency department									
Abbreviations: (+ +, <i>dark green</i>) Definitely low RoB, (+, <i>light green</i>) Probably low RoB, (–, <i>orange</i>) Probably high RoB, (—, <i>red</i>) Definitely high RoB, (NA, <i>white</i>) not applicable									

associations for 0–4 years and 65 years and older. Motreff et al. (2014) investigated several pollen types (not all included here) and found in general decreasing allergic rhinitis cases by age. They speculate, if comorbidities of the elderly might hamper the diagnosis and treatment (due to drug interactions (Busse and Kilaru 2009)) of allergic rhinitis. Caillaud et al. (2015) investigated drug consumptions and made sub-analyses by age for ash and found statistically significant results in all but the youngest age group (5–14 years) for pollen threshold value of 41 grains/m³

and for birch with statistically significant results in all but the 15 to 44 years old for pollen threshold value of 58 grains/m³. Villeneuve et al. (2006) focused their complete study on the age group 65 years and older; however, this decision was not justified on pollen-related susceptibility but based on a higher susceptibility of the elderly regarding particulate matter (Thurston 1996), which was the main focus of their study (Villeneuve et al., 2006)

Table 5 Summary of the included studies according to kind of pollen, country and health outcome

Characteristics		Total	Number by kind of pollen [†]					
			Alder	Ash	Birch	Hazel	Mugwort	Ragweed
Total		22	5	10	11	6	6	9
Total used for result synthesis		17	4	9	8	5	5	8
Country	Belgium	1	2	2	2	2	1	0
	Canada	4	0	1	0	0	0	3
	England	1	0	1	1	0	0	0
	France	6	2	4	4	3	3	3
	Spain	1	0	0	0	0	1	0
	USA	3	0	1	1	0	0	2
Health outcome (number of studies with statistically significant results in brackets)	Drug consumption	6	3 (1)	6 (5)	5 (5)	4 (2)	3 (1)	2 (0)
	HA	10	1 (0)	4 (2)	3 (2)	1 (0)	2 (0)	6 (3 [‡])
	Symptoms	2	0 (0)	0 (0)	1 (1)	0 (0)	0	1 (1)
No conflict of interest declaration		8	1	4	3	1	2	4

HA Hospital admission;

[†]The sum of the number by kind of pollen is higher than total, because several studies investigate more than one kind of pollen.

[‡]One of these three significant studies showed protective effects (Gleason, Bielory et al., 2014)

4 Discussion

4.1 Key findings

Threshold values were found for ash, birch and ragweed. A threshold value of 18–28 grains/m³ could be extracted from four studies examining ash pollen and the number of doctor's visits (Osborne et al., 2017; Dales et al., 2008; Guilbert et al., 2018; Ito et al., 2015). Five studies showed a statistically significant increase in the health outcome of drug consumption beginning at a threshold value of 28 ash grains/m³ for the whole population (Motreff et al., 2014; Ito et al., 2015; Zeghnoun et al., 2005; Fuhrman et al., 2007; D. M. Caillaud et al., 2015) and 24 grains/m³ for the 19–64 age group (Guilbert et al., 2016). For birch pollen and drug consumption, a threshold value of 45 grains/m³ could be extracted from five studies (Guilbert et al., 2016; Ito et al., 2015; Zeghnoun et al., 2005; Fuhrman et al., 2007; D. M. Caillaud et al., 2015). A threshold value of 22.6 grains/m³ could be worked out from four studies examining ragweed pollen and the number of doctor's visits (Villeneuve et al., 2006; Gleason et al., 2014; Zhong et al., 2006; Cakmak et al., 2002).

4.2 Pollen-specific data

Of four studies on alder pollen (Guilbert et al., 2018; Guilbert et al., 2016; D. M. Caillaud et al., 2015; Zeghnoun et al., 2005), only one study found a statistically significant result. An increased risk of oral antihistamine prescription in combination with an increase in alder pollen concentration of 19 grains/m³ was found for the age group over 65 years (Zeghnoun et al., 2005). A possible shift in the daily pollen concentration and the time of purchase of oral antihistamine was not considered in the analysis (Zeghnoun et al., 2005). The authors conclude from this that the results of the study are not reliable. The statistically significant result should be viewed critically, because the result could be confounded by the possible shift in pollen concentration and purchase of pharmaceutical. Additionally, other studies could not find statistically significant results for the age group over 60 years (Guilbert et al., 2018; Guilbert et al., 2016).

Thus, based on drug consumption (D. M. Caillaud et al., 2015; Guilbert et al., 2016; Ito et al., 2015; Fuhrman et al., 2007; Motreff et al., 2014; Zeghnoun et al., 2005) and hospitalization studies (Osborne et al., 2017; Dales et al., 2008; Guilbert et al., 2018; Ito et al.,

Table 6 Characteristics of the included studies

Authors (date)	Kinds of pollen	Health outcomes	Region	Time period	Age in years	Analyzed sample size
Caillaud et al. (2014a)	Birch	Bronchial, nasal, ocular, symptoms	France (Nantes, Angers, Tours, Rouen, Chambéry, Roussillon, Dijon, Paris, Amiens, Chalon-sur-Saône, Clermont-Ferrand)	2010 (March 22–May 16)	≥ 18	61 individuals
Caillaud et al. (2014b)	Ragweed	Nasal, ocular, respiratory symptoms	France (Grenoble, Lyon, Avignon, Saint-Étienne, Nevers) Switzerland (Geneva)	2009 (July 13–October 4), 2010 (August 2–October 10)	≥ 18	30 individuals
Caillaud et al., (2015)	Alder, ash, birch, hazel, mugwort, ragweed	Drug consumption for SAR. A SAR case: the association between an oral antihistamine and a local (nasal or ocular) antiallergic drug on the same prescription	France (Clermont-Ferrand area)	2003–2012	≥ 5	97,611 cases in total (between 7265 and 11,315 per year)
Cakmak et al., (2002)	Ragweed	Rhinitis or sinusitis-related emergency visits	Canada (eastern Ontario)	1993–1997 (May–September)	Children (mean age: 7.7 (SD: 4.8))	502 patients
		Conjunctivitis-related emergency visits			Children (mean age: 5.12 (SD: 4.8))	1,761 patients
Dales et al. (2008)	Ash	Asthma hospital admissions (ICD-9 493)	Canada (Vancouver, Saint John, Toronto, Edmonton, Winnipeg, Ottawa, Halifax, London, Windsor, Calgary)	1993 (March)–2000 (March)	No restrictions	60,066 admissions
Fuhrman et al. (2007)*	Ash, birch, hazel	Antiallergic drug consumption (oral antihistamine and a local antiallergic drug on the same prescription) as indicator for an episode of treated ARC	France (Clermont-Ferrand area)	2000 (January)–2001 (December) and 2003 (January)–2004 (December)	≥ 5	6,780 individuals per years
Gleason et al. (2014)	Ragweed	Asthma emergency department visits (ICD-9 code 493.xx)	USA (New Jersey)	2004–2007 (April–September)	3–17	21,854 visitors
Guilbert et al. (2016)	Alder, ash, birch, hazel	Reimbursable antihistamines for systemic use sales	Belgium (Brussels-Capital Region)	2005–2011	No restrictions	1,370,535 reimbursable allergy medication purchases by 347,034 distinct individuals
Guilbert et al. (2018)	Alder, ash, birch, hazel, mugwort	Asthma hospital admissions (ICD-9 493)	Belgium (Brussels)	2008–2013 (January–April)	No restrictions	5,094 admissions
Heguy et al. (2008)*	Ragweed	Asthma emergency visits (ICD-9 493)	Canada (Montreal)	1994–2004 (April–October)	≤ 9	43,780 visitors

Table 6 continued

Authors (date)	Kinds of pollen	Health outcomes	Region	Time period	Age in years	Analyzed sample size
Ito et al. (2015)	Ash, birch	Asthma syndrome emergency department visits Medication sale (brand name and generic products, which were classified as allergy medications and other medications described with the word "allergy")	USA (New York City)	2002–2011	No restrictions	ED visits reported by 52 hospitals (mean visits per day: 269) Medication sales reported by 200 stores (mean sales per day: 3,493)
Motreff et al. (2014)	Ash, mugwort, ragweed	ARC cases defined as the association of an oral antihistamine drug and a local (nose or eye) antiallergic drug on the same medical prescription	France (urban areas of Montpellier and Nîmes)	2004–2007	5	118,723 cases in total in both areas (Montpellier and Nîmes)
Osborne et al. (2017)	Ash, birch	Asthma hospital admissions (ICD-10 J45 and J46)	England (greater London)	2004–2008 (April–August)	16–64	11,984 admissions
Tobías et al. (2003)	Mugwort	Asthma hospital emergencies, diagnoses: asthma, asthmatic bronchitis, spastic bronchitis, bronchospasm	Spain (Madrid)	1995–1998	No restrictions	4,827 admissions
Villeneuve et al. (2006)	Ragweed	Number of doctor's visits for allergic rhinitis (ICD-9-CM rubric 177)	Canada (Toronto)	1995–2000 (July–October)	≥ 65	52,691 visitors
Zeghnoun et al. (2005)	Alder, ash, birch, hazel, mugwort	ARC cases, defined as a person who, on a given day, had a prescription to obtain an oral antihistamine associated with treatment for allergic rhinitis or allergic conjunctivitis, or both	France (Clermont-Ferrand area)	2000/2001	≥ 5	On average 26 cases per day over the entire study period
Zhong et al. (2006)	Ragweed	Asthma emergency room visit or outpatient clinic visit (ICD-9 codes 493.493.91)	USA (Cincinnati area)	2002 (April–October)	1–18	1,254 visitors

*Reviewer requests for numerical results from figures or results from not presented sub-analyses were sent to Fuhrman et al. (2007), Ito et al. (2015) and Tobias et al. (2003), Ito et al. (2015) provided the requested data.

ARC allergic rhinoconjunctivitis, ED emergency department, ICD International Statistical Classification of Diseases and Related Health Problems, ICD-9 493 Diagnosis Code Asthma, ICD-9-CM rubric 177 classical modification, cause of death; ICD-10 J45 asthma bronchiale; ICD-10 J46 status asthmaticus, SAR seasonal allergic rhinoconjunctivitis, SD standard deviation

Table 7 Results of the included studies by kind of pollen and health outcome

Pollen	Authors	CoI	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect	CI	Covariates	Stratified results
Alder	Drug consumption										
	Cailaud et al. (2015)	N.A.	SAR case	IQR increase	35.5	Lag 0–1 (avg)	RR	1.00	[0.98; 1.02]	Air pollution, weather, day of the week, long-term trend, season, public holidays, school holidays	None
	Guilbert et al. (2016)	None	Sales of reimbursable antihistamines for systemic use	IQR increase	18.25	Lag 0–10 (cum)	RR	1.00	[0.98; 1.03]	Air pollution (PM ₁₀ , NO ₂ , SO ₂ and O ₃), meteorological conditions, flu, seasonal component, day of the week.	Age Sex NO sign. results
	Zeghnoun et al. (2005)	N.A.	ARC case	IQR increase	19	Lag 0–1 (avg)	RR	0.99	[0.96; 1.02]	Trend and seasonal variation, day of the week, school holidays, temperature, humidity, precipitation, O ₃	Age +65 years only sign. result
Ash	Visits to physician										
	Guilbert et al. (2018)	None	Asthma HA	IQR increase	9	Lag 0–6 (cum)	Percentage change	0.2	[− 2.2; 2.7]	Seasonal and long-term trends, day of the week, public holidays, mean temperature, relative humidity	Age PM2.5, NO ₂ , O ₃ Influenza Respiratory infection All not sign.
	Drug consumption		(ICD-9 493)								
	Cailaud et al. (2015)	None	Drug consumption for SAR case	IQR increase	41	Lag 0–1 (avg)	RR	1.019	[1.004; 1.033]	Air pollution, weather, day of the week, long-term trend, season, public holidays, school holidays	Age Some sub-groups with sign. results
	Guilbert et al. (2016)	None	Sales of reimbursable antihistamines for systemic use	IQR increase	24.5	Lag 0–10 (cum)	RR	1.05	[1.04; 1.06]	Air pollution (PM ₁₀ , NO ₂ , SO ₂ and O ₃), meteorological conditions (daily minimal temperature and average relative humidity), flu, seasonal component, day of the week	Age & Sex 19–39 years, ♀ 40–64 years, ♂ 40–64 years, ♀
								1.03	[1.02; 1.04]		
								1.03	[1.02; 1.04]		
								1.02	[1.01; 1.03]		

Table 7 continued

Pollen	Authors	Col	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect CI	Covariates	Stratified results
	Ito et al. (2015)	None	Medication sale	0-98th percentile increase	223.3	Lag 0-3 (cum)	Rate Ratio (cum)	1.91 [1.748; 2.086]	Day of the week, within seasonal trends, humidity, temperature, PM _{2.5} , O ₃	None
	Fuhrman et al. (2007)	None	Antiallergic drug consumption treated ARC	IQR increase	33	Lag 0-1 (avg)	Percentage change	7.3 [4.6; 10.1]	Day of the week, public holiday, temperature, relative humidity, O ₃	Age Sign. in all age groups
	Motreff et al. (2014)	N.A.	ARC case	IQR increase	60 (Montpellier)	Lag 0-5 (cum)	RR	12.7 [1.01; 1.03]	O ₃ , NO ₂ , PM ₁₀ , day of the week, public holidays and vacation, temperature, humidity/precipitations. No significant effect and therefore not included in the final model: O ₃ , NO ₂ , PM ₁₀ , precipitation	age Sign. in two of four age groups
					9 (Nîmes)	Lag 0-1 (avg)		1.04 [1.02; 1.06]		
						Lag 0-5 (cum)		1.00 [0.98; 1.01]		
						Lag 0-5 (cum)		1.01 [0.99; 1.03]		
	Zeghnoun et al. (2005)	N.A.	ARC case	IQR increase	28	Lag 0-1 (avg)	RR	1.22 [1.13; 1.31]	Trend and seasonal variation, day of the week, school holidays, temperature, humidity, precipitation, O ₃	age all sub-groups with sign. result except (65+)
Visits to physician										
	Dales et al. (2008)	N.A.	Asthma HA ICD-9 493	IQR increase	20.18	N.A.	Percentage increase	1.69 [0.38; 3.00]	Other tree pollen types, grasses, fungal spores, NO ₂ , SO ₂ and O ₃ , day of the week, humidity, temperature, temporal trends	None
	Guilbert et al. (2018)	None	Asthma HA ICD-9 493	IQR increase	4	Lag 0-6 (cum)	Percentage change	0.00 [-0.60; 0.50]	Seasonal and long-term trends, day of the week, public holidays, mean temperature, relative humidity	age PM _{2.5} , NO ₂ , O ₃ influenza respiratory infection all not sign
	Ito et al. (2015)	None	Asthma syndrome ED visits	0-98th percentile increase	223.3	Lag 0-7 (cum)	Rate Ratio (cum)	1.695 [1.526; 1.883]	Day of the week, within seasonal trends, humidity, temperature, PM _{2.5} , O ₃	age some sub-groups show sign. results
	Osborne et al. (2017)	N.A.	Asthma HA ICD-10 J45 and J46	0-95th percentile increase	18	Lag 4	Percentage change	3.99 [0.10; 7.89]	Temperature, precipitation, humidity, day of week, public holidays, PM ₁₀ , NO ₂ , SO ₂ and O ₃	none

Table 7 continued

Pollen	Authors	Col	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect CI	Covariates	Stratified results
Birch	Drug consumption									
	Caillaud et al. (2015)	None	Drug consumption for SAR case	IQR increase	58	Lag 0–1 (avg)	RR	1.03 [1.005; 1.055]	Air pollution, weather, day of the week, long-term trend, season, public holidays, school holidays	Age some sub-groups with sign. results
	Fuhrman et al. (2007)	None	Antiallergic drug consumption treated ARC	IQR increase	45	Lag 0–1 (avg) Lag 0–5 (cum)	Percentage change	7 11 [3.8; 10.4] [5.9; 16.3]	Day of the week, public holiday, temperature, relative humidity, O ₃	Age sign. in all but the 65+ age group
	Guilbert et al. (2016)	None	Sales of reimbursable antihistamines for systemic use	IQR increase	84.75	Lag 0–10 (cum)	RR	1.02 1.03 1.02 1.05 1.03 1.04 1.03 1.04 1.03	Air pollution (PM ₁₀ , NO ₂ , SO ₂ and O ₃), meteorological conditions (daily minimal temperature and average relative humidity), flu, seasonal component, day of the week	Age sex 6–12 years, ♂ 13–18 years, ♂ 13–18 years, ♀ 19–39 years, ♂ 19–39 years, ♀ 40–64 years, ♂ 40–64 years, ♀
	Ito et al. (2015)	None	Medication sale	0–98th percentile increase	1680.3	Lag 0–3 (cum)	Rate Ratio (cum)	2.01 [1.831; 2.205]	Day of the week, within seasonal trends, humidity, temperature, PM _{2.5} , O ₃	none
	Zeghnoun et al. (2005)	N.A.	ARC case	IQR increase	45	Lag 0–1 (avg)	RR	1.22 [1.11; 1.35]	Trend and seasonal variation, day of the week, school holidays, temperature, humidity, precipitation, O ₃	Age all sub-groups with sign. results
	Visits to physician									
	Guilbert et al. (2018)	None	Asthma HA (ICD-9 493)	IQR increase	40	Lag 0–6 (cum)	Percentage change	3.2 [1.1; 5.3]	Seasonal and long-term trends, day of the week, public holidays, mean temperature, relative humidity	age, PM _{2.5} , NO ₂ , O ₃ influenza respiratory infections

Table 7 continued

Pollen	Authors	Col	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect	CI	Covariates	Stratified results all not sig
Hazel	Ito et al. (2015)		Asthma syndrome ED visits	0-98th percentile increase	223.3	Lag 0-7 (cum)	Rate ratio (cum)	1.324	[1.184; 1.479]	Day of the week, within seasonal trends, humidity, temperature, PM _{2.5} , O ₃	age some sub-groups show sign. results
	Osborne et al. (2017)	N.A.	Asthma HA (ICD-10 J45 and J46)	0-95th percentile increase	195	Lag 4	Percentage change	3.1	[- 5.56; 11.78]	Temperature, precipitation, humidity, day of week, public holidays, PM ₁₀ , NO ₂ , O ₃ , SO ₂	none
	Symptoms										
	Cailaud et al. (2014a)	N.A.	Symptoms Nasal	Up to 110 grains/m ³	10	Either lag 0, lag 1 or lag 0-1 (avg). The most sign. lag was retained.	OR	1.07	[1.03; 1.12]	Temperature, humidity, wind speed, NO ₂ , O ₃ , PM ₁₀ , age, geographical area of participant	None
			Ocular	above 110 grains/m ³				1	[0.99; 1.01]		
				up to 70 grains/m ³				1.17	[1.08; 1.27]		
				above 70 grains/m ³				1	[0.99; 1.00]		
			bronchial	up to 70 grains/m ³				1.12	[1.03; 1.21]		
				above 70 grains/m ³				0.99	[0.98; 1.00]		
	Drug consumption										
Hazel	Cailaud et al. (2015)	None	Drug consumption for SAR	IQR increase	31	Lag 0-1 (avg)	RR	1	[0.982; 1.013]	Air pollution, weather, day of the week, long-term trend, season, public holidays, school holidays	None
	Fuhrman et al. (2007)	None	drug consumption Treated ARC	IQR increase	23	Lag 0-1 (avg)	Percentage change	2.3	[0.4; 4.3]	Day of the week, public holiday, temperature, relative humidity, O ₃	Age sign. only in the 35-64 years old
						Lag 0-5 (cum)		2.4	[- 0.4; 5.2]		
	Guilbert et al. (2016)	None	Sales of reimbursable antihistamines for systemic use	IQR increase	9	Lag 0-10 (cum)	RR	0.97	[0.94; 1.00]	Air pollution (PM ₁₀ , NO ₂ , SO ₂ and O ₃), meteorological conditions, flu, seasonal component, day of the week.	Age Sex no sign. results
	Zeghnoun et al. (2005)	N.A.	ARC case	IQR increase	15	Lag 0-1 (avg)	RR [age ≥ 5]	1.02	[0.99; 1.06]	Trend and seasonal variation, day of the week, school holidays, O ₃ , temperature, humidity, precipitation,	65+ age group with sign. results
							RR [age 65+]	1.08	[1.00; 1.15]		

Table 7 continued

Pollen	Authors	Col	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect CI	Covariates	Stratified results
Visits to physician										
	Guilbert et al. (2018)	None	Asthma HA	IQR increase	4	Lag 0–6 (cum)	Percentage change	0.5	[-2.5; 3.6]	Age PM _{2.5} , NO ₂ , O ₃ influenza respiratory infections all not sign.
ICD-9 493										
Mugwort										
	Drug consumption Caillaud et al. (2015)	None	Drug consumption for SAR	IQR increase	6.5	Lag 0–1 (avg)	RR	0.96	[0.912; 1.003]	None
	Moret et al. (2014)	N.A.	SAR case ARC case	IQR increase	3 (Montpellier)	Lag 0–1 (avg)	RR	1.09	[1.05; 1.13]	Air pollution, weather, day of the week, long-term trend, season, public holidays, school holidays
						Lag 0–5 (cum)		1.08	[1.05; 1.11]	PM ₁₀ , NO ₂ , O ₃ , day of the week, public holidays and vacation, temperature, humidity/precipitations. No significant effect and therefore not included in the final model: PM ₁₀ , NO ₂ , O ₃ , precipitation
					2 (Nîmes)	Lag 0–1 (avg)		1.01	[0.97; 1.04]	Age sign. in all except age group +65
						Lag 0–5 (cum)		1.02	[0.97; 1.08]	None
	Zeghnoun et al. (2005)	N.A.	ARC case	IQR increase	7	Lag 0–1 (avg)	RR	1.02	[0.95; 1.09]	Seasonal variation, O ₃ , day of the week, school holidays, humidity, temperature, precipitation
Visits to physician										
	Guilbert et al. (2018)	None	Asthma HA	IQR increase	1	Lag 0–6 (cum)	Percentage change	1.4	[-4.4; 7.6]	age, PM _{2.5} , NO ₂ , O ₃ influenza respiratory infections all not sign.
(ICD-9 493)										
	Tobias et al. (2003)	None	Asthma hospital emergencies, diagnoses	Range btw 95th and 99th percentile	2.1	Lag 1	Percentage change	4.4	[-6.6; 16.7]	One pollutant meteorological data, acute respiratory infections, day of the week, public holidays, other pollen
Ragweed										
	Drug consumption	None		IQR increase	5	Lag 0–1 (avg)	RR	1	[0.981; 1.012]	None

Table 7 continued

Pollen	Authors	Col	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect CI	Covariates	Stratified results
Pollen	Caillaud et al., (2015)		Drug consumption for SAR case						Air pollution, weather, day of the week, long-term trend, season, public holidays, school holidays	
	Morreff et al., (2014)		SAR case ARC case	IQR increase	5 (Montpellier)	Lag 0–1 (avg) Lag 0–5 (cum)	RR 	[0.96; 1.02] [0.93; 1.03]	O ₃ , NO ₂ , PM ₁₀ , day of the week, public holidays and vacation, temperature, humidity/precipitations. No significant effect and therefore not included in the final model: O ₃ , NO ₂ , PM ₁₀ , precipitation	None
	Villeneuve et al., (2006)		Physician visits for AR	IQR increase	22.6	Lag 0–10 (avg)	Percentage change	[−0.48; 0.63]	Minimum temperature, change in barometric pressure over the previous 24 h, maximum O ₃ , maximum NO ₂	By further lag days (all not sign.)
	Zhong et al., (2006)		Asthma ED Outpatient clinic ICD-9	Conc. increase	100	Lag 5	RR	[1.02; 2.33]	Effects of season, day of the week, temperature, humidity, O ₃ , PM _{2.5}	By further lag days (all not sign.)
	Heguy et al., (2008)		Asthma ED visits ICD-9 493	Conc. increase	10	Lag 0	MPC	0.08	Temperature, humidity, influenza	By further lag days (all not sign.)
	Gleason et al., (2014)		Rhinitis or sinusitis ED visits Conjunctivitis ED visits Asthma ED visits ICD-9 493	Increase in allergen conc. equal to their mean Conc. increase	72 10	N.A. Lag 0	Percentage increase OR	9.3 0.97 [0.96; 0.97]	Long-term trends, meteorological and air pollution variables (daily and weekly changes, O ₃ , NO ₂ , SO ₂ , daily sulfates, temperature, relative humidity, barometric pressure) Holiday, school in session, temperature, humidity	none By further lags (all not significant)
Symptoms	Caillaud et al., (2014b)		Nasal symptom (WD, 2009) Nasal symptom (WE, 2009) Ocular symptom (2009) Respiratory symptom 2009 Nasal symptom (WD, 2010)	Increase per conc.	10	Either lag 0, lag 1 or lag 0–1 (avg). The most sign. lag was retained.	OR	1.13 [0.99; 1.28] 1.02 [0.98; 1.05] 1.26 [1.11; 1.43] 1.12 [1.01; 1.25] 1.33 [1.07; 1.65]	Temperature, humidity, wind speed, O ₃ , PM ₁₀ , age variables were tested and retained when significant (no information which variables were retained) treatment	Another model without adjustment for treatment

Table 7 continued

Pollen	Authors	Col	Health outcome	Concentration category	Grains/m ³	Lag (days) †	Measure of effect	Effect	CI	Covariates	Stratified results
			Nasal symptom (WE, 2010)					1.20	[1.00; 1.44]		
			Ocular symptom (2010)					1.09	[1.01; 1.07]		
			Respiratory symptom 2010					1.02	[0.97; 1.08]		

AR allergic rhinitis, ARC allergic rhinoconjunctivitis, ARC case allergic rhinoconjunctivitis (ARC) cases, defined as a person who, on a given day, had a prescription to obtain an oral antihistamine associated with treatment for allergic rhinitis or allergic conjunctivitis, or both; *avg* average, *bnw* between, *conc* concentration, *cum* cumulated, *ED* emergency department, *f* female, *HA* hospital admission, *IQR* interquartile ranges, *m* male, *MPC* mean percent change, *OR* odds ratio, *RR* relative risk, *SAR* seasonal allergic rhinoconjunctivitis, *SAR case* seasonal allergic rhinoconjunctivitis case was defined as the association between an oral antihistamine and a local (nasal or ocular) antiallergic drug on the same prescription (Caillaud et al. (2015)), *sign.* significant; treated ARC oral antihistamine and a local antiallergic drug on the same prescription as indicator for an episode of treated ARC; WD Weekdays, WE Weekends

†Explanation of information regarding lag days:

♂ male

♀ female

Lag 0: Outcome and exposure measurements from the same day were compared.

Lag 1: Outcome measurements were compared with exposure measurements from the day before.

Lag 2: Outcome measurements were compared with exposure measurements from two days before.

Lag 0–1 (averaged): Outcome measurements were compared with the average of the exposure measurements from the same day and the day before.

Lag 2–3 (averaged): Outcome measurements were compared with the average of the exposure measurements from two days earlier and three days earlier.

Lag 0–3 (cumulated): Outcome measurements were compared with the cumulated exposure measurements from the same day, the day before, two days earlier and three days earlier

background: studies with statistically significant results only in sub-analyses; white background: studies with statistically nonsignificant results; purple background: study with significant protective effect of visits to physician

there is plausibility to pollen threshold values. Therefore, the authors recognize a threshold value for ash pollen of 18 grains/m³ for the outcome “visits to physician” and a threshold value of 28 grains/m³ for “drug consumption.”

The majority of the studies on threshold values of birch pollen show statistically significant results

(Zeghnoun et al., 2005; Fuhrman et al., 2007; Ito et al., 2015; Guilbert et al., 2016; D. M. Caillaud et al., 2015) and indicated an increasing risk of taking medication above a threshold value of 45 grains/m³. Nevertheless, one study showed no statistically significant results (Osborne et al., 2017). The authors attribute this to confounding or limitations in the study design. Caillaud et al., (2014a) identified statistically significant birch pollen threshold values of 110 grains/m³ for the occurrence of nasal symptoms, 70 grains/m³ for the occurrence of ocular symptoms and 70 grains/m³ for the occurrence of bronchial symptoms. The author's results further indicate that for pollen concentrations above the threshold values just mentioned, the occurrence of symptoms decreases again. This result indicates a nonlinear relationship between birch pollen concentrations and symptoms.

The results of hazel pollen threshold values (Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Guilbert et al., 2018; Guilbert et al., 2016; Fuhrman et al., 2007), mugwort pollen threshold values (Zeghnoun et al., 2005; D. M. Caillaud et al., 2015; Guilbert et al., 2018; Motreff et al., 2014; Tobias et al., 2003) and ragweed pollen threshold values (D. M. Caillaud et al., 2015; D. Caillaud et al., 2014b; Zhong et al., 2006; Cakmak et al., 2002; Heguy et al., 2008; Villeneuve et al., 2006; Motreff et al., 2014; Gleason et al., 2014), respectively, gave a mixed picture. Statistically significant and statistically nonsignificant results were found for both high and low concentrations. Therefore, the authors cannot identify a threshold value for hazel, mugwort and ragweed pollen. From the results identified, it can be concluded that sensitivity is strongly dependent on the individual sensitization of the individual person.

4.3 Sub-analyses by age

The results of the sub-analyses by age of the included studies show a mixed picture. No clear age patterns can be concluded for the observed results. Overall, health effects of pollen and/or the help-seeking behavior determined by exposure to pollen might be influenced by age. However, no clear age patterns were identified.

4.4 Sub-analyses by sex

There was just one study stratifying the results by sex. Guilbert et al. (2016) found stronger associations for males aged 19–64 years. In general, allergic rhinitis is more prevalent in males than in females, which was reviewed by Chen et al. (2008). Thus, differences between males and females regarding pollen-related allergic effects and help-seeking behavior should be investigated in more detail. This could be an explanatory factor for contrasting study results.

4.5 Health outcomes—advantages and restrictions

It must be remarked that the health outcomes mostly investigated (drug consumption and visits to physician) are only proxies for the occurrence of symptoms. Physician's diagnoses underestimate the real number of allergy symptoms because of self-diagnoses and self-treatment, and access to health care (Salo et al., 2011). The determination of health outcomes by the request for prescriptions is sensitive to the preventative behavior of the people affected. They might buy antiallergic drugs in advance or use residual products, for example, over-the-counter medicine (Zeghnoun et al., 2005). It should be noted that in most countries, antihistamines, which are the first-line allergic rhinitis therapy, are over-the-counter or OTC medicine. They might also use medications preventively, before the occurrence of symptoms (Fuhrman et al., 2007). In addition, not every person affected is using drugs or might use another product or alternative therapies than observed by the studies. Another factor influencing the disposal of antiallergic drugs and the documentation of symptoms is a misinterpretation of pollen-related symptoms (Zeghnoun et al., 2005) due to similar effects like common cold diseases and influenza (D'Amato et al., 2007). The considerably lower prevalence of allergy symptoms diagnosed by a physician in contrast to self-reported symptoms was already discussed in the literature (Wise et al., 2018; Salo et al., 2011).

In many cases, symptoms themselves as well as help-seeking behavior do not occur on the same day of exposure but a few days later (Kiotseridis et al., 2013). Thus, the exposure from the days before the outcome is commonly considered. Several possibilities of the

consideration of lag days were reported and uniformly abbreviated as described in the footnote of Table 7.

4.6 Threshold values

Our results indicate that deriving of threshold values for pollen concentrations resulting in allergic reactions in affected people seems to be much more complex than historically thought and handled in respective pollen forecasts. Thus, the same amount of pollen resulted in different reactions in people (Bastl K et al., 2014; Sofiev and Bergmann 2013) and temporal and regional differences were observed (Bastl K et al., 2014).

Several reasons may be responsible for these differences. To begin with, the allergen content per pollen grain may differ substantially (Buters et al., 2012; Jantunen et al., 2012) and the size of allergen-carrying particles (ruptured pollen) may be a factor that could influence study results (Schappi et al., 1997). Thus, much information about pollen itself should be collected and analyzed (Bastl K et al., 2014; Buters et al., 2012). Furthermore, the accuracy of pollen concentration data may vary between the analyzed studies. Rojo et al. (2020) showed that the measured pollen concentrations can vary due to the height of the pollen station. Additionally, pollen stations are usually set up at an average height of ten meters (Buters et al., 2018). Thus, the exposure of the pollen concentration to an individual at ground level could be underestimated (Buters et al., 2018).

Individual differences in tolerance levels leading to allergic reactions could also explain differences in results of the studies investigated. Jantunen et al. (2012) found a higher tolerance for birch pollen of people from Finland in comparison with people from Austria regarding birch pollen. Birch pollen counts from Finland are generally much higher than in Austria, which might result in a local adaptation (Buters et al., 2012). Indeed, the same symptom score was reached in Austria at 250 grains/m³ and Finland at 600 grains/m³ (Buters et al., 2012). Furthermore, symptom awareness and behavior of individuals are influenced by multiple factors (own variable bronchial hyperreactivity, degree of sensitization, influence of drugs, own perception of symptoms, etc.) (Werchan et al., 2017). Additionally, similar pollen concentrations might cause different intensities of symptoms under varying environmental conditions (Damialis

et al., 2019). Different pollen types showed different effects. For example, grass pollen induced a stronger effect than the same amount of tree pollen (Wise et al., 2018). While temperature and other weather conditions are influencing factors for allergy symptoms (e.g., thunder asthma) (Thien et al., 2018; Sofiev and Bergmann 2013), there might also be a difference between pollen in the early season in contrast to pollen in the late season (De Weger et al., 2011; Sofiev and Bergmann 2013). This difference in allergen release is to be expected given the natural variability between the pollen-producing species (Buters et al., 2015). It was observed, that—without an increase in the amount of pollen per m³ of air—the prevalence and severity of its health effects on certain patient has increased with time (D’Amato et al., 2001). A possible explanation is air pollution which may have an effect on the allergenicity of pollen (Mur Gimeno et al., 2007). The aspect of air pollution was identified as a confounder in the current review. In addition, the consideration of air pollution was included in the risk-of-bias analysis. Thus, consideration of air pollution as confounder had been fixed as a rule for the risk-of-bias assessment in the current review. These possible influencing factors may explain the mostly inconclusive results found in the literature for this review and emphasizes the lack of sufficient data on this topic (Kiotseridis et al., 2013).

The aim of this study was to identify pollen threshold values in relation to symptoms of allergy. Many pollen warning systems use the colors of traffic light to indicate the risk for pollen allergy patients. Such a color scale ranges from green (no risk of developing symptoms due to pollen) to red (high risk of developing symptoms due to pollen). Based on our results, such categorization should be avoided, as even low pollen concentrations can be a high burden for a pollen allergy patient. The results show that pollen allergies should be examined and treated individually, as health outcomes are influenced by different influencing factors such as pollen type, air temperature, region and individual sensitivity. Future studies should focus these influencing factors.

4.7 Assessment of RoB: relevance of the conflict of interest criteria for study outcomes

Of the 17 included studies in this review, eight studies published with a CoI (Fuhrman et al., 2007; Guilbert

et al., 2018; Ito et al., 2015; Guilbert et al., 2016; Tobias et al., 2003; Cakmak et al., 2002; Gleason et al., 2014; D. Caillaud et al., 2014b) statement and nine studies without (Osborne et al., 2017; D. Caillaud et al., 2014a; Zeghnoun et al., 2005; Dales et al., 2008; Heguy et al., 2008; Zhong et al., 2006; Villeneuve et al., 2006; D. M. Caillaud et al., 2015; Motreff et al., 2014). The eight studies that provided a CoI statement declared that there are no conflicts of interest. It is noticeable that 83% of the analyses published without CoI show statistically significant results, while only half of the analyses (52%) published with CoI show statistically significant results. Woodruff and Sutton (2014) have summarized evidence that a funding source can influence the study outcome. Thus, it is important to declare whether an external influence is possible.

4.8 Strengths and limitations

Our study had some limitations. The definition of AR, the severity of symptoms, visits to physician and drug consumption vary in the included studies. This variation makes it difficult to compare the results. Therefore, the authors cannot draw general conclusions from the found results. Future studies should define AR, the severity of symptoms, visits to physician or drug consumption in a comparable way.

To the best of our knowledge, the broad scope of this review is unique. There are different reviews on this topic, but our review is uniquely covering a wide variety of allergenic pollen types and health outcomes. One strength of our study is that we had no restricted inclusion criteria regarding the study populations.

Another strength of the study is the broad view on six kinds of pollen types and three categories of health outcomes. A broad search strategy was constructed and applied to PubMed that is recognized as “the primary tool for searching biomedical literature” (Lu 2011). However, the snowball strategy revealed further literature that is not listed in PubMed (Hofman et al., 1996; Motreff et al., 2014) or that is listed in PubMed but was not found with the search term applied (Guilbert et al., 2016; Gleason et al., 2014; Heguy et al., 2008; Ross et al., 2002; Villeneuve et al., 2006).

5 Conclusion

In conclusion, the authors were able to derive indications for pollen threshold values for ash and birch. Due to the many inconsistent results in this review, the factors influencing the association between pollen concentration and health outcomes should be investigated more closely. In this review, the influencing factors age, gender, allergen content of pollen and individual sensitivity could be identified. These influencing factors should be examined more closely in future research.

Acknowledgements The research group thanks the following persons for their great support: Conny Höflich; Environmental Medicine and Health Effects Assessment, Federal Environment Agency, Corrensplatz 1, 14195 Berlin, Germany. Wolfgang Straff; Environmental Medicine and Health Effects Assessment, Federal Environment Agency, Corrensplatz 1, 14195 Berlin, Germany. Klaus Koch; State building authority Amberg-Sulzbach (StBA AS), Gabelsbergerstr. 2, 92637 Weiden in Upper Palatinate, Germany. Additionally, the research group would like to thank all student assistants/research assistants for their great commitment: Sarah Georgi, Sagun Magar, Lena Mandlik

Authors' contributions NS-M, HM, IM, PS, JB, K-CB, SB-O, JB, AD, JH, MK, DN, SW-R, AW, MZ, CH, SK and SH contributed to conceptualization. NS-M, HM and IM performed the literature search. NS-M, HM, IM, PS, K-CB, SB-O', JB, AD, JH, MK, DN, AW, CH, SK and SH were involved in methodology. NS-M, HM, IM, PS, AW, CH, SK and SH analyzed the data. NS-M, HM, IM and SK drafted the article. IM, PS, JB, K-CB, SB-O'R, JB, AD, JH, MK, DN, SW-R, AW, MZ, CH, SK and SH revised the article. NS-M, HM, IM, PS, JB, K-CB, SB-O', JB, AD, JH, MK, DN, SW-R, AW, MZ, CH, SK and SH contributed to final approval. NS-M, HM, IM, PS, JB, K-CB, SB-O', JB, AD, JH, MK, DN, SW-R, AW, MZ, CH, SK and SH contributed to agreement to account for all aspects of the work. NS-M, K-CB, SB-O', AD, JH, DN, CH, SK and SH were involved in supervision. NS-M and HM are the first authors. SK and SH are the senior authors

Funding The German project LUPO was funded by the Bavarian State Ministry of Health and Care and coordinated by the Bavarian Health and Food Safety Authority.

Data availability All listed tables, figures and supplements are included in the paper or available in Electronic Supplementary Material.

Declarations

Conflict of interest K.C. Bergmann who is the author of paper (Bergmann et al., 2016), J. Buters who is the author of papers (Buters et al., 2018), (Buters et al., 2015) and (Buters et al., 2012) and A. Damialis who is the author of paper (Damialis

et al., 2019) included in this review declare that there is no conflict of interest.

References

- Bastl, K., Kmenta, M., Jager, S., & Bergmann, K. C. (2014). Development of a symptom load index: Enabling temporal and regional pollen season comparisons and pointing out the need for personalized pollen information. *Aerobiologia (Bologna)*, 30, 269–280.
- Bergmann, K. C., Heinrich, J., & Niemann, H. (2016). Current status of allergy prevalence in Germany: Position paper of the environmental medicine Commission of the Robert Koch institute. *Allergo Journal International*, 25, 6–10. <https://doi.org/10.1007/s40629-016-0092-6>
- Bousquet, J., Van Cauwenberge, P., Khaltaev, N., Aria Workshop Group, & World Health Organization (2001). Allergic rhinitis and its impact on asthma. *The Journal of Allergy and Clinical Immunology*, 108(5 Suppl), S147–S334. <https://doi.org/10.1067/mai.2001.118891>
- Busse, P. J., & Kilaru, K. (2009). Complexities of diagnosis and treatment of allergic respiratory disease in the elderly. *Drugs Aging*, 26(1), 1–22. <https://doi.org/10.2165/0002512-200926010-00001>
- Buters, J., Antunes, C., Galveias, A., Bergmann, K., Thibaudon, M., Galán, C., et al. (2018). Pollen and spore monitoring in the world. *Clinical and Translational Allergy*. <https://doi.org/10.1186/s13601-018-0197-8>
- Buters, J., Prank, M., Sofiev, M., Pusch, G., Albertini, R., Annesi-Maesano, I., et al. (2015). Variation of the group 5 grass pollen allergen content of airborne pollen in relation to geographic location and time in season. *Journal of Allergy and Clinical Immunology*, 136(1), 87–9586. <https://doi.org/10.1016/j.jaci.2015.01.049>
- Buters, J., Thibaudon, M., Smith, M., Kennedy, R., Rantio-Lehtimäki, A., Albertini, R., et al. (2012). Release of Bet v 1 from birch pollen from 5 European countries Results from the HIALINE study. *Atmospheric Environment*, 55, 496–505. <https://doi.org/10.1016/j.atmosenv.2012.01.054>
- Caillaud, D., Martin, S., Segala, C., Besancenot, J. P., Clot, B., & Thibaudon, M. (2014). Effects of airborne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis. *Int Arch Allergy Immunol*, 163(1), 43–50. <https://doi.org/10.1159/000355630>
- Caillaud, D., Thibaudon, M., Martin, S., Segala, C., Besancenot, J. P., Clot, B., et al. (2014). Short-term effects of airborne ragweed pollen on clinical symptoms of hay fever in a panel of 30 patients. *Journal of Investigation Allergol Clinical Immunology*, 24(4), 249–256.
- Caillaud, D. M., Martin, S., Segala, C., Vidal, P., Lecadet, J., Pellier, S., et al. (2015). Airborne pollen levels and drug consumption for seasonal allergic rhinoconjunctivitis: A 10-year study in France. *Allergy*, 70(1), 99–106. <https://doi.org/10.1111/all.12522>
- Cakmak, S., Dales, R. E., Burnett, R. T., Judek, S., Coates, F., & Brook, J. R. (2002). Effect of airborne allergens on emergency visits by children for conjunctivitis and rhinitis. *Lancet*, 359, 947–948. [https://doi.org/10.1016/s0140-6736\(02\)08045-5](https://doi.org/10.1016/s0140-6736(02)08045-5)
- Chen, W., Mempel, M., Schober, W., Behrendt, H., & Ring, J. (2008). Gender difference, sex hormones, and immediate type hypersensitivity reactions. *Allergy*, 63(11), 1418–1427. <https://doi.org/10.1111/j.1398-9995.2008.01880.x>
- D'Amato, G., Cecchi, L., Bonini, S., Nunes, C., Annesi-Maesano, I., Behrendt, H., et al. (2007). Allergenic pollen and pollen allergy in Europe. *Allergy*, 62(9), 976–990. <https://doi.org/10.1111/j.1398-9995.2007.01393.x>
- D'Amato, G., Liccardi, G., D'Amato, M., & Cazzola, M. (2001). The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy. *Respiratory Medicine*, 95(7), 606–611. <https://doi.org/10.1053/rmed.2001.1112>
- Dales, R. E., Cakmak, S., Judek, S., & Coates, F. (2008). Tree pollen and hospitalization for asthma in urban Canada. *International of Archives of Allergy Immunology*, 146(3), 241–247. <https://doi.org/10.1159/000116360>
- Damialis, A., Häring, F., Gökkaya, M., Rauer, D., Reiger, M., Bezold, S., et al. (2019). Human exposure to airborne pollen and relationships with symptoms and immune responses: Indoors versus outdoors, circadian patterns and meteorological effects in alpine and urban environments. *Science of the Total Environment*, 653, 190–199. <https://doi.org/10.1016/j.scitotenv.2018.10.366>
- De Weger, L. A., Beerthuizen, T., Gast-Strookman, J. M., van der Plas, D. T., Terreehorst, I., Hiemstra, P. S., et al. (2011). Difference in symptom severity between early and late grass pollen season in patients with seasonal allergic rhinitis. *Clinical Translation Allergy*, 1(1), 18. <https://doi.org/10.1186/2045-7022-1-18>
- De Weger, L. A., Bergmann, K. C., Rantio-Lehtimäki, A., Dahl, A., Buters, J., Déchamp, C., et al., (2013). Impact of Pollen. In S. M., & B. K.C. (Eds.), *Allergenic Pollen A Review of the Production, Release, Distribution and Health Impacts*. Springer, New York.
- Fuhrman, C., Sarter, H., Thibaudon, M., Delmas, M. C., Zeghnoun, A., Lecadet, J., et al. (2007). Short-term effect of pollen exposure on antiallergic drug consumption. *Annals of the Allergy Asthma Immunology*, 99(3), 225–231. [https://doi.org/10.1016/s1081-1206\(10\)60657-6](https://doi.org/10.1016/s1081-1206(10)60657-6)
- Genaidy, A., Lemasters, G., Lockey, J., Succop, P., Deddens, J., Sobeih, T., et al. (2007). An epidemiological appraisal instrument a tool for evaluation of epidemiological studies. *Ergonomics*, 50(6), 920–960.
- Gleason, J. A., Bielory, L., & Fagliano, J. A. (2014). Associations between ozone, PM_{2.5}, and four pollen types on emergency department pediatric asthma events during the warm season in New Jersey: a case-crossover study. *Environmental Research*, 132, 421–429. <https://doi.org/10.1016/j.envres.2014.03.035>
- Guilbert, A., Cox, B., Bruffaerts, N., Hoebeke, L., Packeu, A., Hendrickx, M., et al. (2018). Relationships between aeroallergen levels and hospital admissions for asthma in the Brussels-Capital region: A daily time series analysis. *Environ Health*, 17(1), 35. <https://doi.org/10.1186/s12940-018-0378-x>
- Guilbert, A., Simons, K., Hoebeke, L., Packeu, A., Hendrickx, M., De Cremer, K., et al. (2016). Short-term effect of

- pollen and spore exposure on allergy morbidity in the Brussels-Capital Region. *Ecohealth*, 13(2), 303–315. <https://doi.org/10.1007/s10393-016-1124-x>
- Héguy, L., Garneau, M., Goldberg, M. S., Raphoz, M., Guay, F., & Valois, M. F. (2008). Associations between grass and weed pollen and emergency department visits for asthma among children in Montreal. *Environmental Research*, 106(2), 203–211. <https://doi.org/10.1016/j.envres.2007.10.005>
- Hofman, T., Wykretowicz, G., Stach, A., Springer, E., Kolasinska, B., & Ossowski, M. (1996). A multicentre analysis of a population of patients with newly-diagnosed pollinosis in Poznan, Poland, in the year 1995. *Annals of Agriculture and Environmental Medicine*, 3, 171–177.
- Ito, K., Weinberger, K. R., Robinson, G. S., Sheffield, P. E., Lall, R., Mathes, R., et al. (2015). The associations between daily spring pollen counts, over-the-counter allergy medication sales, and asthma syndrome emergency department visits in New York City, 2002–2012. *Environmental Health*, 14, 71. <https://doi.org/10.1186/s12940-015-0057-0>
- Janeway, C. J., Travers, P., Walport, M., & Shlomchik, M. J. (2001). *Immunobiology: The Immune System in Health and Disease*. 5th edition.
- Jantunen, J., Saarinen, K., & Rantio-Lehtimäki, A. (2012). Allergy symptoms in relation to alder and birch pollen concentrations in Finland. *Aerobiologia (Bologna)*, 28(2), 169–176. <https://doi.org/10.1007/s10453-011-9221-3>
- Kiotseridis, H., Cilio, C. M., Bjermer, L., Tunsater, A., Jacobsson, H., & Dahl, A. (2013). Grass pollen allergy in children and adolescents-symptoms, health related quality of life and the value of pollen prognosis. *Clinical and Translational Allergy*, 3, 19. <https://doi.org/10.1186/2045-7022-3-19>
- Lam, J., Sutton, P., Kalkbrenner, A., Windham, G., Halladay, A., Koustas, E., et al. (2016). A systematic review and meta-analysis of multiple airborne pollutants and autism spectrum disorder. *PLoS One*, 11(9), e0161851. <https://doi.org/10.1371/journal.pone.0161851>
- Lu, Z. (2011). PubMed and beyond: A survey of web tools for searching biomedical literature. *Database: The journal of biological databases and curation*, 2011, baq036. <https://doi.org/10.1093/database/baq036>
- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine*, 6(7), e1000097. <https://doi.org/10.1371/journal.pmed.1000097>
- Motreff, Y., Golliot, F., Calleja, M., Le Pape, A., Fuhrman, C., Farrera, I., et al. (2014). Short-term effect of pollen exposure on drug consumption for allergic rhinitis and conjunctivitis. *Aerobiologia*, 30(1), 35–44. <https://doi.org/10.1007/s10453-013-9307-1>
- Mur Gimeno, P., Feo Brito, F., Martínez, C., Tobías, A., Suárez, L., Guerra, F., et al. (2007). Decompensation of pollen-induced asthma in two towns with different pollution levels in La Mancha Spain. *Clinical and Experimental Allergy*, 37(4), 558–563. <https://doi.org/10.1111/j.1365-2222.2007.02684.x>
- Navarro, A., Colas, C., Anton, E., Conde, J., Davila, I., Dordal, M. T., et al. (2009). Epidemiology of allergic rhinitis in allergy consultations in Spain: Alergologica-2005. *Journal of Investigation Allergol Clinical Immunology*, 19(Suppl 2), 7–13.
- OHAT (2015a). Handbook for Conducting Systematic Reviews. Office of Health Assessment and Translation (OHAT), Division of the National Toxicology Program National Institute of Environmental Health Sciences.
- OHAT (2015b). OHAT Risk of Bias Rating Tool for Human and Animal Studies.
- Osborne, N. J., Alcock, I., Wheeler, B. W., Hajat, S., Sarran, C., Clewlow, Y., et al. (2017). Pollen exposure and hospitalization due to asthma exacerbations: Daily time series in a European city. *Int J Biometeorol*, 61(10), 1837–1848. <https://doi.org/10.1007/s00484-017-1369-2>
- Pawankar, R., Wang, J. Y., Wang, I. J., Thien, F., Chang, Y. S., Latiff, A. H. A., et al. (2020). Asia pacific association of allergy asthma and clinical immunology white paper 2020 on climate change, air pollution, and biodiversity in Asia-Pacific and impact on allergic diseases. *Asia Pac Allergy*. <https://doi.org/10.5415/apallergy.2020.10.e11>
- Pfaar, O., Bastl, K., Berger, U., Buters, J., Calderon, M. A., Clot, B., et al. (2017). Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper. *Allergy*, 72(5), 713–722. <https://doi.org/10.1111/all.13092>
- Rojo, J., Oteros, J., Picornell, A., Ruëff, F., Werchan, B., Werchan, M., et al. (2020). Land-use and height of pollen sampling affect pollen exposure in Munich, Germany. *Atmosphere*, 11(2), 145. <https://doi.org/10.3390/atmos11020145>
- Ross, M. A., Persky, V. W., Scheff, P. A., Chung, J., Curtis, L., Ramakrishnan, V., et al. (2002). Effect of ozone and aeroallergens on the respiratory health of asthmatics. *Archives of Environmental Health*, 57(6), 568–578.
- Salo, P. M., Calatroni, A., Gergen, P. J., Hoppin, J. A., Sever, M. L., Jaramillo, R., et al. (2011). Allergy-related outcomes in relation to serum IgE: results from the national health and nutrition examination survey 2005–2006. *Journal of Allergy and Clinical Immunology*, 127(5), 1226–1235.e1227. <https://doi.org/10.1016/j.jaci.2010.12.1106>
- Schappi, G. F., Suphioglu, C., Taylor, P. E., & Knox, R. B. (1997). Concentrations of the major birch tree allergen Bet v 1 in pollen and respirable fine particles in the atmosphere. *Journal of Allergy and Clinical Immunology*, 100(5), 656–661. [https://doi.org/10.1016/s0091-6749\(97\)70170-2](https://doi.org/10.1016/s0091-6749(97)70170-2)
- Schoefer, Y., Schäfer, T., Meisinger, C., Wichmann, H. E., & Heinrich, J. (2008). Predictivity of allergic sensitization (RAST) for the onset of allergic diseases in adults. *Allergy*, 63(1), 81–86. <https://doi.org/10.1111/j.1398-9995.2007.01517.x>
- Sofiev, M., & Bergmann, K. C. (2013). *Allergenic Pollen A review of the production release, distribution and health impacts*. Springer.
- Thien, F., Beggs, P. J., Csutoros, D., Darvall, J., Hew, M., Davies, J. M., et al. (2018). The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. *Lancet Planet Health*, 2(6), e255–e263. [https://doi.org/10.1016/s2542-5196\(18\)30120-7](https://doi.org/10.1016/s2542-5196(18)30120-7)

- Thurston, G. D. (1996). A critical review of PM10-mortality time-series studies. *J Expo Anal Environ Epidemiol*, 6(1), 3–21.
- Tobias, A., Galan, I., Banegas, J. R., & Aranguéz, E. (2003). Short term effects of airborne pollen concentrations on asthma epidemic. *Thorax*, 58(8), 708–710. <https://doi.org/10.1136/thorax.58.8.708>
- Villeneuve, P. J., Doiron, M. S., Stieb, D., Dales, R., Burnett, R. T., & Dugandzic, R. (2006). Is outdoor air pollution associated with physician visits for allergic rhinitis among the elderly in Toronto, Canada? *Allergy*, 61(6), 750–758. <https://doi.org/10.1111/j.1398-9995.2006.01070.x>
- Werchan, B., Werchan, M., Mücke, H. G., Gauger, U., Simoleit, A., Zuberbier, T., et al. (2017). Spatial distribution of allergenic pollen through a large metropolitan area. *Environment Monitoring Assess*, 189(4), 169. <https://doi.org/10.1007/s10661-017-5876-8>
- Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., et al. (2018). International consensus statement on allergy and rhinology: Allergic rhinitis. *Int Forum of Allergy and Rhinology*, 8(2), 108–352. <https://doi.org/10.1002/alr.22073>
- Woodruff, T. J., & Sutton, P. (2014). The Navigation Guide systematic review methodology: A rigorous and transparent method for translating environmental health science into better health outcomes. *Environment Health Perspect*, 122(10), 1007–1014. <https://doi.org/10.1289/ehp.1307175>
- Zeghnoun, A., Ravault, C., Fabres, B., Lecadet, J., Quenel, P., Thibaudon, M., et al. (2005). Short-term effects of airborne pollen on the risk of allergic rhinoconjunctivitis. *Archives Environment and Occupational Health*, 60(3), 170–176. <https://doi.org/10.3200/aeoh.60.3.170-176>
- Zhao, T., Markevych, I., Romanos, M., Nowak, D., & Heinrich, J. (2018). Ambient ozone exposure and mental health: A systematic review of epidemiological studies. *Environment Research*, 165, 459–472. <https://doi.org/10.1016/j.envres.2018.04.015>
- Zhong, W., Levin, L., Reponen, T., Hershey, G. K., Adhikari, A., Shukla, R., et al. (2006). Analysis of short-term influences of ambient aeroallergens on pediatric asthma hospital visits. *Science Total Environ*, 370(2–3), 330–336. <https://doi.org/10.1016/j.scitotenv.2006.06.019>

Title: A systematic review of threshold values of pollen concentrations for symptoms of allergy

Journal: Aerobiologia

Authors:

Nadine Steckling-Muschack^{1,2}, Hanna Mertes¹, Isabella Mittermeier³, Paul Schutzmeier¹, Jana Becker^{1,4}, Karl-Christian Bergmann^{5,6}, Stephan Böse-O'Reilly^{1,2,7}, Jeroen Buters⁸, Athanasios Damialis⁹, Joachim Heinrich^{1,10,11}, Michael Kabesch^{7,12}, Dennis Nowak^{1,10}, Sandra Walser-Reichenbach³, Alisa Weinberger³, Mihai Zamfir³, Caroline Herr^{1,3}, Susanne Kutzora³, Stefanie Heinze^{1,3}

Affiliations:

¹ Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany

² Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-Private University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center I, Hall in Tyrol 6060, Austria

³ Department for occupational and environmental medicine, Bavarian State Office for Health and Food Safety, Pfarrstr. 3, 80538 Munich, Germany

⁴ Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

⁵ Allergy-Center Charité, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Luisenstr. 2, 10117 Berlin, Germany

⁶ German Pollen Information Foundation, Robert-Koch-Platz 7, 10115 Berlin, Germany

⁷ University Children's Hospital Regensburg (KUNO-Clinics), University of Regensburg, Clinic St. Hedwig, Steinmetzstr. 1-3, 93049 Regensburg, Germany.

⁸ ZAUM, Center of Allergy & Environment, Helmholtz Center Munich/Technische Universität München, Member of the German Center for Lung Research (DZL), Biedersteiner Str. 29, 80802 Munich, Germany

⁹ Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Neusässer Str. 47 86156 Augsburg, Germany

¹⁰ Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung Research, Max-Lebsche-Platz 31, 81377 Munich, Germany

¹¹ Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, 07 Bouverie St, Carlton VIC 3053 Melbourne, Australia

¹² Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Prüfeningerstr. 21, 93049 Regensburg, Germany

Corresponding Author:

Isabella Mittermeier
Bavarian Health and Food Safety Authority
Pfarrstr. 3
80538 Munich
09131- 6808- 4292
Isabella.Mittermeier@lgl.bayern.de

Electronic Supplementary Material 1: PRISMA checklist (adapted from (Moher et al. 2009))

Section/topic	#	Checklist item	Page
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5 Table 2
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4-5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4-5 Table 1 ESM 2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5 Table 2
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4-5

Section/topic	#	Checklist item	Page
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5 Table 4 Table 5 ESM. 3
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5-6 Table 3
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6 Table 6 Table 7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).	5-6 Table 5
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot.	6-8 Table 6 Table 7 Table 8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	ESM 4
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	5-6 Table 5

Section/topic	#	Checklist item	Page
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).	8
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	11
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	8-11
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

Referenzen:

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*, 6(7), e1000097, doi:10.1371/journal.pmed.1000097.

Title: A systematic review of threshold values of pollen concentrations for symptoms of allergy

Journal: Aerobiologia

Authors:

Nadine Steckling-Muschack^{1,2}, Hanna Mertes¹, Isabella Mittermeier³, Paul Schutzmeier¹, Jana Becker^{1,4}, Karl-Christian Bergmann^{5,6}, Stephan Böse-O'Reilly^{1,2,7}, Jeroen Buters⁸, Athanasios Damialis⁹, Joachim Heinrich^{1,10,11}, Michael Kabesch^{7,12}, Dennis Nowak^{1,10}, Sandra Walser-Reichenbach³, Alisa Weinberger³, Mihai Zamfir³, Caroline Herr^{1,3}, Susanne Kutzora³, Stefanie Heinze^{1,3}

Affiliations:

¹ Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany

² Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-Private University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center I, Hall in Tyrol 6060, Austria

³ Department for occupational and environmental medicine, Bavarian State Office for Health and Food Safety, Pfarrstr. 3, 80538 Munich, Germany

⁴ Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

⁵ Allergy-Center Charité, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Luisenstr. 2, 10117 Berlin, Germany

⁶ German Pollen Information Foundation, Robert-Koch-Platz 7, 10115 Berlin, Germany

⁷ University Children's Hospital Regensburg (KUNO-Clinics), University of Regensburg, Clinic St. Hedwig, Steinmetzstr. 1-3, 93049 Regensburg, Germany.

⁸ ZAUM, Center of Allergy & Environment, Helmholtz Center Munich/Technische Universität München, Member of the German Center for Lung Research (DZL), Biedersteiner Str. 29, 80802 Munich, Germany

⁹ Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Neusässer Str. 47 86156 Augsburg, Germany

¹⁰ Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung Research, Max-Lebsche-Platz 31, 81377 Munich, Germany

¹¹ Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, 07 Bouverie St, Carlton VIC 3053 Melbourne, Australia

¹² Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Prüfeningstr. 21, 93049 Regensburg, Germany

Corresponding Author:

Isabella Mittermeier
Bavarian Health and Food Safety Authority
Pfarrstr. 3
80538 Munich
09131- 6808- 4292
Isabella.Mittermeier@lgl.bayern.de

Electronic Supplementary Material 2: Search term

Search term separated by topic

Pollen [tiab]

AND

ragweed OR Ambrosia OR "Ambrosia artemisiifolia" OR mugwort OR Artemisia OR "Artemisia vulgaris" OR birch OR Betula OR alder OR Alnus OR ash OR Fraxinus OR grass OR Poaceae OR hazel OR Corylus OR rye OR Secale

AND

"pollen threshold" OR "pollen thresholds" OR "pollen level" OR "pollen levels" OR "pollen load" OR "pollen count" OR "pollen counts" OR "pollen quantification" OR "pollen quantifications" OR "pollen concentration" OR "pollen concentrations" OR "aeroallergen concentration" OR "aeroallergen concentrations" OR "aeroallergen level" OR "aeroallergen levels" OR "atmospheric pollen counts" OR "symptom load index" OR "pollen symptom score" OR "pollen symptoms score"

AND

("pollen induced allergy" OR "pollen-associated allergic risk" OR allergy OR allergies OR "pollen allergy" OR "pollen allergies" OR "seasonal allergy" OR asthma OR "allergic asthma" OR "asthma exacerbation" OR "asthma exacerbations" OR rhinitis OR "allergic rhinitis" OR rhinoconjunctivitis OR "allergic rhinoconjunctivitis" OR conjunctivitis OR "allergic conjunctivitis" OR "conjunctival symptoms" OR "seasonal conjunctivitis" OR hayfever OR "hay fever" OR pollinosis OR rhinitis OR "seasonal rhinitis" OR "pollen-induced rhinitis" OR "allergic rhinitis" OR "seasonal allergic rhinitis" OR "allergic reaction" OR "allergic reactions" OR "allergic symptoms" OR "allergic symptoms" OR "allergic response" OR "allergic responses" OR "clinical response" OR "clinical symptoms" OR "clinical symptom" OR wheeze OR "hospital admission" OR "hospital admissions" OR "emergency department" OR "learning ability" OR "working ability" OR "working capacity" OR "allergy symptoms" OR "initiation of symptoms" OR "conjunctival symptoms" OR "nasal symptoms" OR "bronchial symptoms" OR "ocular symptoms" OR "respiratory symptoms" OR "itchy eyes" OR "itchy-watery eyes" OR "blocked nose" OR "runny blocked nose" OR "itchy nose" OR sneezing OR "itchy skin" OR wheeze OR wheezing OR "whistling in the chest" OR "shortness of breath" OR "chest tightness" OR "persistent cough" OR cough OR asthma OR "allergic symptoms" OR "atopic eczema" OR "asthma medication" OR "allergy medicines" OR "rescue medication" OR antihistamine)

AND

association OR associated OR relationship OR related OR relation OR significant OR significance OR correlation OR correlated

NOT

Animals

NOT

Placebo

Filters: english[la] OR german [la] OR french[la] OR spanish[la]

Date of search: 14th of August 2018

Search term translated into PubMed operators

Search term in pubmed translation (filter not included here):

(((((pollen[tiab] AND (((("ambrosia"[MeSH Terms] OR "ambrosia"[All Fields] OR "ragweed"[All Fields]) OR ("ambrosia"[MeSH Terms] OR "ambrosia"[All Fields]) OR "Ambrosia artemisiifolia"[All Fields] OR ("artemisia"[MeSH Terms] OR "artemisia"[All Fields] OR "mugwort"[All Fields]) OR ("artemisia"[MeSH Terms] OR "artemisia"[All Fields]) OR "Artemisia vulgaris"[All Fields] OR ("betula"[MeSH Terms] OR "betula"[All Fields] OR "birch"[All Fields]) OR ("betula"[MeSH Terms] OR "betula"[All Fields]) OR ("alnus"[MeSH Terms] OR "alnus"[All Fields] OR "alder"[All Fields]) OR ("alnus"[MeSH Terms] OR "alnus"[All Fields]) OR ash[All Fields] OR ("fraxinus"[MeSH Terms] OR "fraxinus"[All Fields]) OR ("poaceae"[MeSH Terms] OR "poaceae"[All Fields] OR "grass"[All Fields]) OR ("poaceae"[MeSH Terms] OR "poaceae"[All Fields]) OR ("corylus"[MeSH Terms] OR "corylus"[All Fields] OR "hazel"[All Fields]) OR ("corylus"[MeSH Terms] OR "corylus"[All Fields]) OR rye[All Fields] OR ("secale"[MeSH Terms] OR "secale"[All Fields])))) AND (((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND threshold[All Fields]) OR ((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND thresholds[All Fields]) OR "pollen level"[All Fields] OR "pollen levels"[All Fields] OR "pollen load"[All Fields] OR "pollen count"[All Fields] OR "pollen counts"[All Fields] OR ((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND quantification[All Fields]) OR ((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND quantifications[All Fields]) OR "pollen concentration"[All Fields] OR "pollen concentrations"[All Fields] OR "aeroallergen concentration"[All Fields] OR "aeroallergen concentrations"[All Fields] OR "aeroallergen level"[All Fields] OR "aeroallergen levels"[All Fields] OR "atmospheric pollen counts"[All Fields] OR "symptom load index"[All Fields] OR ((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND symptom[All Fields] AND score[All Fields]) OR ((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "symptoms"[All Fields] OR "diagnosis"[MeSH Terms] OR "symptoms"[All Fields]) AND score[All Fields])))) AND ("pollen induced allergy"[All Fields] OR ("Psychopathol Rev"[Journal] OR "Pharmacol Rep"[Journal] OR "Pharmacognosy Res"[Journal] OR "Partis Rev"[Journal] OR "pr"[All Fields]) AND (pollen-associated[All Fields] AND allergic[All Fields] AND ("risk"[MeSH Terms] OR "risk"[All Fields])) OR ("hypersensitivity"[MeSH Terms] OR "hypersensitivity"[All Fields] OR "allergy"[All Fields] OR "allergy and immunology"[MeSH Terms] OR ("allergy"[All Fields] AND "immunology"[All Fields]) OR "allergy and immunology"[All Fields]) OR ("hypersensitivity"[MeSH Terms] OR "hypersensitivity"[All Fields] OR "allergies"[All Fields]) OR "pollen allergy"[All Fields] OR "pollen allergies"[All Fields] OR "seasonal allergy"[All Fields] OR ("asthma"[MeSH Terms] OR "asthma"[All Fields]) OR "allergic asthma"[All Fields] OR "asthma exacerbation"[All Fields] OR "asthma exacerbations"[All Fields] OR ("rhinitis"[MeSH Terms] OR "rhinitis"[All Fields]) OR "allergic rhinitis"[All Fields] OR rhinoconjunctivitis[All Fields] OR "allergic rhinoconjunctivitis"[All Fields] OR ("conjunctivitis"[MeSH Terms] OR "conjunctivitis"[All Fields]) OR "allergic conjunctivitis"[All Fields] OR "conjunctival symptoms"[All Fields] OR "seasonal conjunctivitis"[All Fields] OR ("rhinitis, allergic, seasonal"[MeSH Terms] OR ("rhinitis"[All Fields] AND "allergic"[All Fields] AND "seasonal"[All Fields]) OR "seasonal allergic rhinitis"[All Fields] OR "hayfever"[All Fields]) OR "hay fever"[All Fields] OR ("rhinitis, allergic, seasonal"[MeSH Terms] OR ("rhinitis"[All Fields] AND "allergic"[All Fields] AND "seasonal"[All Fields]) OR "seasonal allergic rhinitis"[All Fields] OR "pollinosis"[All Fields]) OR ("rhinitis"[MeSH Terms] OR "rhinitis"[All Fields]) OR "seasonal rhinitis"[All Fields] OR "pollen-induced rhinitis"[All Fields] OR "allergic rhinitis"[All Fields] OR "seasonal allergic rhinitis"[All Fields] OR "allergic reaction"[All Fields] OR "allergic reactions"[All Fields] OR "allergic symptoms"[All Fields] OR "allergic symptoms"[All Fields] OR "allergic response"[All Fields] OR "allergic responses"[All Fields] OR "clinical response"[All Fields] OR "clinical symptoms"[All Fields] OR "clinical symptom"[All Fields] OR ("respiratory sounds"[MeSH Terms] OR ("respiratory"[All Fields] AND "sounds"[All Fields]) OR "respiratory sounds"[All Fields] OR "wheeze"[All Fields]) OR "hospital admission"[All Fields] OR "hospital admissions"[All Fields] OR "emergency department"[All Fields] OR "learning ability"[All Fields] OR "working ability"[All Fields] OR "working capacity"[All Fields] OR "allergy symptoms"[All Fields] OR (initiation[All Fields] AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "symptoms"[All Fields] OR "diagnosis"[MeSH Terms] OR "symptoms"[All Fields])) OR "conjunctival symptoms"[All Fields] OR "nasal symptoms"[All Fields] OR "bronchial symptoms"[All Fields] OR "ocular symptoms"[All Fields] OR "respiratory symptoms"[All Fields] OR "itchy eyes"[All Fields] OR "itchy-watery eyes"[All Fields] OR "blocked nose"[All Fields] OR (runny[All Fields] AND ("nasal obstruction"[MeSH Terms] OR ("nasal"[All Fields] AND "obstruction"[All Fields]) OR "nasal obstruction"[All Fields] OR ("blocked"[All Fields] AND "nose"[All Fields]) OR "blocked nose"[All Fields])) OR "itchy nose"[All Fields] OR ("sneezing"[MeSH Terms] OR "sneezing"[All Fields]) OR "itchy skin"[All Fields] OR ("respiratory sounds"[MeSH Terms] OR ("respiratory"[All Fields] AND "sounds"[All Fields]) OR respiratory sounds[All Fields] OR "wheeze"[All Fields]) OR ("respiratory sounds"[MeSH Terms]

OR ("respiratory"[All Fields] AND "sounds"[All Fields]) OR "respiratory sounds"[All Fields] OR "wheezing"[All Fields] OR (("singing"[MeSH Terms] OR "singing"[All Fields] OR "whistling"[All Fields]) AND ("thorax"[MeSH Terms] OR "thorax"[All Fields] OR "chest"[All Fields])) OR "shortness of breath"[All Fields] OR "chest tightness"[All Fields] OR "persistent cough"[All Fields] OR ("cough"[MeSH Terms] OR "cough"[All Fields]) OR ("asthma"[MeSH Terms] OR "asthma"[All Fields]) OR "allergic symptoms"[All Fields] OR "atopic eczema"[All Fields] OR "asthma medication"[All Fields] OR (("hypersensitivity"[MeSH Terms] OR "hypersensitivity"[All Fields] OR "allergy"[All Fields] OR "allergy and immunology"[MeSH Terms] OR ("allergy"[All Fields] AND "immunology"[All Fields]) OR "allergy and immunology"[All Fields]) AND ("Medicines (Basel)"[Journal] OR "medicines"[All Fields])) OR "rescue medication"[All Fields] OR ("histamine h1 antagonists"[Pharmacological Action] OR "histamine h1 antagonists"[MeSH Terms] OR ("histamine"[All Fields] AND "h1"[All Fields] AND "antagonists"[All Fields]) OR "histamine h1 antagonists"[All Fields] OR "antihistamine"[All Fields])) AND (("association"[MeSH Terms] OR "association"[All Fields]) OR associated[All Fields] OR relationship[All Fields] OR related[All Fields] OR ("family"[MeSH Terms] OR "family"[All Fields] OR "relation"[All Fields]) OR significant[All Fields] OR ("Signif (Oxf)"[Journal] OR "significance"[All Fields]) OR correlation[All Fields] OR correlated[All Fields])) NOT ("animals"[MeSH Terms:noexp] OR animals[All Fields]) NOT ("placebos"[MeSH Terms] OR "placebos"[All Fields] OR "placebo"[All Fields])

Later addition to the search term separated by topic

Pollen [tiab]

AND

ragweed OR Ambrosia OR "Ambrosia artemisiifolia" OR mugwort OR Artemisia OR "Artemisia vulgaris" OR birch OR Betula OR alder OR Alnus OR ash OR Fraxinus OR grass OR Poaceae OR hazel OR Corylus OR rye OR Secale

AND

"pollen threshold" OR "pollen thresholds" OR "pollen level" OR "pollen levels" OR "pollen load" OR "pollen count" OR "pollen counts" OR "pollen quantification" OR "pollen quantifications" OR "pollen concentration" OR "pollen concentrations" OR "aeroallergen concentration" OR "aeroallergen concentrations" OR "aeroallergen level" OR "aeroallergen levels" OR "atmospheric pollen counts" OR "symptom load index" OR "pollen symptom score" OR "pollen symptoms score"

AND

("drug consumption")

AND

association OR associated OR relationship OR related OR relation OR significant OR significance OR correlation OR correlated

NOT

Animals

NOT

Placebo

Filters: english[la] OR german [la] OR french[la] OR spanish[la]

Date of search: 14th of August 2018

Later addition search term translated into PubMed operators

(((((pollen[tiab] AND (("ambrosia"[MeSH Terms] OR "ambrosia"[All Fields] OR "ragweed"[All Fields]) OR ("ambrosia"[MeSH Terms] OR "ambrosia"[All Fields]) OR "Ambrosia artemisiifolia"[All Fields] OR ("artemisia"[MeSH Terms] OR "artemisia"[All Fields] OR "mugwort"[All Fields]) OR ("artemisia"[MeSH Terms] OR "artemisia"[All Fields]) OR "Artemisia vulgaris"[All Fields] OR ("betula"[MeSH Terms] OR "betula"[All Fields] OR "birch"[All Fields]) OR ("betula"[MeSH Terms] OR "betula"[All Fields]) OR ("alnus"[MeSH Terms] OR "alnus"[All Fields] OR "alder"[All Fields]) OR ("alnus"[MeSH Terms] OR "alnus"[All Fields]) OR ash[All Fields] OR ("fraxinus"[MeSH Terms] OR "fraxinus"[All Fields]) OR ("poaceae"[MeSH Terms] OR "poaceae"[All Fields] OR "grass"[All Fields]) OR ("poaceae"[MeSH Terms] OR "poaceae"[All Fields]) OR ("corylus"[MeSH Terms] OR "corylus"[All Fields] OR "hazel"[All Fields]) OR ("corylus"[MeSH Terms] OR "corylus"[All Fields]) OR rye[All Fields] OR ("secale"[MeSH Terms] OR "secale"[All Fields])))) AND (((("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND threshold[All Fields]) OR (("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND thresholds[All Fields]) OR "pollen level"[All Fields] OR "pollen levels"[All Fields] OR "pollen load"[All Fields] OR "pollen count"[All Fields] OR "pollen counts"[All Fields] OR (("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND quantification[All Fields]) OR (("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND quantifications[All Fields]) OR "pollen concentration"[All Fields] OR "pollen concentrations"[All Fields] OR "aeroallergen concentration"[All Fields] OR "aeroallergen concentrations"[All Fields] OR "aeroallergen level"[All Fields] OR "aeroallergen levels"[All Fields] OR "atmospheric pollen counts"[All Fields] OR "symptom load index"[All Fields] OR (("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND symptom[All Fields] AND score[All Fields]) OR (("pollen"[MeSH Terms] OR "pollen"[All Fields]) AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "symptoms"[All Fields] OR "diagnosis"[MeSH Terms] OR "symptoms"[All Fields]) AND score[All Fields])))) AND ("drug consumption")))) AND (("association"[MeSH Terms] OR "association"[All Fields]) OR associated[All Fields] OR relationship[All Fields] OR related[All Fields] OR ("family"[MeSH Terms] OR "family"[All Fields] OR "relation"[All Fields]) OR significant[All Fields] OR ("Signif (Oxf)"[Journal] OR "significance"[All Fields]) OR correlation[All Fields] OR correlated[All Fields])) NOT ("animals"[MeSH Terms:noexp] OR animals[All Fields])) NOT ("placebos"[MeSH Terms] OR "placebos"[All Fields] OR "placebo"[All Fields])

PubMed hits of search

- 1: Geller-Bernstein C, Portnoy JM. The Clinical Utility of Pollen Counts. Clin Rev Allergy Immunol. 2018 Jul 24. doi: 10.1007/s12016-018-8698-8. [Epub ahead of print] Review. PubMed PMID: 30043255.

- 2: Susanto NH, Schoos AM, Standl M, Lowe AJ, Dharmage SC, Svanes C, Salim A, von Berg A, Lehmann I, Rasmussen MA, Werchan M, Bergmann KC, Lodge C, Abramson MJ, Heinrich J, Bisgaard H, Erbas B. Environmental grass pollen levels in utero and at birth and cord blood IgE: Analysis of three birth cohorts. Environ Int. 2018 Jul 6;119:295-301. doi: 10.1016/j.envint.2018.06.036. [Epub ahead of print] PubMed PMID: 29990949.

- 3: Shrestha SK, Katelaris C, Dharmage SC, Burton P, Vicendese D, Tham R, Abramson MJ, Erbas B. High ambient levels of grass, weed and other pollen are associated with asthma admissions in children and adolescents: A large 5-year case-crossover study. Clin Exp Allergy. 2018 Jul 5. doi: 10.1111/cea.13225. [Epub ahead of print] PubMed PMID: 29975808.

- 4: Agnew M, Banic I, Lake IR, Goodess C, Grossi CM, Jones NR, Plavec D, Epstein M, Turkalj M. Modifiable Risk Factors for Common Ragweed (*Ambrosia artemisiifolia*) Allergy and Disease in Children: A Case-Control Study. Int J Environ Res Public Health. 2018 Jun 26;15(7). pii: E1339. doi: 10.3390/ijerph15071339. PubMed PMID: 29949854; PubMed Central PMCID: PMC6069153.

- 5: Vörös K, Bobvos J, Varró JM, Málnási T, Kói T, Magyar D, Rudnai P, Páldy A. Impacts of long-term ragweed pollen load and other potential risk factors on ragweed pollen allergy among schoolchildren in Hungary. Ann Agric Environ Med. 2018 Jun 20;25(2):307-313. doi: 10.26444/aaem/82624. Epub 2018 Mar 7. PubMed PMID: 29936806.

- 6: Thien F, Beggs PJ, Csutoros D, Darvall J, Hew M, Davies JM, Bardin PG, Bannister T, Barnes S, Bellomo R, Byrne T, Casamento A, Conron M, Cross A, Crosswell A, Douglass JA, Durie M, Dyett J, Ebert E, Erbas B, French C, Gelbart B, Gillman A, Harun NS, Huete A, Irving L, Karalapillai D, Ku D, Lachapelle P, Langton D, Lee J, Looker C, MacIsaac C, McCaffrey J, McDonald CF, McGain F, Newbiggin E, O'Hehir R, Pilcher D, Prasad S, Rangamuwa K, Ruane L, Sarode V, Silver JD, Southcott AM, Subramaniam A, Suphioglu C, Susanto NH, Sutherland MF, Taori G, Taylor P, Torre P, Vetro J, Wigmore G, Young AC, Guest C. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planet Health. 2018 Jun;2(6):e255-e263. doi: 10.1016/S2542-5196(18)30120-7. PubMed PMID: 29880157.

- 7: Karatzas K, Katsifarakis N, Riga M, Werchan B, Werchan M, Berger U, Pfaar O, Bergmann KC. New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis. Allergy. 2018 May 23. doi: 10.1111/all.13487. [Epub ahead of print] PubMed PMID: 29791010.

- 8: Motruk II, Antomonov MY, Rodinkova VV, Aleksandrova OE, Yermishev OV. Allergenic weed pollen forecast under the mathematical modeling method implementation in ukraine. Wiad Lek. 2018;71(3 pt 1):592-598. PubMed PMID:

29783231.

9: Pfaar O, Claßen DP, Astvatsatourov A, Klimek L, Mösges R. Reliability of a New Symptom Score in a Titrated Quantitative Conjunctival Provocation Test Supported by an Objective Photodocumentation. *Int Arch Allergy Immunol*. 2018;176(3-4):215-224. doi: 10.1159/000487884. Epub 2018 May 16. PubMed PMID: 29768274.

10: Silver JD, Sutherland MF, Johnston FH, Lampugnani ER, McCarthy MA, Jacobs SJ, Pezza AB, Newbigin EJ. Seasonal asthma in Melbourne, Australia, and some observations on the occurrence of thunderstorm asthma and its predictability. *PLoS One*. 2018 Apr 12;13(4):e0194929. doi: 10.1371/journal.pone.0194929. eCollection 2018. PubMed PMID: 29649224; PubMed Central PMCID: PMC5896915.

11: Guilbert A, Cox B, Bruffaerts N, Hoebeke L, Packeu A, Hendrickx M, De Cremer K, Bladt S, Brasseur O, Van Nieuwenhuysse A. Relationships between aeroallergen levels and hospital admissions for asthma in the Brussels-Capital Region: a daily time series analysis. *Environ Health*. 2018 Apr 11;17(1):35. doi: 10.1186/s12940-018-0378-x. PubMed PMID: 29642904; PubMed Central PMCID: PMC5896062.

12: Rogol AD, Tkachenko N, Badorrek P, Hohlfeld JM, Bryson N. Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies. *Can Urol Assoc J*. 2018 Jul;12(7):E349-E356. doi: 10.5489/cuaj.4898. Epub 2018 Mar 19. PubMed PMID: 29603916.

13: Zielen S, Gabrielpillai J, Herrmann E, Schulze J, Schubert R, Rosewich M. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. *Immunotherapy*. 2018 Jun;10(7):529-536. doi: 10.2217/imt-2018-0004. Epub 2018 Mar 22. PubMed PMID: 29562801.

14: Erbas B, Jazayeri M, Lambert KA, Katelaris CH, Prendergast LA, Tham R, Parrodi MJ, Davies J, Newbigin E, Abramson MJ, Dharmage SC. Outdoor pollen is a trigger of child and adolescent asthma emergency department presentations: A systematic review and meta-analysis. *Allergy*. 2018 Aug;73(8):1632-1641. doi: 10.1111/all.13407. Epub 2018 Mar 2. Review. PubMed PMID: 29331087.

15: Wang XY, Ma TT, Wang XY, Zhuang Y, Wang XD, Ning HY, Shi HY, Yu RL, Yan D, Huang HD, Bai YF, Shan GL, Zhang B, Song QK, Zhang YF, Zhang TJ, Jia DZ, Liu XL, Kang ZX, Yan WJ, Yang BT, Bao XZ, Sun SH, Zhang FF, Yu WH, Bai CL, Wei T, Yang T, Ma TQ, Wu XB, Liu JG, Du H, Zhang L, Yan Y, Wang DY. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. *Allergy*. 2018 Jun;73(6):1232-1243. doi: 10.1111/all.13388. Epub 2018 Mar 23. PubMed PMID: 29322523; PubMed Central PMCID: PMC6033040.

16: Brüggjenjürgen B, Reinhold T. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland. *J Med Econ*. 2018 Apr;21(4):374-381. doi: 10.1080/13696998.2017.1419959. Epub 2018 Jan 8. PubMed PMID: 29271271.

17: Qin X, Li Y, Sun X, Meng L, Wang X. Transport pathway and source area for *Artemisia* pollen in Beijing, China. *Int J Biometeorol*. 2017 Dec 13. doi: 10.1007/s00484-017-1467-1. [Epub ahead of print] PubMed PMID: 29236152.

18: Antolín-Amerigo D, Tabar IA, Del Mar Fernández-Nieto M, Callejo-Melgosa AM, Muñoz-Bellido FJ, Martínez-Alonso JC, Méndez-Alcalde JD, Reche M, Rodríguez-Trabado A, Rosado-Ingelmo A, Alonso-Gómez A, Blanco-González R, Alvarez-Fernandez JA, Botella I, Valls A, Cimarra M, Blanco C. Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain. *Drugs Context*. 2017 Nov 29;6:212309. doi: 10.7573/dic.212309. eCollection 2017. PubMed PMID: 29225657; PubMed Central PMCID: PMC5710189.

19: Brier S, Le Mignon M, Jain K, Lebrun C, Peurois F, Kellenberger C, Bordas-Le Floch V, Mascarell L, Nony E, Moingeon P. Characterization of epitope specificities of reference antibodies used for the quantification of the birch pollen allergen Bet v 1. *Allergy*. 2018 May;73(5):1032-1040. doi: 10.1111/all.13364. Epub 2017 Dec 12. PubMed PMID: 29171882.

20: Müller-Germann I, Pickersgill DA, Paulsen H, Alberternst B, Pöschl U, Fröhlich-Nowoisky J, Després VR. Allergenic Asteraceae in air particulate matter: quantitative DNA analysis of mugwort and ragweed. *Aerobiologia (Bologna)*. 2017;33(4):493-506. doi: 10.1007/s10453-017-9485-3. Epub 2017 Jun 6. PubMed PMID: 29167600; PubMed Central PMCID: PMC5674138.

21: Grundström M, Dahl Å, Ou T, Chen D, Pleijel H. The relationship between birch pollen, air pollution and weather types and their effect on antihistamine purchase in two Swedish cities. *Aerobiologia (Bologna)*. 2017;33(4):457-471. doi: 10.1007/s10453-017-9478-2. Epub 2017 Apr 6. PubMed PMID: 29167598; PubMed Central PMCID: PMC5674136.

22: Bruffaerts N, De Smedt T, Delcloo A, Simons K, Hoebeke L, Verstraeten C, Van Nieuwenhuysse A, Packeu A, Hendrickx M. Comparative long-term trend analysis of daily weather conditions with daily pollen concentrations in Brussels, Belgium. *Int J Biometeorol*. 2018 Mar;62(3):483-491. doi: 10.1007/s00484-017-1457-3. Epub 2017 Oct 24. PubMed PMID: 29064036; PubMed Central PMCID: PMC5854748.

23: Albertini R, Ugolotti M, Ghillani L, Adorni M, Vitali P, Signorelli C, Pasquarella C. Aerobiological monitoring and mapping of Ambrosia plants in the province of Parma (northern Italy, southern Po valley), a useful tool for targeted preventive measures. *Ann Ig*. 2017 Nov-Dec;29(6):515-528. doi: 10.7416/ai.2017.2182. PubMed PMID: 29048450.

24: Katotomichelakis M, Iliou T, Karvelis I, Giotakis E, Daniilides G, Erkotidou E, Lazaridis C, Anastassopoulos GK. Symptomatology Patterns in Children with Allergic Rhinitis. *Med Sci Monit*. 2017 Oct 16;23:4939-4946. PubMed PMID: 29033449; PubMed Central PMCID: PMC5654957.

25: Hugg TT, Hjort J, Antikainen H, Rusanen J, Tuokila M, Korkkonen S, Weckström J, Jaakkola MS, Jaakkola JJK. Urbanity as a determinant of exposure to grass pollen in Helsinki Metropolitan area, Finland. *PLoS One*. 2017 Oct 12;12(10):e0186348. doi: 10.1371/journal.pone.0186348. eCollection 2017. PubMed PMID: 29023565; PubMed Central PMCID: PMC5638505.

26: Olaniyan T, Jeebhay M, Rösli M, Naidoo R, Baatjies R, Künzli N, Tsai M, Davey M, de Hoogh K, Berman D, Parker B, Leaner J, Dalvie MA. A prospective

cohort study on ambient air pollution and respiratory morbidities including childhood asthma in adolescents from the western Cape Province: study protocol. BMC Public Health. 2017 Sep 16;17(1):712. doi: 10.1186/s12889-017-4726-5. PubMed PMID: 28915873; PubMed Central PMCID: PMC5602849.

27: Spiric J, Schulenburg T, Schwaben L, Engin AM, Karas M, Reuter A. Model for Quality Control of Allergen Products with Mass Spectrometry. J Proteome Res. 2017 Oct 6;16(10):3852-3862. doi: 10.1021/acs.jproteome.7b00490. Epub 2017 Aug 29. PubMed PMID: 28821210.

28: So HJ, Moon SJ, Hwang SY, Kim JH, Jang HJ, Jo JH, Sung TJ, Lim DH. Characteristics of airborne pollen in Incheon and Seoul (2015-2016). Asia Pac Allergy. 2017 Jul;7(3):138-147. doi: 10.5415/apallergy.2017.7.3.138. Epub 2017 Jul 26. PubMed PMID: 28765818; PubMed Central PMCID: PMC5537078.

29: Ciprandi G, Scala E, Ariano R; AAIITO Study Group on Pollen Allergy; Laboratory Study Group on Pollen Sensitization. Phleum pratense molecular pattern across Italy. Eur Ann Allergy Clin Immunol. 2017 Jul;49(4):176-180. PubMed PMID: 28752721.

30: Pfaar O, Lang S, Pieper-Fürst U, Astvatsatourov A, Gerich F, Klimek L, Kramer MF, Reydelet Y, Shah-Hosseini K, Mösges R. Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis. Allergy. 2018 Jan;73(1):187-195. doi: 10.1111/all.13240. Epub 2017 Sep 5. PubMed PMID: 28675499; PubMed Central PMCID: PMC5763416.

31: Sikoparija B, Skjøth CA, Celenk S, Testoni C, Abramidze T, Alm Kübler K, Belmonte J, Berger U, Bonini M, Charalampopoulos A, Damialis A, Clot B, Dahl Å, de Weger LA, Gehrig R, Hendrickx M, Hoebeke L, Ianovici N, Kofol Seliger A, Magyar D, Mányoki G, Milkovska S, Myszkowska D, Páldy A, Pashley CH, Rasmussen K, Ritenberga O, Rodinkova V, Rybníček O, Shalaboda V, Šaulienė I, Ščevková J, Stjepanović B, Thibaudon M, Verstraeten C, Vokou D, Yankova R, Smith M. Spatial and temporal variations in airborne Ambrosia pollen in Europe. Aerobiologia (Bologna). 2017;33(2):181-189. doi: 10.1007/s10453-016-9463-1. Epub 2016 Nov 17. PubMed PMID: 28579673; PubMed Central PMCID: PMC5432595.

32: García-Mozo H. Poaceae pollen as the leading aeroallergen worldwide: A review. Allergy. 2017 Dec;72(12):1849-1858. doi: 10.1111/all.13210. Epub 2017 Jun 20. Review. PubMed PMID: 28543717.

33: Osborne NJ, Alcock I, Wheeler BW, Hajat S, Sarran C, Clewlow Y, McInnes RN, Hemming D, White M, Vardoulakis S, Fleming LE. Pollen exposure and hospitalization due to asthma exacerbations: daily time series in a European city. Int J Biometeorol. 2017 Oct;61(10):1837-1848. doi: 10.1007/s00484-017-1369-2. Epub 2017 May 12. PubMed PMID: 28500390; PubMed Central PMCID: PMC5643363.

34: Shah-Hosseini K, Krudewig EM, Hadler M, Karagiannis E, Mösges R. Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study. Adv Ther. 2017 Jun;34(6):1382-1397. doi: 10.1007/s12325-017-0535-6. Epub 2017 Apr 28. PubMed PMID: 28455783; PubMed Central PMCID: PMC5487874.

35: di Coste A, Occasi F, De Castro G, Zicari AM, Galandrini R, Giuffrida A,

Indinnimeo L, Duse M. Predictivity of clinical efficacy of sublingual immunotherapy (SLIT) based on sensitisation pattern to molecular allergens in children with allergic rhinoconjunctivitis. *Allergol Immunopathol (Madr)*. 2017 Sep - Oct;45(5):452-456. doi: 10.1016/j.aller.2017.01.001. Epub 2017 Apr 11. PubMed PMID: 28410874.

36: Kruczek A, Puc M, Wolski T. Poaceae, Secale spp. and Artemisia spp. pollen in the air at two sites of different degrees of urbanisation. *Ann Agric Environ Med*. 2017 Mar 21;24(1):70-74. doi: 10.5604/12321966.1233895. PubMed PMID: 28378978.

37: Singh N, Singh U, Singh D, Daya M, Singh V. Correlation of pollen counts and number of hospital visits of asthmatic and allergic rhinitis patients. *Lung India*. 2017 Mar-Apr;34(2):127-131. doi: 10.4103/0970-2113.201313. PubMed PMID: 28360459; PubMed Central PMCID: PMC5351353.

38: Badorrek P, Müller M, Koch W, Hohlfeld JM, Krug N. Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure. *Ann Allergy Asthma Immunol*. 2017 Mar;118(3):290-297. doi: 10.1016/j.anai.2017.01.018. PubMed PMID: 28284536.

39: Celenk S, Malyer H. The occurrence of Ambrosia pollen in the atmosphere of Northwest Turkey: investigation of possible source regions. *Int J Biometeorol*. 2017 Aug;61(8):1499-1510. doi: 10.1007/s00484-017-1328-y. Epub 2017 Feb 28. PubMed PMID: 28243727.

40: Di Berardino F, Zanetti D, D'Amato G. Nasal rinsing with an atomized spray improves mucociliary clearance and clinical symptoms during peak grass pollen season. *Am J Rhinol Allergy*. 2017 Jan 26;31(1):40-43. doi: 10.2500/ajra.2016.30.4383. PubMed PMID: 28234152.

41: Bergmann KC, Sehlinger T, Gildemeister J, Zuberbier T. A novel experimental technology for testing efficacy of air purifiers on pollen reduction. *Allergo J Int*. 2017;26(1):1-6. doi: 10.1007/s40629-016-0001-z. Epub 2016 Nov 16. PubMed PMID: 28217431; PubMed Central PMCID: PMC5288418.

42: Marchetti P, Pesce G, Villani S, Antonicelli L, Ariano R, Attena F, Bono R, Bellisario V, Fois A, Gibelli N, Nicolis M, Olivieri M, Pirina P, Scopano E, Siniscalco C, Verlato G, Marcon A. Pollen concentrations and prevalence of asthma and allergic rhinitis in Italy: Evidence from the GEIRD study. *Sci Total Environ*. 2017 Apr 15;584-585:1093-1099. doi: 10.1016/j.scitotenv.2017.01.168. Epub 2017 Feb 4. PubMed PMID: 28169023.

43: Maya-Manzano JM, Sadyś M, Tormo-Molina R, Fernández-Rodríguez S, Oteros J, Silva-Palacios I, Gonzalo-Garijo A. Relationships between airborne pollen grains, wind direction and land cover using GIS and circular statistics. *Sci Total Environ*. 2017 Apr 15;584-585:603-613. doi: 10.1016/j.scitotenv.2017.01.085. Epub 2017 Jan 27. PubMed PMID: 28132776.

44: Jacobs RL, Ramirez DA, Rather CG, Andrews CP, Jupiter DC, Trujillo F, Shulman DG. Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. *Ann Allergy Asthma Immunol*. 2017 Jan;118(1):86-93.e2. doi: 10.1016/j.anai.2016.10.023. PubMed PMID: 28007090.

- 45: Smiljanic K, Apostolovic D, Trifunovic S, Ognjenovic J, Perusko M, Mihajlovic L, Burazer L, van Hage M, Cirkovic Velickovic T. Subpollen particles are rich carriers of major short ragweed allergens and NADH dehydrogenases: quantitative proteomic and allergomic study. *Clin Exp Allergy*. 2017 Jun;47(6):815-828. doi: 10.1111/cea.12874. Epub 2017 Jan 19. PubMed PMID: 28000951.
- 46: Süring K, Bach S, Höflich C, Straff W. Flow Cytometric Analysis of Particle-bound Bet v 1 Allergen in PM10. *J Vis Exp*. 2016 Nov 19;(117). doi: 10.3791/54721. PubMed PMID: 27911374; PubMed Central PMCID: PMC5226252.
- 47: Khwarahm NR, Dash J, Skjøth CA, Newnham RM, Adams-Groom B, Head K, Caulton E, Atkinson PM. Mapping the birch and grass pollen seasons in the UK using satellite sensor time-series. *Sci Total Environ*. 2017 Feb 1;578:586-600. doi: 10.1016/j.scitotenv.2016.11.004. Epub 2016 Nov 14. PubMed PMID: 27856057.
- 48: Devillier P, Bousquet J, Salvator H, Naline E, Grassin-Delyle S, de Beaumont O. In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures. *Clin Exp Allergy*. 2016 Nov;46(11):1456-1464. doi: 10.1111/cea.12801. Epub 2016 Oct 10. PubMed PMID: 27562177.
- 49: Ellis AK, Soliman M, Steacy LM, Adams DE, Hobsbawn B, Walker TJ. Clinical validation of controlled exposure to birch pollen in the Environmental Exposure Unit (EEU). *Allergy Asthma Clin Immunol*. 2016 Oct 19;12:53. eCollection 2016. PubMed PMID: 27777594; PubMed Central PMCID: PMC5069953.
- 50: Jeon-Slaughter H, Claassen CA, Khan DA, Mihalakos P, Lee KB, Brown ES. Temporal Association Between Nonfatal Self-Directed Violence and Tree and Grass Pollen Counts. *J Clin Psychiatry*. 2016 Sep;77(9):1160-1167. doi: 10.4088/JCP.15m09864. PubMed PMID: 27314288.
- 51: Stępańska D, Myszkowska D, Katarzyna L, Katarzyna P, Katarzyna B, Kazimiera C, Łukasz G, Idalia K, Barbara MW, Małgorzata M, Małgorzata N, Krystyna PW, Małgorzata P, Elżbieta WC. Co-occurrence of Artemisia and Ambrosia pollen seasons against the background of the synoptic situations in Poland. *Int J Biometeorol*. 2017 Apr;61(4):747-760. doi: 10.1007/s00484-016-1254-4. Epub 2016 Oct 8. PubMed PMID: 27722901; PubMed Central PMCID: PMC5378757.
- 52: Tagawa Y, Namba K, Nakazono Y, Iwata D, Ishida S. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis. *Allergol Int*. 2017 Apr;66(2):338-343. doi: 10.1016/j.alit.2016.08.011. Epub 2016 Oct 6. PubMed PMID: 27720602.
- 53: Navares R, Aznarte JL. Predicting the Poaceae pollen season: six month-ahead forecasting and identification of relevant features. *Int J Biometeorol*. 2017 Apr;61(4):647-656. doi: 10.1007/s00484-016-1242-8. Epub 2016 Sep 16. PubMed PMID: 27633563.
- 54: Nowosad J, Stach A, Kasprzyk I, Weryszko-Chmielewska E, Piotrowska-Weryszko K, Puc M, Grewling Ł, Pędziszewska A, Uruska A, Myszkowska D, Chłopek K, Majkowska-Wojciechowska B. Forecasting model of Corylus, Alnus, and Betula pollen concentration levels using spatiotemporal correlation properties of pollen count.

Aerobiologia (Bologna). 2016;32(3):453-468. Epub 2015 Dec 14. PubMed PMID: 27616811; PubMed Central PMCID: PMC4996891.

55: Malkiewicz M, Drzeniecka-Osiadacz A, Krynicka J. The dynamics of the *Corylus*, *Alnus*, and *Betula* pollen seasons in the context of climate change (SW Poland). *Sci Total Environ*. 2016 Dec 15;573:740-750. doi: 10.1016/j.scitotenv.2016.08.103. Epub 2016 Aug 31. PubMed PMID: 27591524.

56: Wölbing F, Kunz J, Kempf WE, Grimm C, Fischer J, Biedermann T. The clinical relevance of birch pollen profilin cross-reactivity in sensitized patients. *Allergy*. 2017 Apr;72(4):562-569. doi: 10.1111/all.13040. Epub 2016 Sep 28. PubMed PMID: 27588729.

57: Sun L, Xu Y, Wang Y, Lou Y, Xu Y, Guo Y. Species and quantity of airborne pollens in Shanghai as monitored by gravitational and volumetric methods. *Asian Pac J Allergy Immunol*. 2017 Mar;35(1):38-45. doi: 10.12932/AP0743. PubMed PMID: 27543732.

58: Duman H, Bostanci I, Ozmen S, Dogru M. The Relevance of Nasal Provocation Testing in Children with Nonallergic Rhinitis. *Int Arch Allergy Immunol*. 2016;170(2):115-21. doi: 10.1159/000447635. Epub 2016 Jul 30. PubMed PMID: 27475650.

59: Bogawski P, Grewling Ł, Frątczak A. Flowering phenology and potential pollen emission of three *Artemisia* species in relation to airborne pollen data in Poznań (Western Poland). *Aerobiologia (Bologna)*. 2016;32:265-276. Epub 2015 Jul 17. PubMed PMID: 27340330; PubMed Central PMCID: PMC4871921.

60: Kmenta M, Bastl K, Kramer MF, Hewings SJ, Mwange J, Zetter R, Berger U. The grass pollen season 2014 in Vienna: A pilot study combining phenology, aerobiology and symptom data. *Sci Total Environ*. 2016 Oct 1;566-567:1614-1620. doi: 10.1016/j.scitotenv.2016.06.059. Epub 2016 Jun 15. PubMed PMID: 27317132.

61: Larenas-Linnemann D. How does the efficacy and safety of Oralair® compare to other products on the market? *Ther Clin Risk Manag*. 2016 May 27;12:831-50. doi: 10.2147/TCRM.S70363. eCollection 2016. Review. PubMed PMID: 27313458; PubMed Central PMCID: PMC4892828.

62: Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study. *Clin Transl Allergy*. 2016 May 25;6:19. doi: 10.1186/s13601-016-0107-x. eCollection 2016. PubMed PMID: 27231527; PubMed Central PMCID: PMC4880857.

63: Fahey L, Robinson G, Weinberger K, Giambrone AE, Solomon AB. Correlation Between Aeroallergen Levels and New Diagnosis of Eosinophilic Esophagitis in New York City. *J Pediatr Gastroenterol Nutr*. 2017 Jan;64(1):22-25. doi: 10.1097/MPG.0000000000001245. PubMed PMID: 27111345; PubMed Central PMCID: PMC5074923.

64: Witting Christensen SK, Krohn IK, Thuraiiah J, Skjold T, Schmid JM, Hoffmann HJH. Increasing time interval and decreasing allergen dose interval

improves ex vivo desensitization of human blood basophils. *Cytometry B Clin Cytom.* 2017 Sep;92(5):340-347. doi: 10.1002/cyto.b.21377. Epub 2016 May 24. PubMed PMID: 27071698.

65: Gilles-Stein S, Beck I, Chaker A, Bas M, McIntyre M, Cifuentes L, Petersen A, Gutermuth J, Schmidt-Weber C, Behrendt H, Traidl-Hoffmann C. Pollen derived low molecular compounds enhance the human allergen specific immune response in vivo. *Clin Exp Allergy.* 2016 Oct;46(10):1355-65. doi: 10.1111/cea.12739. Epub 2016 May 18. PubMed PMID: 27061126.

66: Park HJ, Lee JH, Park KH, Kim KR, Han MJ, Choe H, Oh JW, Hong CS. A Six-Year Study on the Changes in Airborne Pollen Counts and Skin Positivity Rates in Korea: 2008-2013. *Yonsei Med J.* 2016 May;57(3):714-20. doi: 10.3349/ymj.2016.57.3.714. PubMed PMID: 26996572; PubMed Central PMCID: PMC4800362.

67: Florack J, Brighetti MA, Perna S, Pizzulli A, Pizzulli A, Tripodi S, Costa C, Travaglini A, Pelosi S, Bianchi A, Tsilochristou O, Gabrielli F, Matricardi PM. Comparison of six disease severity scores for allergic rhinitis against pollen counts a prospective analysis at population and individual level. *Pediatr Allergy Immunol.* 2016 Jun;27(4):382-90. doi: 10.1111/pai.12562. PubMed PMID: 26992008.

68: Devillier P, Bousquet PJ, Grassin-Delyle S, Salvator H, Demoly P, Bousquet J, de Beaumont O. Comparison of outcome measures in allergic rhinitis in children, adolescents and adults. *Pediatr Allergy Immunol.* 2016 Jun;27(4):375-81. doi: 10.1111/pai.12561. PubMed PMID: 26949928.

69: Höflich C, Balakirski G, Hajdu Z, Baron JM, Kaiser L, Czaja K, Merk HF, Gerdson S, Strassen U, Bas M, Bier H, Dott W, Mücke HG, Straff W, Chaker A, Röseler S. Potential health risk of allergenic pollen with climate change associated spreading capacity: Ragweed and olive sensitization in two German federal states. *Int J Hyg Environ Health.* 2016 May;219(3):252-60. doi: 10.1016/j.ijheh.2016.01.007. Epub 2016 Feb 1. PubMed PMID: 26906017.

70: Vara A, Fernández-González M, Aira MJ, Rodríguez-Rajo FJ. Fraxinus pollen and allergen concentrations in Ourense (South-western Europe). *Environ Res.* 2016 May;147:241-8. doi: 10.1016/j.envres.2016.02.014. Epub 2016 Feb 19. PubMed PMID: 26901381.

71: Beyer S, Franke A, Simon JC, Treudler R. Measurement of health-related quality of life in adult patients with birch pollen-associated food allergy. *J Dtsch Dermatol Ges.* 2016 Apr;14(4):397-404. doi: 10.1111/ddg.12731. Epub 2016 Feb 10. English, German. PubMed PMID: 26861505.

72: Rojo J, Rapp A, Lara B, Sabariego S, Fernández-González F, Pérez-Badia R. Characterisation of the airborne pollen spectrum in Guadalajara (central Spain) and estimation of the potential allergy risk. *Environ Monit Assess.* 2016 Mar;188(3):130. doi: 10.1007/s10661-016-5129-2. Epub 2016 Feb 1. PubMed PMID: 26832913.

73: García-Mozo H, Oteros JA, Galán C. Impact of land cover changes and climate on the main airborne pollen types in Southern Spain. *Sci Total Environ.* 2016 Apr 1;548-549:221-228. doi: 10.1016/j.scitotenv.2016.01.005. Epub 2016 Jan 21. PubMed

PMID: 26802350.

74: Nikolaidis C, Katotomichelakis M, Nena E, Makris M, Tsakas M, Michopoulos I, Constantinidis TC, Danielides V. Seasonal variations of allergenic pollen in a Mediterranean region - Alexandroupolis, north-east Greece. *Ann Agric Environ Med*. 2015;22(4):685-9. doi: 10.5604/12321966.1185776. PubMed PMID: 26706978.

75: Ariano R, Berra D, Chiodini E, Ortolani V, Cremonte LG, Mazzarello MG, Galdi E, Calosso C, Ciprandi G. Ragweed allergy: Pollen count and sensitization and allergy prevalence in two Italian allergy centers. *Allergy Rhinol (Providence)*. 2015 Jan;6(3):177-83. doi: 10.2500/ar.2015.6.0141. PubMed PMID: 26686209; PubMed Central PMCID: PMC5391486.

76: Sun X, Waller A, Yeatts KB, Thie L. Pollen concentration and asthma exacerbations in Wake County, North Carolina, 2006-2012. *Sci Total Environ*. 2016 Feb 15;544:185-91. doi: 10.1016/j.scitotenv.2015.11.100. Epub 2015 Dec 3. PubMed PMID: 26657364.

77: Fölster-Holst R, Galecka J, Weißmantel S, Dickschat U, Rippke F, Bohnsack K, Werfel T, Wichmann K, Buchner M, Schwarz T, Vogt A, Lademann J, Meinke MC. Birch pollen influence the severity of atopic eczema - prospective clinical cohort pilot study and ex vivo penetration study. *Clin Cosmet Investig Dermatol*. 2015 Oct 29;8:539-48. doi: 10.2147/CCID.S81700. eCollection 2015. PubMed PMID: 26604810; PubMed Central PMCID: PMC4629950.

78: Vara A, Fernández-González M, Aira MJ, Rodríguez-Rajo FJ. Oleaceae cross-reactions as potential pollinosis cause in urban areas. *Sci Total Environ*. 2016 Jan 15;542(Pt A):435-40. doi: 10.1016/j.scitotenv.2015.10.107. Epub 2015 Nov 3. PubMed PMID: 26520268.

79: Müller-Germann I, Vogel B, Vogel H, Pauling A, Fröhlich-Nowoisky J, Pöschl U, Després VR. Quantitative DNA Analyses for Airborne Birch Pollen. *PLoS One*. 2015 Oct 22;10(10):e0140949. doi: 10.1371/journal.pone.0140949. eCollection 2015. PubMed PMID: 26492534; PubMed Central PMCID: PMC4619600.

80: Ščevková J, Dušička J, Hrubisko M, Mičieta K. Influence of airborne pollen counts and length of pollen season of selected allergenic plants on the concentration of sIgE antibodies on the population of Bratislava, Slovakia. *Ann Agric Environ Med*. 2015;22(3):451-5. doi: 10.5604/12321966.1167712. PubMed PMID: 26403113.

81: Shah-Hosseini K, Mioc K, Hadler M, Karagiannis E, Mösges R. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial. *Curr Med Res Opin*. 2015 Dec;31(12):2249-59. doi: 10.1185/03007995.2015.1094653. Epub 2015 Oct 6. PubMed PMID: 26366617.

82: Pfaar O, Richter HG, Klimek L, Sieber J, Hadler M, Karagiannis E. Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study. *Biomed Res Int*. 2015;2015:584291. doi: 10.1155/2015/584291. Epub 2015 Aug 16. PubMed PMID: 26351635; PubMed Central PMCID: PMC4553179.

83: Nowosad J, Stach A, Kasprzyk I, Grewling Ł, Latałowa M, Puc M, Myszkowska D, Weryszko-Chmielewska E, Piotrowska-Weryszko K, Chłopek K, Majkowska-Wojciechowska B, Uruska A. Temporal and spatiotemporal autocorrelation of daily concentrations of *Alnus*, *Betula*, and *Corylus* pollen in Poland. *Aerobiologia* (Bologna). 2015;31(2):159-177. Epub 2014 Nov 15. PubMed PMID: 26346759; PubMed Central PMCID: PMC4555345.

84: Javier F, Emilio F, Montserrat V, Victor S, Purificaci N G. Evolution of the incidence of pollen grains and sensitivity to pollen in the city of Elche (Spain). *Asian Pac J Allergy Immunol*. 2015 Sep;33(3):196-202. doi: 10.12932/AP0542.33.3.2015. PubMed PMID: 26342116.

85: Klimek L, Bachert C, Lukat KF, Pfaar O, Meyer H, Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. *Clin Transl Allergy*. 2015 Aug 3;5:28. doi: 10.1186/s13601-015-0071-x. eCollection 2015. PubMed PMID: 26328056; PubMed Central PMCID: PMC4553934.

86: Rojo J, Rapp A, Lara B, Fernández-González F, Pérez-Badia R. Effect of land uses and wind direction on the contribution of local sources to airborne pollen. *Sci Total Environ*. 2015 Dec 15;538:672-82. doi: 10.1016/j.scitotenv.2015.08.074. Epub 2015 Aug 30. PubMed PMID: 26327635.

87: Ito K, Weinberger KR, Robinson GS, Sheffield PE, Lall R, Mathes R, Ross Z, Kinney PL, Matte TD. The associations between daily spring pollen counts, over-the-counter allergy medication sales, and asthma syndrome emergency department visits in New York City, 2002-2012. *Environ Health*. 2015 Aug 27;14:71. doi: 10.1186/s12940-015-0057-0. PubMed PMID: 26310854; PubMed Central PMCID: PMC4549916.

88: Katotomichelakis M, Nikolaidis C, Makris M, Zhang N, Aggelides X, Constantinidis TC, Bachert C, Danielides V. The clinical significance of the pollen calendar of the Western Thrace/northeast Greece region in allergic rhinitis. *Int Forum Allergy Rhinol*. 2015 Dec;5(12):1156-63. doi: 10.1002/alr.21623. Epub 2015 Aug 8. PubMed PMID: 26256270.

89: Van Hoeyveld E, Nickmans S, Ceuppens JL, Bossuyt X. Defining thresholds of specific IgE levels to grass pollen and birch pollen allergens improves clinical interpretation. *Clin Chim Acta*. 2015 Oct 23;450:46-50. doi: 10.1016/j.cca.2015.07.023. Epub 2015 Jul 29. PubMed PMID: 26232158.

90: Iemoli E, Borgonovo L, Fusi A, Magni C, Ricci ED, Rizzardini G, Piconi S. Sublingual allergen immunotherapy in HIV-positive patients. *Allergy*. 2016 Mar;71(3):412-5. doi: 10.1111/all.12713. Epub 2015 Dec 24. PubMed PMID: 26228482.

91: Xue CC, Zhang AL, Zhang CS, DaCosta C, Story DF, Thien FC. Acupuncture for seasonal allergic rhinitis: a randomized controlled trial. *Ann Allergy Asthma Immunol*. 2015 Oct;115(4):317-324.e1. doi: 10.1016/j.anai.2015.05.017. Epub 2015 Jun 11. PubMed PMID: 26073163.

92: García de León D, García-Mozo H, Galán C, Alcázar P, Lima M, González-Andújar JL. Disentangling the effects of feedback structure and climate on Poaceae annual airborne pollen fluctuations and the possible consequences of climate change. *Sci*

Total Environ. 2015 Oct 15;530-531:103-109. doi: 10.1016/j.scitotenv.2015.05.104. Epub 2015 May 28. PubMed PMID: 26026414.

93: Gruzieva O, Pershagen G, Wickman M, Melén E, Hallberg J, Bellander T, Löhmus M. Exposure to grass pollen--but not birch pollen--affects lung function in Swedish children. *Allergy*. 2015 Sep;70(9):1181-3. doi: 10.1111/all.12653. Epub 2015 Jun 11. PubMed PMID: 26011717; PubMed Central PMCID: PMC4744686.

94: Buters J, Prank M, Sofiev M, Pusch G, Albertini R, Annesi-Maesano I, Antunes C, Behrendt H, Berger U, Brandao R, Celenk S, Galan C, Grewling L, Jackowiak B, Kennedy R, Rantio-Lehtimäki A, Reese G, Sauliene I, Smith M, Thibaudon M, Weber B, Cecchi L. Variation of the group 5 grass pollen allergen content of airborne pollen in relation to geographic location and time in season. *J Allergy Clin Immunol*. 2015 Jul;136(1):87-95.e6. doi: 10.1016/j.jaci.2015.01.049. Epub 2015 May 6. PubMed PMID: 25956508.

95: Toro A R, Córdova J A, Canales M, Morales S RG, Mardones P P, Leiva G MA. Trends and threshold exceedances analysis of airborne pollen concentrations in Metropolitan Santiago Chile. *PLoS One*. 2015 May 6;10(5):e0123077. doi: 10.1371/journal.pone.0123077. eCollection 2015. PubMed PMID: 25946339; PubMed Central PMCID: PMC4422675.

96: Bastl K, Kmenta M, Geller-Bernstein C, Berger U, Jäger S. Can we improve pollen season definitions by using the symptom load index in addition to pollen counts? *Environ Pollut*. 2015 Sep;204:109-16. doi: 10.1016/j.envpol.2015.04.016. Epub 2015 May 2. PubMed PMID: 25935611.

97: Glaumann S, Nilsson C, Johansson SG, Asarnoj A, Wickman M, Borres MP, Nopp A. Evaluation of basophil allergen threshold sensitivity (CD-sens) to peanut and Ara h 8 in children IgE-sensitized to Ara h 8. *Clin Mol Allergy*. 2015 Apr 15;13(1):5. doi: 10.1186/s12948-014-0007-3. eCollection 2015. PubMed PMID: 25878561; PubMed Central PMCID: PMC4397898.

98: Philpott HL, Nandurkar S, Thien F, Bloom S, Lin E, Goldberg R, Boyapati R, Finch A, Royce SG, Gibson PR. Seasonal recurrence of food bolus obstruction in eosinophilic esophagitis. *Intern Med J*. 2015 Sep;45(9):939-43. doi: 10.1111/imj.12790. PubMed PMID: 25871330.

99: Tanaka J, Tanaka H, Mizuki N, Nomura E, Ito N, Nomura N, Yamane M, Hida T, Goshima Y, Hatano H, Nakagawa H. Semaphorin 3A controls allergic and inflammatory responses in experimental allergic conjunctivitis. *Int J Ophthalmol*. 2015 Feb 18;8(1):1-10. doi: 10.3980/j.issn.2222-3959.2015.01.01. eCollection 2015. PubMed PMID: 25709899; PubMed Central PMCID: PMC4325233.

100: Beggs PJ, Katelaris CH, Medek D, Johnston FH, Burton PK, Campbell B, Jaggard AK, Vicendese D, Bowman DM, Godwin I, Huete AR, Erbas B, Green BJ, Newnham RM, Newbiggin E, Haberle SG, Davies JM. Differences in grass pollen allergen exposure across Australia. *Aust N Z J Public Health*. 2015 Feb;39(1):51-5. doi: 10.1111/1753-6405.12325. PubMed PMID: 25648730; PubMed Central PMCID: PMC4704082.

101: Ciebiada M, Górski P, Antczak A. Evaluation of eicosanoids in nasal lavage as biomarkers of inflammation in patients with allergic rhinitis. *Arch Med Sci*. 2014 Dec 22;10(6):1123-8. doi: 10.5114/aoms.2015.47655. PubMed PMID: 25624848;

PubMed Central PMCID: PMC4296063.

102: Zhang Y, Bielory L, Cai T, Mi Z, Georgopoulos P. Predicting Onset and Duration of Airborne Allergenic Pollen Season in the United States. *Atmos Environ* (1994). 2015 Feb;103:297-306. PubMed PMID: 25620875; PubMed Central PMCID: PMC4302955.

103: Kruse K, Gerwin E, Eichel A, Shah-Hosseini K, Mösges R. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms. *J Allergy Clin Immunol Pract*. 2015 May-Jun;3(3):381-6. doi: 10.1016/j.jaip.2014.10.015. Epub 2015 Jan 22. PubMed PMID: 25609338.

104: Perveen A, Khan M, Zeb S, Imam AA. Impact and correlation of environmental conditions on pollen counts in Karachi, Pakistan. *Iran J Allergy Asthma Immunol*. 2015 Feb;14(1):83-90. PubMed PMID: 25530143.

105: Myszkowska D, Majewska R. Pollen grains as allergenic environmental factors--new approach to the forecasting of the pollen concentration during the season. *Ann Agric Environ Med*. 2014;21(4):681-8. doi: 10.5604/12321966.1129914. PubMed PMID: 25528901.

106: Brandelius A, Andersson M, Uller L. Topical dsRNA challenges may induce overexpression of airway antiviral cytokines in symptomatic allergic disease. A pilot in vivo study in nasal airways. *Respir Med*. 2014 Dec;108(12):1816-9. doi: 10.1016/j.rmed.2014.10.010. Epub 2014 Oct 25. PubMed PMID: 25456711.

107: Albertine JM, Manning WJ, DaCosta M, Stinson KA, Muilenberg ML, Rogers CA. Projected carbon dioxide to increase grass pollen and allergen exposure despite higher ozone levels. *PLoS One*. 2014 Nov 5;9(11):e111712. doi: 10.1371/journal.pone.0111712. eCollection 2014. PubMed PMID: 25372614; PubMed Central PMCID: PMC4221106.

108: Howard LE, Levetin E. Ambrosia pollen in Tulsa, Oklahoma: aerobiology, trends, and forecasting model development. *Ann Allergy Asthma Immunol*. 2014 Dec;113(6):641-6. doi: 10.1016/j.anai.2014.08.019. Epub 2014 Sep 17. PubMed PMID: 25240331.

109: Caillaud D, Thibaudon M, Martin S, Ségala C, Besancenot JP, Clot B, François H; French Aerobiology Network. Short-term effects of airborne ragweed pollen on clinical symptoms of hay fever in a panel of 30 patients. *J Investig Allergol Clin Immunol*. 2014;24(4):249-56. PubMed PMID: 25219107.

110: Caillaud DM, Martin S, Ségala C, Vidal P, Lecadet J, Pellier S, Rouzaire P, Tridon A, Evrard B. Airborne pollen levels and drug consumption for seasonal allergic rhinoconjunctivitis: a 10-year study in France. *Allergy*. 2015 Jan;70(1):99-106. doi: 10.1111/all.12522. Epub 2014 Nov 28. PubMed PMID: 25204990.

111: Brandt O, Zuberbier T, Bergmann KC. Risk of sensitization and allergy in Ragweed workers - a pilot study. *Allergy Asthma Clin Immunol*. 2014 Aug 8;10(1):42. doi: 10.1186/1710-1492-10-42. eCollection 2014. PubMed PMID:

25147570; PubMed Central PMCID: PMC4140137.

112: Klimek L, Sperl A, van Twuijver E, van Ree R, Kleijnans H, Boot JD, Pfaar O. A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. *Clin Transl Allergy*. 2014 Jul 23;4:23. doi: 10.1186/2045-7022-4-23. eCollection 2014. PubMed PMID: 25097754; PubMed Central PMCID: PMC4122029.

113: González Parrado Z, Fernández-González D, Camazón B, Valencia-Barrera RM, Vega-Maray AM, Asturias JA, Monsalve RI, Mandrioli P. Molecular aerobiology - Plantago allergen Pla l 1 in the atmosphere. *Ann Agric Environ Med*. 2014;21(2):282-9. doi: 10.5604/1232-1966.1108592. PubMed PMID: 24959777.

114: Tlachi-Corona L, Caballero-López CG, López-García AI, Papaqui-Tapia S, Arana-Muñoz O, Carcaño-Pérez MS, Marín-Marín A, Garrido-Priego F. [Correlation between the magnitude of skin prick test reactivity and pollen-specific serum IgE levels in patients with respiratory allergy]. *Rev Alerg Mex*. 2014 Jan-Mar;61(1):3-8. Spanish. PubMed PMID: 24912996.

115: Migueres M, Dávila I, Frati F, Azpeitia A, Jeanpetit Y, Lhéritier-Barrand M, Incorvaia C, Ciprandi G. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. *Clin Transl Allergy*. 2014 May 1;4:16. doi: 10.1186/2045-7022-4-16. eCollection 2014. Review. PubMed PMID: 24817997; PubMed Central PMCID: PMC4016618.

116: Sposato B, Liccardi G, Russo M, Folletti I, Siracusa A, Scichilone N, Ventura MT, Rolla G, Raie A, Milanese M, Pio R, Pio A, Scala R, Pareo C, Micucci C, Micheletto C, Billeri L, Musarra A, Cavaliere C, Agolli G, Masieri S, Scalese M, Capitani D. Cypress pollen: an unexpected major sensitizing agent in different regions of Italy. *J Investig Allergol Clin Immunol*. 2014;24(1):23-8. PubMed PMID: 24765877.

117: Katz DSW, Carey TS. Heterogeneity in ragweed pollen exposure is determined by plant composition at small spatial scales. *Sci Total Environ*. 2014 Jul 1;485-486:435-440. doi: 10.1016/j.scitotenv.2014.03.099. Epub 2014 Apr 16. PubMed PMID: 24742553.

118: Grewling L, Jenerowicz D, Nowak M, Polańska A, Jackowiak B, Czarnecka-Operacz M, Smith M. Clinical relevance of Corylus pollen in Poznań, western Poland. *Ann Agric Environ Med*. 2014;21(1):64-9. PubMed PMID: 24738499.

119: Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, Steven G, Hartert T, Teo KK, Pare G, McCarty CA, Brown NJ. Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema. *J Allergy Clin Immunol Pract*. 2013 Sep-Oct;1(5):468-73.e1-4. doi: 10.1016/j.jaip.2013.05.003. Epub 2013 Jun 21. PubMed PMID: 24565618; PubMed Central PMCID: PMC4042396.

120: Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, Ahuja SK. Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure. *J Allergy Clin Immunol*. 2014 May;133(5):1340-6, 1346.e1-7. doi: 10.1016/j.jaci.2013.09.051. Epub 2013 Dec 9. PubMed PMID: 24331377.

121: Peel RG, Hertel O, Smith M, Kennedy R. Personal exposure to grass pollen: relating inhaled dose to background concentration. *Ann Allergy Asthma Immunol.* 2013 Dec;111(6):548-54. doi: 10.1016/j.anai.2013.09.002. Epub 2013 Sep 26. PubMed PMID: 24267367.

122: Caillaud D, Martin S, Segala C, Besancenot JP, Clot B, Thibaudon M; French Aerobiology Network. Effects of airborne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis. *Int Arch Allergy Immunol.* 2014;163(1):43-50. doi: 10.1159/000355630. Epub 2013 Nov 16. PubMed PMID: 24247974.

123: Petersen KD, Kronborg C, Larsen JN, Dahl R, Gyrd-Hansen D. Patient related outcomes in a real life prospective follow up study: Allergen immunotherapy increase quality of life and reduce sick days. *World Allergy Organ J.* 2013 Sep 9;6(1):15. doi: 10.1186/1939-4551-6-15. PubMed PMID: 24229439; PubMed Central PMCID: PMC3846409.

124: Cloutier-Hurteau B, Gauthier S, Turmel MC, Comtois P, Courchesne F. Trace elements in the pollen of *Ambrosia artemisiifolia*: what is the effect of soil concentrations? *Chemosphere.* 2014 Jan;95:541-9. doi: 10.1016/j.chemosphere.2013.09.113. Epub 2013 Oct 30. Erratum in: *Chemosphere.* 2014 Jun;104:271-2. PubMed PMID: 24183625.

125: Jariwala S, Toh J, Shum M, de Vos G, Zou K, Sindher S, Patel P, Geevarghese A, Tavdy A, Rosenstreich D. The association between asthma-related emergency department visits and pollen and mold spore concentrations in the Bronx, 2001-2008. *J Asthma.* 2014 Feb;51(1):79-83. doi: 10.3109/02770903.2013.853779. Epub 2013 Nov 25. PubMed PMID: 24131032.

126: Ventura I, Vega A, Chamorro C, Aroca R, Gómez E, Pineda F, Palacios R, Blanca M, Monteseirín J. Allergen immunotherapy decreases LPS-induced NF- κ B activation in neutrophils from allergic patients. *Pediatr Allergy Immunol.* 2014 Mar;25(2):129-35. doi: 10.1111/pai.12145. Epub 2013 Oct 7. PubMed PMID: 24118194.

127: Bokanovic D, Aberer W, Hemmer W, Heinemann A, Komericki P, Scheffel J, Sturm GJ. Determination of sIgE to rPhl p 1 is sufficient to diagnose grass pollen allergy. *Allergy.* 2013 Nov;68(11):1403-9. doi: 10.1111/all.12263. Epub 2013 Oct 11. PubMed PMID: 24117513.

128: Sánchez-López J, Tordesillas L, Pascal M, Muñoz-Cano R, Garrido M, Rueda M, Vilella R, Valero A, Díaz-Perales A, Picado C, Bartra J. Role of Art v 3 in pollinosis of patients allergic to Pru p 3. *J Allergy Clin Immunol.* 2014 Apr;133(4):1018-25. doi: 10.1016/j.jaci.2013.08.005. Epub 2013 Sep 27. PubMed PMID: 24080266.

129: Crisp HC, Gomez RA, White KM, Quinn JM. A side-by-side comparison of Rotorod and Burkard pollen and spore collections. *Ann Allergy Asthma Immunol.* 2013 Aug;111(2):118-25. doi: 10.1016/j.anai.2013.05.021. PubMed PMID: 23886230.

130: Kiotseridis H, Cilio CM, Bjermer L, Tunsäter A, Jacobsson H, Dahl A. Grass pollen allergy in children and adolescents-symptoms, health related quality of

life and the value of pollen prognosis. *Clin Transl Allergy*. 2013 Jun 22;3:19. doi: 10.1186/2045-7022-3-19. eCollection 2013. PubMed PMID: 23799882; PubMed Central PMCID: PMC3699361.

131: Nybom H, Cervin-Hoberg C, Andersson M. Oral challenges with four apple cultivars result in significant differences in oral allergy symptoms. *Int Arch Allergy Immunol*. 2013;161(3):258-64. doi: 10.1159/000345954. Epub 2013 Mar 15. PubMed PMID: 23548468.

132: Puc M, Wolski T. Forecasting of the selected features of Poaceae (R. Br.) Barnh., Artemisia L. and Ambrosia L. pollen season in Szczecin, north-western Poland, using Gumbel's distribution. *Ann Agric Environ Med*. 2013;20(1):36-47. PubMed PMID: 23540210.

133: Chung YJ, Cho IK, Lee KI, Bae SH, Lee JW, Chung PS, Mo JH. Seasonal Specificity of Seasonal Allergens and Validation of the ARIA Classification in Korea. *Allergy Asthma Immunol Res*. 2013 Mar;5(2):75-80. doi: 10.4168/aaair.2013.5.2.75. Epub 2012 Nov 27. PubMed PMID: 23450145; PubMed Central PMCID: PMC3579095.

134: Brinkhaus B, Ortiz M, Witt CM, Roll S, Linde K, Pfab F, Niggemann B, Hummelsberger J, Treszl A, Ring J, Zuberbier T, Wegscheider K, Willich SN. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. *Ann Intern Med*. 2013 Feb 19;158(4):225-34. doi: 10.7326/0003-4819-158-4-201302190-00002. PubMed PMID: 23420231.

135: Erbas B, Lowe AJ, Lodge CJ, Matheson MC, Hosking CS, Hill DJ, Vicendese D, Allen KJ, Abramson MJ, Dharmage SC. Persistent pollen exposure during infancy is associated with increased risk of subsequent childhood asthma and hayfever. *Clin Exp Allergy*. 2013 Mar;43(3):337-43. doi: 10.1111/cea.12071. PubMed PMID: 23414542.

136: Puc M. Influence of meteorological parameters and air pollution on hourly fluctuation of birch (*Betula L.*) and ash (*Fraxinus L.*) airborne pollen. *Ann Agric Environ Med*. 2012;19(4):660-5. PubMed PMID: 23311785.

137: Mardones P, Grau M, Araya J, Córdova A, Pereira I, Peñailillo P, Silva R, Moraga A, Aguilera-Insunza R, Yepes-Nuñez JJ, Palomo I. First annual register of allergenic pollen in Talca, Chile. *Allergol Immunopathol (Madr)*. 2013 Jul-Aug;41(4):233-8. doi: 10.1016/j.aller.2012.06.001. Epub 2012 Nov 9. PubMed PMID: 23141838.

138: Marogna M, Braidì C, Bruno ME, Colombo C, Colombo F, Massolo A, Palumbo L, Compalati E. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. *Allergol Immunopathol (Madr)*. 2013 Jul-Aug;41(4):216-24. doi: 10.1016/j.aller.2012.07.004. Epub 2012 Nov 9. PubMed PMID: 23141837.

139: Ghosh D, Chakraborty P, Gupta J, Biswas A, Roy I, Das S, Gupta-Bhattacharya S. Associations between pollen counts, pollutants, and asthma-related hospital admissions in a high-density Indian metropolis. *J Asthma*. 2012 Oct;49(8):792-9. doi: 10.3109/02770903.2012.716473. PubMed PMID: 22978307.

140: Casquete-Román E, Rosado-Gil T, Postigo I, Guisantes JA, Fernández M, Torres HE, Martínez-Quesada J. Profilin cross-reactive panallergen causes latex sensitization in the pediatric population allergic to pollen. *Ann Allergy Asthma Immunol.* 2012 Sep;109(3):215-9. doi: 10.1016/j.anai.2012.07.003. Epub 2012 Aug 1. PubMed PMID: 22920078.

141: Röder E, Berger MY, Hop WC, de Groot H, van Wijk RG. The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis. *Pediatr Allergy Immunol.* 2013 Feb;24(1):39-48. doi: 10.1111/j.1399-3038.2012.01329.x. Epub 2012 Aug 13. PubMed PMID: 22882319.

142: Darrow LA, Hess J, Rogers CA, Tolbert PE, Klein M, Sarnat SE. Ambient pollen concentrations and emergency department visits for asthma and wheeze. *J Allergy Clin Immunol.* 2012 Sep;130(3):630-638.e4. doi: 10.1016/j.jaci.2012.06.020. Epub 2012 Jul 26. PubMed PMID: 22840851; PubMed Central PMCID: PMC3432157.

143: Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, Togias A, Phippard D, Turka LA, Hansel TT, Durham SR, Wurtzen PA. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. *J Immunol Methods.* 2012 Oct 31;384(1-2):25-32. doi: 10.1016/j.jim.2012.06.013. Epub 2012 Jun 30. PubMed PMID: 22759401.

144: Aboulaich N, Achmakh L, Bouziane H, Trigo MM, Recio M, Kadiri M, Cabezudo B, Riadi H, Kazzaz M. Effect of meteorological parameters on Poaceae pollen in the atmosphere of Tetouan (NW Morocco). *Int J Biometeorol.* 2013 Mar;57(2):197-205. doi: 10.1007/s00484-012-0566-2. Epub 2012 Jun 29. Review. PubMed PMID: 22744802.

145: Kiotseridis H, Cilio CM, Bjermer L, Aurivillius M, Jacobsson H, Dahl Å, Tunsäter A. Quality of life in children and adolescents with respiratory allergy, assessed with a generic and disease-specific instrument. *Clin Respir J.* 2013 Apr;7(2):168-75. PubMed PMID: 22621438.

146: Mimura T, Usui T, Yamagami S, Miyai T, Amano S. Relationship between total tear IgE and specific serum IgE in autumnal allergic conjunctivitis. *Cornea.* 2013 Jan;32(1):14-9. doi: 10.1097/ICO.0b013e318253214b. PubMed PMID: 22580438.

147: Erbas B, Akram M, Dharmage SC, Tham R, Dennekamp M, Newbiggin E, Taylor P, Tang ML, Abramson MJ. The role of seasonal grass pollen on childhood asthma emergency department presentations. *Clin Exp Allergy.* 2012 May;42(5):799-805. doi: 10.1111/j.1365-2222.2012.03995.x. PubMed PMID: 22515396.

148: Annesi-Maesano I, Rouve S, Desqueyroux H, Jankovski R, Klossek JM, Thibaudon M, Demoly P, Didier A. Grass pollen counts, air pollution levels and allergic rhinitis severity. *Int Arch Allergy Immunol.* 2012;158(4):397-404. doi: 10.1159/000332964. Epub 2012 Apr 4. PubMed PMID: 22487690.

149: Kim JH, Oh JW, Lee HB, Kim SW, Kang IJ, Kook MH, Kim BS, Park KS, Baek HS, Kim KR, Choi YJ. Changes in sensitization rate to weed allergens in children with increased weeds pollen counts in Seoul metropolitan area. *J Korean Med Sci.* 2012 Apr;27(4):350-5. doi: 10.3346/jkms.2012.27.4.350. Epub 2012 Mar 21. PubMed PMID: 22468096; PubMed Central PMCID: PMC3314845.

150: Quercia O, Bruno ME, Compalati E, Falagiani P, Mistrello G, Stefanini GF. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. *Eur Ann Allergy Clin Immunol.* 2011 Dec;43(6):176-83. PubMed PMID: 22360134.

151: Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. *Inflamm Res.* 2012 Jun;61(6):547-50. doi: 10.1007/s00011-012-0443-9. Epub 2012 Feb 15. PubMed PMID: 22349136; PubMed Central PMCID: PMC3345109.

152: Vaquero C, Rodríguez-Torres A, Rojo J, Pérez-Badia R. Airborne pollen of allergenic herb species in Toledo (Spain). *Environ Monit Assess.* 2013 Jan;185(1):335-46. doi: 10.1007/s10661-012-2556-6. Epub 2012 Feb 14. PubMed PMID: 22331454.

153: Manalai P, Hamilton RG, Langenberg P, Kosisky SE, Lapidus M, Sleemi A, Scrandis D, Cabassa JA, Rogers CA, Regenold WT, Dickerson F, Vittone BJ, Guzman A, Balis T, Tonelli LH, Postolache TT. Pollen-specific immunoglobulin E positivity is associated with worsening of depression scores in bipolar disorder patients during high pollen season. *Bipolar Disord.* 2012 Feb;14(1):90-8. doi: 10.1111/j.1399-5618.2012.00983.x. PubMed PMID: 22329476; PubMed Central PMCID: PMC3293700.

154: Toth I, Peternel R, Srncic L, Vojniković B. Diurnal variation in airborne pollen concentrations of the selected taxa in Zagreb, Croatia. *Coll Antropol.* 2011 Sep;35 Suppl 2:43-50. PubMed PMID: 22220402.

155: Toth I, Peternel R, Gajnik D, Vojniković B. Micro-regional hypersensitivity variations to inhalant allergens in the city of Zagreb and Zagreb County. *Coll Antropol.* 2011 Sep;35 Suppl 2:31-7. PubMed PMID: 22220400.

156: Negrini AC, Negrini S, Giunta V, Quaglini S, Ciprandi G. Thirty-year survey on airborne pollen concentrations in Genoa, Italy: relationship with sensitizations, meteorological data, and air pollution. *Am J Rhinol Allergy.* 2011 Nov-Dec;25(6):e232-41. doi: 10.2500/ajra.2011.25.3729. PubMed PMID: 22185731.

157: Pauling A, Rotach MW, Gehrig R, Clot B; Contributors to the European Aeroallergen Network (EAN). A method to derive vegetation distribution maps for pollen dispersion models using birch as an example. *Int J Biometeorol.* 2012 Sep;56(5):949-58. doi: 10.1007/s00484-011-0505-7. Epub 2011 Nov 17. PubMed PMID: 22086367.

158: DellaValle CT, Triche EW, Leaderer BP, Bell ML. Effects of ambient pollen concentrations on frequency and severity of asthma symptoms among asthmatic children. *Epidemiology.* 2012 Jan;23(1):55-63. doi: 10.1097/EDE.0b013e31823b66b8. PubMed PMID: 22082997; PubMed Central PMCID: PMC3246281.

159: Tosi A, Wüthrich B, Bonini M, Pietragalla-Köhler B. Time lag between Ambrosia sensitisation and Ambrosia allergy: a 20-year study (1989-2008) in Legnano, northern Italy. *Swiss Med Wkly.* 2011 Oct 9;141:w13253. doi: 10.4414/smw.2011.13253. eCollection 2011. PubMed PMID: 21984071.

160: Milani M, Pecora S; Rainbow Study Investigator Group. Clinical relevance of non-grass pollens respiratory allergies in Italy and effects of specific sublingual immunotherapy: The Rainbow Trial, a multicentre 3-year prospective observational study. *Eur Ann Allergy Clin Immunol.* 2011 Aug;43(4):111-6. PubMed PMID: 21980798.

161: Pajno GB, Caminiti L, Crisafulli G, Vita D, Valenzise M, De Luca R, Passalacqua G. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. *Pediatr Allergy Immunol.* 2011 Dec;22(8):803-7. doi: 10.1111/j.1399-3038.2011.01196.x. Epub 2011 Sep 19. PubMed PMID: 21929600.

162: Kosina-Hagyó K, Veres A, Fodor E, Mezei G, Csákány B, Németh J. Tear film function in patients with seasonal allergic conjunctivitis outside the pollen season. *Int Arch Allergy Immunol.* 2012;157(1):81-8. doi: 10.1159/000324657. Epub 2011 Sep 7. PubMed PMID: 21912177.

163: Puc M. Threat of allergenic airborne grass pollen in Szczecin, NW Poland: the dynamics of pollen seasons, effect of meteorological variables and air pollution. *Aerobiologia (Bologna).* 2011 Sep;27(3):191-202. Epub 2010 Nov 12. PubMed PMID: 21892248; PubMed Central PMCID: PMC3150813.

164: Puc M. Artificial neural network model of the relationship between Betula pollen and meteorological factors in Szczecin (Poland). *Int J Biometeorol.* 2012 Mar;56(2):395-401. doi: 10.1007/s00484-011-0446-1. Epub 2011 May 15. PubMed PMID: 21573820; PubMed Central PMCID: PMC3278628.

165: Rodríguez D, Davila I, Sánchez E, Barber D, Lorente F, Sánchez J. Relationship between airborne pollen counts and the results obtained using 2 diagnostic methods: allergen-specific immunoglobulin E concentrations and skin prick tests. *J Invest Allergol Clin Immunol.* 2011;21(3):222-8. PubMed PMID: 21548451.

166: Bosch-Cano F, Bernard N, Sudre B, Gillet F, Thibaudon M, Richard H, Badot PM, Ruffaldi P. Human exposure to allergenic pollens: a comparison between urban and rural areas. *Environ Res.* 2011 Jul;111(5):619-25. doi: 10.1016/j.envres.2011.04.001. Epub 2011 May 4. PubMed PMID: 21531404.

167: Huss-Marp J, Darsow U, Brockow K, Pfab F, Weichenmeier I, Schober W, Petersson CJ, Borres MP, Ring J, Behrendt H. Can immunoglobulin E-measurement replace challenge tests in allergic rhinoconjunctivitis to grass pollen? *Clin Exp Allergy.* 2011 Aug;41(8):1116-24. doi: 10.1111/j.1365-2222.2011.03745.x. Epub 2011 Apr 25. PubMed PMID: 21518042.

168: Sieber J, Gross A, Shah-Hosseini K, Mösges R. The RHINASTHMA GAV scores without SLIT, at the beginning and at the end of seasonal SLIT. *Asian Pac J Allergy Immunol.* 2010 Dec;28(4):232-6. PubMed PMID: 21337905.

169: Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Jarzebska M, Kowalski ML. Mast cell and eosinophil activation during early phase of grass pollen-induced ocular allergic reaction. *Allergy Asthma Proc.* 2011 Jan-Feb;32(1):43-8. doi:

10.2500/aap.2011.32.3402. PubMed PMID: 21262097.

170: Saarinen K, Jantunen J, Haahtela T. Birch pollen honey for birch pollen allergy--a randomized controlled pilot study. *Int Arch Allergy Immunol*. 2011;155(2):160-6. doi: 10.1159/000319821. Epub 2010 Dec 23. PubMed PMID: 21196761.

171: Sheffield PE, Weinberger KR, Ito K, Matte TD, Mathes RW, Robinson GS, Kinney PL. The association of tree pollen concentration peaks and allergy medication sales in new york city: 2003-2008. *ISRN Allergy*. 2011 Apr 20;2011:537194. doi: 10.5402/2011/537194. Print 2011. PubMed PMID: 23724230; PubMed Central PMCID: PMC3658798.

172: de Weger LA, Beerthuizen T, Gast-Strookman JM, van der Plas DT, Terreehorst I, Hiemstra PS, Sont JK. Difference in symptom severity between early and late grass pollen season in patients with seasonal allergic rhinitis. *Clin Transl Allergy*. 2011 Dec 21;1(1):18. doi: 10.1186/2045-7022-1-18. PubMed PMID: 22410160; PubMed Central PMCID: PMC3339365.

173: Pérez-Badia R, Vaquero C, Sardinero S, Galán C, García-Mozo H. Intradiurnal variations of allergenic tree pollen in the atmosphere of Toledo (central Spain). *Ann Agric Environ Med*. 2010;17(2):269-75. PubMed PMID: 21186770.

174: Krasznai M, Szaniszló K, Kraxner H, Vargha E, Kovacs M, Borocz Z, Kaszas E, Mezei G, Cserhati E, Cseh K. Association of TLR-4 and TNF-alpha polymorphisms with clinical symptoms and cytokine levels in patients with allergic rhinitis. *Eur Arch Otorhinolaryngol*. 2011 Apr;268(4):561-7. doi: 10.1007/s00405-010-1424-7. Epub 2010 Nov 20. PubMed PMID: 21103885.

175: Verguts MM, Eggermont A, Decoster W, de Jong FI, Hellings PW. Laryngeal effects of nasal allergen provocation in singers with allergic rhinitis. *Eur Arch Otorhinolaryngol*. 2011 Mar;268(3):419-27. doi: 10.1007/s00405-010-1420-y. Epub 2010 Nov 12. PubMed PMID: 21072528.

176: Pyrhönen K, Läärä E, Hiltunen L, Kaila M, Hugg T, Näyhä S. Season of the first trimester of pregnancy predicts sensitisation to food allergens in childhood: a population-based cohort study from Finland. *J Epidemiol Community Health*. 2012 Jan;66(1):49-56. doi: 10.1136/jech.2009.105411. Epub 2010 Oct 19. PubMed PMID: 20959386.

177: Kizilpinar I, Civelek E, Tuncer A, Dogan C, Karabulut E, Sahiner UM, Yavuz ST, Sackesen C. Pollen counts and their relationship to meteorological factors in Ankara, Turkey during 2005-2008. *Int J Biometeorol*. 2011 Jul;55(4):623-31. doi: 10.1007/s00484-010-0363-8. Epub 2010 Oct 15. PubMed PMID: 20953636.

178: Feo Brito F, Mur Gimeno P, Carnés J, Fernández-Caldas E, Lara P, Alonso AM, García R, Guerra F. Grass pollen, aeroallergens, and clinical symptoms in Ciudad Real, Spain. *J Investig Allergol Clin Immunol*. 2010;20(4):295-302. PubMed PMID: 20815307.

179: Brehmer D, Schön MP. Endonasal phototherapy significantly alleviates symptoms of allergic rhinitis, but has a limited impact on the nasal mucosal

immune cells. *Eur Arch Otorhinolaryngol*. 2011 Mar;268(3):393-9. doi: 10.1007/s00405-010-1375-z. Epub 2010 Sep 3. PubMed PMID: 20814689.

180: Fernández-González D, González-Parrado Z, Vega-Maray AM, Valencia-Barrera RM, Camazón-Izquierdo B, De Nuntiis P, Mandrioli P. *Platanus* pollen allergen, Pla a 1: quantification in the atmosphere and influence on a sensitizing population. *Clin Exp Allergy*. 2010 Nov;40(11):1701-8. doi: 10.1111/j.1365-2222.2010.03595.x. Epub 2010 Aug 31. PubMed PMID: 20813013.

181: Randhawa PS, Nouraei S, Mansuri S, Rubin JS. Allergic laryngitis as a cause of dysphonia: a preliminary report. *Logoped Phoniatr Vocol*. 2010 Dec;35(4):169-74. doi: 10.3109/14015431003599012. Epub 2010 Aug 16. PubMed PMID: 20712433.

182: Munoz Rodriguez AF, Palacios I, Molina R. Influence of meteorological parameters in hourly patterns of grass (*Poaceae*) pollen concentrations. *Ann Agric Environ Med*. 2010;17(1):87-100. PubMed PMID: 20684485.

183: Lund G, Jacobi H, Skov PS, Holm J, Lund K. Effect on cell surface markers following allergen-induced desensitization of human whole-blood basophils. *Int Arch Allergy Immunol*. 2010;153(4):323-34. doi: 10.1159/000316343. Epub 2010 Jun 17. PubMed PMID: 20558998.

184: Huynh BT, Tual S, Turbelin C, Pelat C, Cecchi L, D'Amato G, Blanchon T, Annesi-Maesano I. Short-term effects of airborne pollens on asthma attacks as seen by general practitioners in the Greater Paris area, 2003-2007. *Prim Care Respir J*. 2010 Sep;19(3):254-9. doi: 10.4104/pcrj.2010.00027. PubMed PMID: 20532465.

185: Lalek N, Kosnik M, Silar M, Korosec P. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. *Clin Exp Allergy*. 2010 Aug;40(8):1186-93. doi: 10.1111/j.1365-2222.2010.03524.x. Epub 2010 May 31. PubMed PMID: 20528883.

186: Hohlfeld JM, Holland-Letz T, Larbig M, Lavae-Mokhtari M, Wierenga E, Kapsenberg M, van Ree R, Krug N, Bufe A. Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions. *Clin Exp Allergy*. 2010 Jul;40(7):998-1006. doi: 10.1111/j.1365-2222.2010.03498.x. Epub 2010 Apr 13. PubMed PMID: 20412138.

187: Kurt E, Aktas A, Gulbas Z, Erginel S, Arslan S. The effects of natural pollen exposure on inflammatory cytokines and their relationship with nonspecific bronchial hyperresponsiveness in seasonal allergic rhinitis. *Allergy Asthma Proc*. 2010 Mar-Apr;31(2):126-31. doi: 10.2500/aap.2010.31.3325. PubMed PMID: 20406594.

188: Kasprzyk I, Walanus A. Description of the main *Poaceae* pollen season using bi-Gaussian curves, and forecasting methods for the start and peak dates for this type of season in Rzeszów and Ostrowiec Sw. (SE Poland). *J Environ Monit*. 2010 Apr;12(4):906-16. doi: 10.1039/b912256g. Epub 2010 Jan 25. PubMed PMID: 20383372.

189: Ariano R, Canonica GW, Passalacqua G. Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. *Ann*

Allergy Asthma Immunol. 2010 Mar;104(3):215-22. doi: 10.1016/j.anai.2009.12.005. PubMed PMID: 20377111.

190: Schäper C, Gustavus B, Koch B, Ewert R, Hanf G, Kunkel G, Noga O, Gläser S. Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis. *J Investig Allergol Clin Immunol*. 2009;19(6):459-64. PubMed PMID: 20128420.

191: Zhu DD, Zhu XW, Jiang XD, Dong Z. Thymic stromal lymphopoietin expression is increased in nasal epithelial cells of patients with mugwort pollen sensitive-seasonal allergic rhinitis. *Chin Med J (Engl)*. 2009 Oct 5;122(19):2303-7. PubMed PMID: 20079130.

192: Can IH, Islam A, Karasoy DS, Samim EE. Does regional pollen load affect the prevalence of clinical allergy to those pollen groups? *J Laryngol Otol*. 2010 Mar;124(3):297-301. doi: 10.1017/S0022215109991873. Epub 2009 Nov 23. PubMed PMID: 19930752.

193: Yuksel H, Sogut A, Yilmaz H, Yilmaz O, Dinc G. Sleep actigraphy evidence of improved sleep after treatment of allergic rhinitis. *Ann Allergy Asthma Immunol*. 2009 Oct;103(4):290-4. doi: 10.1016/S1081-1206(10)60527-3. PubMed PMID: 19852192.

194: Ebo DG, Bridts CH, Verweij MM, De Knop KJ, Hagendorens MM, De Clerck LS, Stevens WJ. Sensitization profiles in birch pollen-allergic patients with and without oral allergy syndrome to apple: lessons from multiplexed component-resolved allergy diagnosis. *Clin Exp Allergy*. 2010 Feb;40(2):339-47. doi: 10.1111/j.1365-2222.2009.03345.x. Epub 2009 Aug 26. PubMed PMID: 19709127.

195: Rodríguez-Rajo FJ, Astray G, Ferreira-Lage JA, Aira MJ, Jato-Rodríguez MV, Mejuto JC. Evaluation of atmospheric Poaceae pollen concentration using a neural network applied to a coastal Atlantic climate region. *Neural Netw*. 2010 Apr;23(3):419-25. doi: 10.1016/j.neunet.2009.06.006. Epub 2009 Jun 27. PubMed PMID: 19604673.

196: Lourenço O, Fonseca AM, Taborda-Barata L. Asthma is more frequently associated with non-allergic than allergic rhinitis in Portuguese patients. *Rhinology*. 2009 Jun;47(2):207-13. PubMed PMID: 19593980.

197: Johnston FH, Hanigan IC, Bowman DM. Pollen loads and allergic rhinitis in Darwin, Australia: a potential health outcome of the grass-fire cycle. *Ecohealth*. 2009 Mar;6(1):99-108. doi: 10.1007/s10393-009-0225-1. Epub 2009 May 8. PubMed PMID: 19424756.

198: Woschnagg C, Forsberg J, Engström A, Odreman F, Venge P, Garcia RC. The human eosinophil proteome. Changes induced by birch pollen allergy. *J Proteome Res*. 2009 Jun;8(6):2720-32. doi: 10.1021/pr800984e. PubMed PMID: 19348509.

199: Jato V, Rodríguez-Rajo FJ, Seijo MC, Aira MJ. Poaceae pollen in Galicia (N.W. Spain): characterisation and recent trends in atmospheric pollen season. *Int J Biometeorol*. 2009 Jul;53(4):333-44. doi: 10.1007/s00484-009-0220-9. Epub 2009 Apr 4. PubMed PMID: 19347372.

200: Nopp A, Cardell LO, Johansson SG, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. *Allergy*. 2009 May;64(5):811-4. doi: 10.1111/j.1398-9995.2008.01900.x. Epub 2009 Feb 13. PubMed PMID: 19220221.

201: Sudre B, Vacheyrou M, Braun-Fahrlander C, Normand AC, Waser M, Reboux G, Ruffaldi P, von Mutius E, Piarroux R; PASTURE study group. High levels of grass pollen inside European dairy farms: a role for the allergy-protective effects of environment? *Allergy*. 2009 Jul;64(7):1068-73. doi: 10.1111/j.1398-9995.2009.01958.x. Epub 2009 Feb 13. PubMed PMID: 19220219.

202: Marogna M, Spadolini I, Massolo A, Berra D, Zanon P, Chiodini E, Canonica GW, Passalacqua G. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. *Ann Allergy Asthma Immunol*. 2009 Jan;102(1):69-75. doi: 10.1016/S1081-1206(10)60111-1. PubMed PMID: 19205289.

203: Berna Dursun A, Celik GE, Alan S, Münevver Pinar N, Mungan D, Misirligil Z. Regional pollen load: effect on sensitisation and clinical presentation of seasonal allergic rhinitis in patients living in Ankara, Turkey. *Allergol Immunopathol (Madr)*. 2008 Nov-Dec;36(6):371-8. PubMed PMID: 19150039.

204: Ribeiro H, Oliveira M, Ribeiro N, Cruz A, Ferreira A, Machado H, Reis A, Abreu I. Pollen allergenic potential nature of some trees species: a multidisciplinary approach using aerobiological, immunochemical and hospital admissions data. *Environ Res*. 2009 Apr;109(3):328-33. doi: 10.1016/j.envres.2008.11.008. Epub 2009 Jan 14. PubMed PMID: 19147130.

205: Sahney M, Chaurasia S. Seasonal variations of airborne pollen in Allahabad, India. *Ann Agric Environ Med*. 2008;15(2):287-93. PubMed PMID: 19061265.

206: Frei T, Gassner E. Trends in prevalence of allergic rhinitis and correlation with pollen counts in Switzerland. *Int J Biometeorol*. 2008 Nov;52(8):841-7. doi: 10.1007/s00484-008-0178-z. Epub 2008 Aug 27. PubMed PMID: 18751737.

207: Yuksel H, Yilmaz O, Sogut A, Ertan P, Onur E. Correlation of quality of life with clinical parameters and eosinophilic cation protein levels in children with allergic rhinoconjunctivitis. *Int Arch Allergy Immunol*. 2009;148(1):18-22. doi: 10.1159/000151501. Epub 2008 Aug 21. PubMed PMID: 18716399.

208: Ballmer-Weber BK, Vieths S. Soy allergy in perspective. *Curr Opin Allergy Clin Immunol*. 2008 Jun;8(3):270-5. doi: 10.1097/ACI.0b013e3282ffb157. Review. PubMed PMID: 18560305.

209: Erkara IP, Cingi C, Ayranci U, Gurbuz KM, Pehlivan S, Tokur S. Skin prick test reactivity in allergic rhinitis patients to airborne pollens. *Environ Monit Assess*. 2009 Apr;151(1-4):401-12. doi: 10.1007/s10661-008-0284-8. Epub 2008 May 7. PubMed PMID: 18461463.

210: Subiza J, Feliú A, Subiza JL, Uhlig J, Fernández-Caldas E. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of

treatment. *Clin Exp Allergy*. 2008 Jun;38(6):987-94. doi: 10.1111/j.1365-2222.2008.02995.x. Epub 2008 Apr 25. PubMed PMID: 18445082.

211: Bergmann KC, Wolf H, Schnitker J. Effect of pollen-specific sublingual immunotherapy on oral allergy syndrome: an observational study. *World Allergy Organ J*. 2008 May;1(5):79-84. doi: 10.1097/WOX.0b013e3181752d1c. PubMed PMID: 23282323; PubMed Central PMCID: PMC3650975.

212: Moingeon P, Hrabina M, Bergmann KC, Jaeger S, Frati F, Bordas V, Peltre G. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. *Int Arch Allergy Immunol*. 2008;146(4):338-42. doi: 10.1159/000121468. Epub 2008 Mar 21. Review. PubMed PMID: 18362477.

213: Dales RE, Cakmak S, Judek S, Coates F. Tree pollen and hospitalization for asthma in urban Canada. *Int Arch Allergy Immunol*. 2008;146(3):241-7. doi: 10.1159/000116360. Epub 2008 Feb 13. PubMed PMID: 18270491.

214: Raap U, Fokkens W, Bruder M, Hoogsteden H, Kapp A, Braunstahl GJ. Modulation of neurotrophin and neurotrophin receptor expression in nasal mucosa after nasal allergen provocation in allergic rhinitis. *Allergy*. 2008 Apr;63(4):468-75. doi: 10.1111/j.1398-9995.2008.01626.x. Epub 2008 Feb 11. PubMed PMID: 18266897.

215: Wang HC, Yousef E. Air quality and pediatric asthma-related emergencies. *J Asthma*. 2007 Dec;44(10):839-41. PubMed PMID: 18097860.

216: Kasprzyk I. Non-native *Ambrosia* pollen in the atmosphere of Rzeszów (SE Poland); evaluation of the effect of weather conditions on daily concentrations and starting dates of the pollen season. *Int J Biometeorol*. 2008 May;52(5):341-51. Epub 2007 Nov 28. PubMed PMID: 18046583.

217: Stach A, Emberlin J, Smith M, Adams-Groom B, Myszkowska D. Factors that determine the severity of *Betula* spp. pollen seasons in Poland (Poznań and Krakow) and the United Kingdom (Worcester and London). *Int J Biometeorol*. 2008 Mar;52(4):311-21. Epub 2007 Oct 30. PubMed PMID: 17968596.

218: Fuhrman C, Sarter H, Thibaudon M, Delmas MC, Zeghnoun A, Lecadet J, Caillaud D. Short-term effect of pollen exposure on antiallergic drug consumption. *Ann Allergy Asthma Immunol*. 2007 Sep;99(3):225-31. PubMed PMID: 17910325.

219: Hanigan IC, Johnston FH. Respiratory hospital admissions were associated with ambient airborne pollen in Darwin, Australia, 2004-2005. *Clin Exp Allergy*. 2007 Oct;37(10):1556-65. PubMed PMID: 17883735.

220: Erbas B, Chang JH, Dharmage S, Ong EK, Hyndman R, Newbigin E, Abramson M. Do levels of airborne grass pollen influence asthma hospital admissions? *Clin Exp Allergy*. 2007 Nov;37(11):1641-7. Epub 2007 Sep 17. PubMed PMID: 17877763.

221: Smith M, Emberlin J, Stach A, Czarnecka-Operacz M, Jenerowicz D, Silny W. Regional importance of *Alnus* pollen as an aeroallergen: a comparative study of *Alnus* pollen counts from Worcester (UK) and Poznań (Poland). *Ann Agric Environ Med*. 2007;14(1):123-8. PubMed PMID: 17655189.

- 222: Peternel R, Milanović SM, Hrga I, Mileta T, Culig J. Incidence of Betulaceae pollen and pollinosis in Zagreb, Croatia, 2002-2005. *Ann Agric Environ Med*. 2007;14(1):87-91. PubMed PMID: 17655183.
- 223: Skjøth CA, Sommer J, Stach A, Smith M, Brandt J. The long-range transport of birch (*Betula*) pollen from Poland and Germany causes significant pre-season concentrations in Denmark. *Clin Exp Allergy*. 2007 Aug;37(8):1204-12. PubMed PMID: 17651151.
- 224: Horak F, Stübner P, Zieglmayer R, Kawina A, Moser M, Lanz R. Onset and duration of action of ketotifen 0.025% and emedastine 0.05% in seasonal allergic conjunctivitis : efficacy after repeated pollen challenges in the vienna challenge chamber. *Clin Drug Investig*. 2003;23(5):329-37. PubMed PMID: 17535045.
- 225: Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. *Eur Ann Allergy Clin Immunol*. 2007 Apr;39(4):119-22. PubMed PMID: 17523385.
- 226: Stach A, García-Mozo H, Prieto-Baena JC, Czarnecka-Operacz M, Jenerowicz D, Silny W, Galán C. Prevalence of *Artemisia* species pollinosis in western Poland: impact of climate change on aerobiological trends, 1995-2004. *J Investig Allergol Clin Immunol*. 2007;17(1):39-47. PubMed PMID: 17323862.
- 227: Peternel R, Hrga I, Culig J. Variations in mugwort (*Artemisia* spp.) airborne pollen concentrations at three sites in central Croatia, in period from 2002 to 2003. *Coll Antropol*. 2006 Dec;30(4):895-900. PubMed PMID: 17243566.
- 228: Sikoparija B, Radisic P, Pejak T, Simic S. Airborne grass and ragweed pollen in the southern Panonnian Valley--consideration of rural and urban environment. *Ann Agric Environ Med*. 2006;13(2):263-6. PubMed PMID: 17195999.
- 229: Zeghnoun A, Ravault C, Fabres B, Lecadet J, Quénel P, Thibaudon M, Caillaud D. Short-term effects of airborne pollen on the risk of allergic rhinoconjunctivitis. *Arch Environ Occup Health*. 2005 May-Jun;60(3):170-6. PubMed PMID: 17153090.
- 230: Gonianakis M, Neonakis I, Gonianakis I, Baritaki M, Kypriotakis Z, Potamias G, Bouros D, Kontou-Fili K. A 10-year aerobiological study (1994-2003) in the Mediterranean island of Crete, Greece: grasses and other weeds, aerobiological data, and botanical and clinical correlations. *Allergy Asthma Proc*. 2006 Sep-Oct;27(5):363-70. PubMed PMID: 17063665.
- 231: Michova A, Abugalia M, Ivanova Ts, Nikolov G, Taskov H, Petrunov B. Comparison of two-flow cytometry methods for basophil degranulation in patients sensitized to grass pollen. *Allergy*. 2006 Sep;61(9):1078-83. PubMed PMID: 16918510.
- 232: Zhong W, Levin L, Reponen T, Hershey GK, Adhikari A, Shukla R, LeMasters G. Analysis of short-term influences of ambient aeroallergens on pediatric asthma

hospital visits. *Sci Total Environ*. 2006 Nov 1;370(2-3):330-6. Epub 2006 Aug 14. PubMed PMID: 16904733; PubMed Central PMCID: PMC2233936.

233: Breton MC, Garneau M, Fortier I, Guay F, Louis J. Relationship between climate, pollen concentrations of *Ambrosia* and medical consultations for allergic rhinitis in Montreal, 1994-2002. *Sci Total Environ*. 2006 Oct 15;370(1):39-50. Epub 2006 Aug 8. PubMed PMID: 16899280.

234: Rodríguez-Rajo FJ, Valencia-Barrera RM, Vega-Maray AM, Suárez FJ, Fernández-González D, Jato V. Prediction of airborne *Alnus* pollen concentration by using ARIMA models. *Ann Agric Environ Med*. 2006;13(1):25-32. PubMed PMID: 16841868.

235: Astier C, Morisset M, Roitel O, Codreanu F, Jacquenet S, Franck P, Ogier V, Petit N, Proust B, Moneret-Vautrin DA, Burks AW, Bihain B, Sampson HA, Kanny G. Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. *J Allergy Clin Immunol*. 2006 Jul;118(1):250-6. PubMed PMID: 16815163.

236: Vahlkvist S, Sinding M, Skamstrup K, Bisgaard H. Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure. *J Allergy Clin Immunol*. 2006 Jun;117(6):1272-6. PubMed PMID: 16750986.

237: Port A, Hein J, Wolff A, Bielory L. Aeroallergen prevalence in the northern New Jersey-New York City metropolitan area: a 15-year summary. *Ann Allergy Asthma Immunol*. 2006 May;96(5):687-91. PubMed PMID: 16729781.

238: Nopp A, Johansson SG, Ankerst J, Bylin G, Cardell LO, Grönneberg R, Irander K, Palmqvist M, Oman H. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. *Allergy*. 2006 Mar;61(3):298-302. PubMed PMID: 16436137.

239: Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. *Allergy*. 2006 Feb;61(2):198-201. PubMed PMID: 16409196.

240: Tamarcaz P, Lambelet B, Clot B, Keimer C, Hauser C. Ragweed (*Ambrosia*) progression and its health risks: will Switzerland resist this invasion? *Swiss Med Wkly*. 2005 Sep 17;135(37-38):538-48. Review. PubMed PMID: 16333764.

241: Baars EW, De Bruin A. The effect of Gencydo injections on hayfever symptoms: a therapeutic causality report. *J Altern Complement Med*. 2005 Oct;11(5):863-9. PubMed PMID: 16296919.

242: Roberts G, Mylonopoulou M, Hurley C, Lack G. Impairment in quality of life is directly related to the level of allergen exposure and allergic airway inflammation. *Clin Exp Allergy*. 2005 Oct;35(10):1295-300. PubMed PMID: 16238788.

243: Bellinghausen I, König B, Böttcher I, Knop J, Saloga J. Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor. *Immunology*. 2005 Sep;116(1):103-11. PubMed PMID:

16108822; PubMed Central PMCID: PMC1802407.

244: Sánchez Mesa JA, Brandao R, Lopes L, Galan C. Correlation between pollen counts and symptoms in two different areas of the Iberian Peninsula: Cordoba (Spain) and Evora (Portugal). *J Investig Allergol Clin Immunol*. 2005;15(2):112-6. PubMed PMID: 16047711.

245: Stefanic E, Kovacevic V, Lazanin Z. Airborne ragweed pollen concentration in north-eastern Croatia and its relationship with meteorological parameters. *Ann Agric Environ Med*. 2005;12(1):75-9. PubMed PMID: 16028870.

246: Lipiec A, Rapiejko P, Samoliński B, Krzych E. Correlation between conjunctival provocation test results and conjunctival symptoms in pollinosis - preliminary report. *Ann Agric Environ Med*. 2005;12(1):17-20. PubMed PMID: 16028860.

247: Celik G, Mungan D, Pinar M, Misirligil Z. Poplar pollen-related allergy in Ankara, Turkey: how important for patients living in a city with high pollen load? *Allergy Asthma Proc*. 2005 Mar-Apr;26(2):113-9. PubMed PMID: 15971469.

248: Garavello W, Di Berardino F, Romagnoli M, Sambataro G, Gaini RM. Nasal rinsing with hypertonic solution: an adjunctive treatment for pediatric seasonal allergic rhinoconjunctivitis. *Int Arch Allergy Immunol*. 2005 Aug;137(4):310-4. Epub 2005 Jun 20. PubMed PMID: 15970639.

249: Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. *J Allergy Clin Immunol*. 2005 Jun;115(6):1184-8. PubMed PMID: 15940132.

250: Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. *Allergy*. 2005 Jul;60(7):952-6. PubMed PMID: 15932387.

251: Richard C, Bibas P, Lablache-Combier M, Allaire C. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone]. *J Fr Ophtalmol*. 2005 Mar;28(3):244-50. French. PubMed PMID: 15883488.

252: Langewitz W, Izakovic J, Wyler J, Schindler C, Kiss A, Bircher AJ. Effect of self-hypnosis on hay fever symptoms - a randomised controlled intervention study. *Psychother Psychosom*. 2005;74(3):165-72. PubMed PMID: 15832067.

253: Stelmach I, Majak P, Jerzynska J, Kuna P. The effect of treatment with montelukast on in vitro interleukin-10 production of mononuclear cells of children with asthma. *Clin Exp Allergy*. 2005 Feb;35(2):213-20. PubMed PMID: 15725194.

254: Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck LS, Stevens WJ. Flow cytometric analysis of in vitro activated basophils, specific IgE and skin tests in the diagnosis of pollen-associated food allergy. *Cytometry B Clin Cytom*.

2005 Mar;64(1):28-33. PubMed PMID: 15668987.

255: Castellano-Méndez M, Aira MJ, Iglesias I, Jato V, González-Manteiga W. Artificial neural networks as a useful tool to predict the risk level of *Betula* pollen in the air. *Int J Biometeorol*. 2005 May;49(5):310-6. Epub 2005 Jan 13. PubMed PMID: 15647908.

256: Puc M, Puc MI. Allergenic airborne grass pollen in Szczecin, Poland. *Ann Agric Environ Med*. 2004;11(2):237-44. PubMed PMID: 15627331.

257: Horak F, Stübner P, Ziegelmayer R, Kavina A, Corrado ME, Assandri A, Mion A. Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. *Arzneimittelforschung*. 2004;54(10):666-72. PubMed PMID: 15553106.

258: Corrado ME, Radicioni MM, Hartwig J, Assandri A, Oldeman HG, Mion A. Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis. *Arzneimittelforschung*. 2004;54(10):660-5. PubMed PMID: 15553105.

259: Roberts G, Hurley C, Bush A, Lack G. Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. *Thorax*. 2004 Sep;59(9):752-6. PubMed PMID: 15333850; PubMed Central PMCID: PMC1747120.

260: Fransson M, Benson M, Wennergren G, Cardell LO. A role for neutrophils in intermittent allergic rhinitis. *Acta Otolaryngol*. 2004 Jun;124(5):616-20. PubMed PMID: 15267182.

261: Weryszko-Chmielewska E, Piotrowska K. Airborne pollen calendar of Lublin, Poland. *Ann Agric Environ Med*. 2004;11(1):91-7. PubMed PMID: 15236504.

262: Boral D, Chatterjee S, Bhattacharya K. The occurrence and allergising potential of airborne pollen in West Bengal, India. *Ann Agric Environ Med*. 2004;11(1):45-52. PubMed PMID: 15236497.

263: Tobías A, Galán I, Banegas JR. Non-linear short-term effects of airborne pollen levels with allergenic capacity on asthma emergency room admissions in Madrid, Spain. *Clin Exp Allergy*. 2004 Jun;34(6):871-8. PubMed PMID: 15196273.

264: Celik G, Mungan D, Abadoğlu O, Pinar NM, Misirligil Z. Direct cost assessments in subjects with seasonal allergic rhinitis living in Ankara, Turkey. *Allergy Asthma Proc*. 2004 Mar-Apr;25(2):107-13. PubMed PMID: 15176495.

265: Altıntaş DU, Karakoç GB, Yilmaz M, Pinar M, Kendirli SG, Cakan H. Relationship between pollen counts and weather variables in east-Mediterranean coast of Turkey. Does it affect allergic symptoms in pollen allergic children? *Clin Dev Immunol*. 2004 Mar;11(1):87-96. PubMed PMID: 15154617; PubMed Central PMCID: PMC2275411.

266: Subiza Garrido-Lestache J. [Allergenic pollens in Spain]. *Allergol Immunopathol (Madr)*. 2004 May-Jun;32(3):121-4. Review. Spanish. PubMed PMID: 15120027.

267: Newhouse CP, Levetin E. Correlation of environmental factors with asthma and rhinitis symptoms in Tulsa, OK. *Ann Allergy Asthma Immunol*. 2004 Mar;92(3):356-66. PubMed PMID: 15049401.

268: Green BJ, Dettmann M, Yli-Panula E, Rutherford S, Simpson R. Atmospheric Poaceae pollen frequencies and associations with meteorological parameters in Brisbane, Australia: a 5-year record, 1994-1999. *Int J Biometeorol*. 2004 May;48(4):172-8. Epub 2004 Mar 2. PubMed PMID: 14997370.

269: Armentia A, Asensio T, Subiza J, Arranz ML, Martín Gil FJ, Callejo A. Living in towers as risk factor of pollen allergy. *Allergy*. 2004 Mar;59(3):302-5. PubMed PMID: 14982512.

270: Peternel R, Srncic L, Culig J, Zaninović K, Mitić B, Vukusić I. Atmospheric pollen season in Zagreb (Croatia) and its relationship with temperature and precipitation. *Int J Biometeorol*. 2004 May;48(4):186-91. Epub 2004 Feb 10. PubMed PMID: 14770305.

271: Behbehani N, Arifhodzic N, Al-Mousawi M, Marafie S, Ashkanani L, Moussa M, Al-Duwaisan A. The seasonal variation in allergic rhinitis and its correlation with outdoor allergens in Kuwait. *Int Arch Allergy Immunol*. 2004 Feb;133(2):164-7. Epub 2004 Feb 5. PubMed PMID: 14764943.

272: Sen MM, Adhikari A, Gupta-Bhattacharya S, Chanda S. Airborne rice pollen and pollen allergen in an agricultural field: aerobiological and immunochemical evidence. *J Environ Monit*. 2003 Dec;5(6):959-62. PubMed PMID: 14710939.

273: Burr ML, Emberlin JC, Treu R, Cheng S, Pearce NE; ISAAC Phase One Study Group. Pollen counts in relation to the prevalence of allergic rhinoconjunctivitis, asthma and atopic eczema in the International Study of Asthma and Allergies in Childhood (ISAAC). *Clin Exp Allergy*. 2003 Dec;33(12):1675-80. PubMed PMID: 14656354.

274: Arifhodzic N, Behbehani N, Duwaisan AR, Al-Mosawi M, Khan M. Safety of subcutaneous specific immunotherapy with pollen allergen extracts for respiratory allergy. *Int Arch Allergy Immunol*. 2003 Nov;132(3):258-62. PubMed PMID: 14646387.

275: Galán I, Tobías A, Banegas JR, Aránguez E. Short-term effects of air pollution on daily asthma emergency room admissions. *Eur Respir J*. 2003 Nov;22(5):802-8. PubMed PMID: 14621088.

276: Vural C, Gungor A. The effect of topical fluticasone on nasal nitric oxide levels in a patient with allergic rhinitis. *Ear Nose Throat J*. 2003 Aug;82(8):592-7. PubMed PMID: 14503095.

277: Stevens WJ, Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS. Is the prevalence of specific IgE to classical inhalant aeroallergens among patients

with respiratory allergy changing? Evidence from two surveys 15 years apart. *Acta Clin Belg*. 2003 May-Jun;58(3):178-82. PubMed PMID: 12945477.

278: Tobías A, Galán I, Banegas JR, Aránguez E. Short term effects of airborne pollen concentrations on asthma epidemic. *Thorax*. 2003 Aug;58(8):708-10. PubMed PMID: 12885991; PubMed Central PMCID: PMC1746765.

279: Jahnz-Rózyk K, Targowski T, Głodzinska-Wyszogrodzka E, Plusa T. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. *Allergy*. 2003 Jul;58(7):595-601. PubMed PMID: 12823117.

280: Steerenberg PA, Bischoff EW, de Klerk A, Verlaan AP, Jongbloets LM, van Loveren H, Opperhuizen A, Zomer G, Heisterkamp SH, Hady M, Spijksma FT, Fischer PH, Dormans JA, van Amsterdam JG. Acute effect of air pollution on respiratory complaints, exhaled NO and biomarkers in nasal lavages of allergic children during the pollen season. *Int Arch Allergy Immunol*. 2003 Jun;131(2):127-37. PubMed PMID: 12811021.

281: Cirila AM, Cirila PE, Parmiani S, Pecora S. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study. *Allergol Immunopathol (Madr)*. 2003 Jan-Feb;31(1):31-43. Erratum in: *Allergol Immunopathol (Madr)*. 2003 May-Jun;31(3):114. PubMed PMID: 12573207.

282: Sánchez-Mesa JA, Galan C, Martínez-Heras JA, Hervás-Martínez C. The use of a neural network to forecast daily grass pollen concentration in a Mediterranean region: the southern part of the Iberian Peninsula. *Clin Exp Allergy*. 2002 Nov;32(11):1606-12. PubMed PMID: 12569982.

283: Ferreiro M, Dopazo A, Aira MJ. Incidence of pollinosis in the city of A Coruña: correlation with aerobiological data. *J Investig Allergol Clin Immunol*. 2002;12(2):124-9. PubMed PMID: 12371529.

284: Porsbjerg C, Linstow ML, Nepper-christensen SC, Rasmussen A, Korsgaard J, Nolte H, Backer V; Greenlandic Population Study Group. Allergen sensitization and allergen exposure in Greenlandic Inuit residing in Denmark and Greenland. *Respir Med*. 2002 Sep;96(9):736-44. PubMed PMID: 12243321.

285: Valencia-Barrera RM, Comtois P, Fernández-González D. Bioclimatic indices as a tool in pollen forecasting. *Int J Biometeorol*. 2002 Sep;46(4):171-5. Epub 2002 Jul 16. PubMed PMID: 12242472.

286: Emberlin J, Detandt M, Gehrig R, Jaeger S, Nolard N, Rantio-Lehtimäki A. Responses in the start of Betula (birch) pollen seasons to recent changes in spring temperatures across Europe. *Int J Biometeorol*. 2002 Sep;46(4):159-70. Epub 2002 Jul 26. Erratum in: *Int J Biometeorol*. 2003 Mar;47(2):113-5. PubMed PMID: 12242471.

287: Lin RY, Clauss AE, Bennett ES. Hypersensitivity to common tree pollens in New York City patients. *Allergy Asthma Proc*. 2002 Jul-Aug;23(4):253-8. PubMed PMID: 12221895.

288: Tormo Molina R, Gonzalo Garijo MA, Muñoz Rodríguez AF, Silva Palacios I. Pollen and spores in the air of a hospital out-patient ward. *Allergol Immunopathol (Madr)*. 2002 Jul-Aug;30(4):232-8. PubMed PMID: 12199968.

289: Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, Bühring HJ, Valenta R, Valent P. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. *J Allergy Clin Immunol*. 2002 Jul;110(1):102-9. PubMed PMID: 12110828.

290: Vural C, Gungor A. Variations of nasal nitric oxide in a subject with allergic rhinitis: a longitudinal study. *Am J Otolaryngol*. 2002 Jul-Aug;23(4):191-5. PubMed PMID: 12105782.

291: Cabrera M, Martínez-Cócera C, Fernández-Caldas E, Carnés Sánchez J, Boluda L, Tejada J, Subiza JL, Subiza J, Jerez M. Trisetum paniceum (wild oats) pollen counts and aeroallergens in the ambient air of Madrid, Spain. *Int Arch Allergy Immunol*. 2002 Jun;128(2):123-9. PubMed PMID: 12065912.

292: Centanni S, Di Marco F, Castagna F, Santus P, Guarnieri R, Allegra L. Atopy prevalence and spirometric performance in asymptomatic schoolchildren exposed to air pollution. *Monaldi Arch Chest Dis*. 2001 Aug;56(4):304-8. PubMed PMID: 11770209.

293: Penel V, Buclet D, Couturier P, Xavier M, de Sousa P. [Variation in eosinophilia and measures of pollen counts of grasses (Poaceae) and ragweed (Ambrosia) in the Rhone valley]. *Allerg Immunol (Paris)*. 2001 Oct;33(8):327-30. French. PubMed PMID: 11763724.

294: Chakraborty P, Gupta-Bhattacharya S, Chowdhury I, Majumdar MR, Chanda S. Differences in concentrations of allergenic pollens and spores at different heights on an agricultural farm in West Bengal, India. *Ann Agric Environ Med*. 2001;8(2):123-30. PubMed PMID: 11748868.

295: Dvorin DJ, Lee JJ, Belecanech GA, Goldstein MF, Dunskey EH. A comparative, volumetric survey of airborne pollen in Philadelphia, Pennsylvania (1991-1997) and Cherry Hill, New Jersey (1995-1997). *Ann Allergy Asthma Immunol*. 2001 Nov;87(5):394-404. PubMed PMID: 11730182.

296: Domínguez Ortega J, Martín Santos S, Hinojosa Mena-Bernal J, Alonso Llamazares A, Llamas C, Plaza A, Robledo J, Martínez-Cócera C. [Analysis of 83 bronchospasm episodes seen at urgent care during one spring night]. *Allergol Immunopathol (Madr)*. 2001 Sep-Oct;29(5):197-200. Spanish. PubMed PMID: 11720653.

297: Riediker M, Monn C, Koller T, Stahel WA, Wüthrich B. Air pollutants enhance rhinoconjunctivitis symptoms in pollen-allergic individuals. *Ann Allergy Asthma Immunol*. 2001 Oct;87(4):311-8. PubMed PMID: 11686424.

298: Vidal C, Dopazo A, Aira MJ. Parietaria pollinosis in an Atlantic area: clinical and palynological data. *J Investig Allergol Clin Immunol*. 2001;11(2):107-11. PubMed PMID: 11642568.

299: Laaidi K. Predicting days of high allergenic risk during *Betula* pollination using weather types. *Int J Biometeorol*. 2001 Sep;45(3):124-32. PubMed PMID: 11594632.

300: Marks GB, Colquhoun JR, Girgis ST, Koski MH, Treloar AB, Hansen P, Downs SH, Car NG. Thunderstorm outflows preceding epidemics of asthma during spring and summer. *Thorax*. 2001 Jun;56(6):468-71. PubMed PMID: 11359963; PubMed Central PMCID: PMC1746065.

301: Sin BA, Inceoglu O, Mungan D, Celik G, Kaplan A, Misirligil Z. Is it important to perform pollen skin prick tests in the season? *Ann Allergy Asthma Immunol*. 2001 Apr;86(4):382-6. PubMed PMID: 11345279.

302: Bardin M, Viallard MS, Ballotte B, Storme D, Ferracci C, Chalmet CP. [Calls to the SAMU Centre 15 (Emergency Medical Service Center 15): an indicator of peak pollen concentrations]. *Allerg Immunol (Paris)*. 2001 Feb;33(2):90-7. French. PubMed PMID: 11339059.

303: Di Gioacchino M, Cavallucci E, Di Stefano F, Paolini F, Ramondo S, Di Sciascio MB, Ciuffreda S, Riccioni G, Della Vecchia R, Romano A, Boscolo P. Effect of natural allergen exposure on non-specific bronchial reactivity in asthmatic farmers. *Sci Total Environ*. 2001 Apr 10;270(1-3):43-8. PubMed PMID: 11327397.

304: Barnes C, Pacheco F, Landuyt J, Hu F, Portnoy J. Hourly variation of airborne ragweed pollen in Kansas City. *Ann Allergy Asthma Immunol*. 2001 Feb;86(2):166-71. PubMed PMID: 11258685.

305: Frenz DA. Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomatology. *Ann Allergy Asthma Immunol*. 2001 Feb;86(2):150-7, quiz 158. Review. PubMed PMID: 11258684.

306: Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The impact of allergies and allergy treatment on worker productivity. *J Occup Environ Med*. 2001 Jan;43(1):64-71. PubMed PMID: 11201771.

307: Lewis SA, Corden JM, Forster GE, Newlands M. Combined effects of aerobiological pollutants, chemical pollutants and meteorological conditions on asthma admissions and A & E attendances in Derbyshire UK, 1993-96. *Clin Exp Allergy*. 2000 Dec;30(12):1724-32. PubMed PMID: 11122210.

308: Stokes JR, Hartel R, Ford LB, Casale TB. Cannabis (hemp) positive skin tests and respiratory symptoms. *Ann Allergy Asthma Immunol*. 2000 Sep;85(3):238-40. PubMed PMID: 11030280.

309: Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. *Allergy*. 2000 Sep;55(9):827-35. PubMed PMID: 11003446.

- 310: Winther L, Malling HJ, Moseholm L, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. *Allergy*. 2000 Sep;55(9):818-26. PubMed PMID: 11003445.
- 311: Díaz-Perales A, Lombardero M, Sánchez-Monge R, García-Selles FJ, Pernas M, Fernández-Rivas M, Barber D, Salcedo G. Lipid-transfer proteins as potential plant panallergens: cross-reactivity among proteins of *Artemisia* pollen, *Castanea* nut and *Rosaceae* fruits, with different IgE-binding capacities. *Clin Exp Allergy*. 2000 Oct;30(10):1403-10. PubMed PMID: 10998016.
- 312: Dupin O, Trinquand C, Persi L, Bousquet J, Robert F, Arnaud B. A comparison of topical mequitazine and disodium cromoglycate in allergic conjunctivitis induced by a specific conjunctival provocation test. *Eur J Ophthalmol*. 2000 Jan-Mar;10(1):15-21. PubMed PMID: 10744200.
- 313: Fiorina A, Mincarini M, Sivori M, Brichetto L, Scordamaglia A, Canonica GW. Aeropollinic sampling at three different heights by personal volumetric collector (Partrap FA 52). *Allergy*. 1999 Dec;54(12):1309-15. PubMed PMID: 10688436.
- 314: Barnes C, Schreiber K, Pacheco F, Landuyt J, Hu F, Portnoy J. Comparison of outdoor allergenic particles and allergen levels. *Ann Allergy Asthma Immunol*. 2000 Jan;84(1):47-54. PubMed PMID: 10674565.
- 315: Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica GW, Ciprandi G. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. *J Allergy Clin Immunol*. 2000 Jan;105(1 Pt 1):54-7. PubMed PMID: 10629452.
- 316: Schäfer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. *J Allergy Clin Immunol*. 1999 Dec;104(6):1280-4. PubMed PMID: 10589013.
- 317: Munuera Giner M, Carrión García JS, García Sellés J. Aerobiology of *Artemisia* airborne pollen in Murcia (SE Spain) and its relationship with weather variables: annual and intradiurnal variations for three different species. Wind vectors as a tool in determining pollen origin. *Int J Biometeorol*. 1999 Oct;43(2):51-63. PubMed PMID: 10552308.
- 318: Ariano R, Passalacqua G, Panzani R, Scordamaglia A, Venturi S, Zoccali P, Canonica GW. Airborne pollens and prevalence of pollenosis in western Liguria: a 10-year study. *J Investig Allergol Clin Immunol*. 1999 Jul-Aug;9(4):229-34. PubMed PMID: 10513349.
- 319: Florido JF, Delgado PG, de San Pedro BS, Quiralte J, de Saavedra JM, Peralta V, Valenzuela LR. High levels of *Olea europaea* pollen and relation with clinical findings. *Int Arch Allergy Immunol*. 1999 Jun;119(2):133-7. PubMed PMID: 10394105.
- 320: Winther L, Moseholm L, Reimert CM, Stahl Skov P, Kaergaard Poulsen L. Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. *Allergy*. 1999

May;54(5):436-45. PubMed PMID: 10380774.

321: Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. *J Allergy Clin Immunol*. 1999 Jun;103(6):1025-30. PubMed PMID: 10359881.

322: Schäppi GF, Taylor PE, Pain MC, Cameron PA, Dent AW, Staff IA, Suphioglu C. Concentrations of major grass group 5 allergens in pollen grains and atmospheric particles: implications for hay fever and allergic asthma sufferers sensitized to grass pollen allergens. *Clin Exp Allergy*. 1999 May;29(5):633-41. PubMed PMID: 10231323.

323: Anderson HR, Ponce de Leon A, Bland JM, Bower JS, Emberlin J, Strachan DP. Air pollution, pollens, and daily admissions for asthma in London 1987-92. *Thorax*. 1998 Oct;53(10):842-8. PubMed PMID: 10193370; PubMed Central PMCID: PMC1745078.

324: Baraldi E, Carrá S, Dario C, Azzolin N, Ongaro R, Marcer G, Zacchello F. Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children. *Am J Respir Crit Care Med*. 1999 Jan;159(1):262-6. PubMed PMID: 9872848.

325: Dupin O, Compeyre S, Trinquand C, Persi L, Arnaud B. [Value of the conjunctival provocation test in evaluating the activity of 2 concentrations of anti-allergy eyedrops, mequitazine]. *J Fr Ophtalmol*. 1998 Jan;21(1):12-8. French. PubMed PMID: 9834894.

326: Acevedo F, Vesterberg O, Bayard C. Visualization and quantification of birch-pollen allergens directly on air-sampling filters. *Allergy*. 1998 Jun;53(6):594-601. PubMed PMID: 9689341.

327: Fujimura M, Kasahara K, Yasui M, Myou S, Ishiura Y, Kamio Y, Hashimoto T, Matsuda T. Atopy in cough sensitivity to capsaicin and bronchial responsiveness in young females. *Eur Respir J*. 1998 May;11(5):1060-3. PubMed PMID: 9648955.

328: Klimek L. [Sense of smell in allergic rhinitis]. *Pneumologie*. 1998 Apr;52(4):196-202. German. PubMed PMID: 9610182.

329: Newson R, Strachan D, Archibald E, Emberlin J, Hardaker P, Collier C. Acute asthma epidemics, weather and pollen in England, 1987-1994. *Eur Respir J*. 1998 Mar;11(3):694-701. PubMed PMID: 9596123.

330: Stjärne P, Rinder J, Hedén-Blomquist E, Cardell LO, Lundberg J, Zetterström O, Anggård A. Capsaicin desensitization of the nasal mucosa reduces symptoms upon allergen challenge in patients with allergic rhinitis. *Acta Otolaryngol*. 1998 Mar;118(2):235-9. PubMed PMID: 9583792.

331: Varela S, Subiza J, Subiza JL, Rodríguez R, García B, Jerez M, Jiménez JA, Panzani R. Platanus pollen as an important cause of pollinosis. *J Allergy Clin Immunol*. 1997 Dec;100(6 Pt 1):748-54. PubMed PMID: 9438481.

332: Hiltermann TJ, de Bruijne CR, Stolk J, Zwinderman AH, Spijksma FT, Roemer W, Steerenberg PA, Fischer PH, van Bree L, Hiemstra PS. Effects of photochemical air pollution and allergen exposure on upper respiratory tract inflammation in asthmatics. *Am J Respir Crit Care Med*. 1997 Dec;156(6):1765-72. PubMed PMID: 9412553.

333: Schäppi GF, Suphioglu C, Taylor PE, Knox RB. Concentrations of the major birch tree allergen Bet v 1 in pollen and respirable fine particles in the atmosphere. *J Allergy Clin Immunol*. 1997 Nov;100(5):656-61. PubMed PMID: 9389296.

334: Newson R, Strachan D, Archibald E, Emberlin J, Hardaker P, Collier C. Effect of thunderstorms and airborne grass pollen on the incidence of acute asthma in England, 1990-94. *Thorax*. 1997 Aug;52(8):680-5. PubMed PMID: 9337825; PubMed Central PMCID: PMC1758625.

335: Ramírez J, Carpizo JA, Ipsen H, Carreira J, Lombardero M. Quantification in mass units of Bet v 1, the main allergen of *Betula verrucosa* pollen, by a monoclonal antibody based-ELISA. *Clin Exp Allergy*. 1997 Aug;27(8):926-31. PubMed PMID: 9291291.

336: Klimek L, Eggers G. Olfactory dysfunction in allergic rhinitis is related to nasal eosinophilic inflammation. *J Allergy Clin Immunol*. 1997 Aug;100(2):158-64. PubMed PMID: 9275134.

337: Martín-Muñoz F, Moreno-Ancillo A, Pestaña JA, Contreras-Porta J, Díaz-Peña JM, Ojeda JA. Atopy and bronchial hyperresponsiveness in pure extrinsic childhood asthma. *J Invest Allergol Clin Immunol*. 1997 Jul-Aug;7(4):229-33. PubMed PMID: 9330186.

338: Venables KM, Allitt U, Collier CG, Emberlin J, Greig JB, Hardaker PJ, Highham JH, Laing-Morton T, Maynard RL, Murray V, Strachan D, Tee RD. Thunderstorm-related asthma--the epidemic of 24/25 June 1994. *Clin Exp Allergy*. 1997 Jul;27(7):725-36. PubMed PMID: 9249264.

339: Nolte H, DuBuske LM. Performance characteristics of a new automated enzyme immunoassay for the measurement of allergen-specific IgE. Summary of the probability outcomes comparing results of allergen skin testing to results obtained with the HYTEC system and CAP system. *Ann Allergy Asthma Immunol*. 1997 Jul;79(1):27-34. PubMed PMID: 9236496.

340: Kosisky SE, Carpenter GB. Predominant tree aeroallergens of the Washington, DC area: a six year survey (1989-1994). *Ann Allergy Asthma Immunol*. 1997 Apr;78(4):381-92. PubMed PMID: 9109706.

341: Liccardi G, Russo M, Piccolo A, Lobefalo G, Salzillo A, D'Amato M, D'Amato G. The perennial pattern of clinical symptoms in children monosensitized to *Olea europaea* pollen allergens in comparison with subjects with *Parietaria* and *Gramineae* pollinosis. *Allergy Asthma Proc*. 1997 Mar-Apr;18(2):99-105. PubMed PMID: 9134068.

342: Hinriksdóttir I, Murphy C, Bende M. Olfactory threshold after nasal allergen challenge. *ORL J Otorhinolaryngol Relat Spec*. 1997 Jan-Feb;59(1):36-8. PubMed

PMID: 9104747.

343: Tang C, Rolland IM, Ward C, Bish R, Thien F, Walters EH. Seasonal comparison of cytokine profiles in atopic asthmatics and atopic non-asthmatics. *Am J Respir Crit Care Med.* 1996 Dec;154(6 Pt 1):1615-22. PubMed PMID: 8970344.

344: Fernvik E, Grönneberg R, Lundahl J, Hed J, Andersson O, Johansson SG, Halldén G. The degree of natural allergen exposure modifies eosinophil activity markers in the circulation of patients with mild asthma. *Allergy.* 1996 Oct;51(10):697-705. PubMed PMID: 8904997.

345: Ross AM, Corden JM, Fleming DM. The role of oak pollen in hay fever consultations in general practice and the factors influencing patients' decisions to consult. *Br J Gen Pract.* 1996 Aug;46(409):451-5. PubMed PMID: 8949322; PubMed Central PMCID: PMC1239713.

346: Schäppi GF, Monn C, Wüthrich B, Wanner HU. Direct determination of allergens in ambient aerosols: methodological aspects. *Int Arch Allergy Immunol.* 1996 Aug;110(4):364-70. PubMed PMID: 8768804.

347: Djukanović R, Feather I, Gratziau C, Walls A, Peroni D, Bradding P, Judd M, Howarth PH, Holgate ST. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. *Thorax.* 1996 Jun;51(6):575-81. PubMed PMID: 8693436; PubMed Central PMCID: PMC1090485.

348: Nelson HS, Oppenheimer J, Buchmeier A, Kordash TR, Freshwater LL. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. *J Allergy Clin Immunol.* 1996 Jun;97(6):1193-201. PubMed PMID: 8648012.

349: Berkowitz RB, Dockhorn R, Lockey R, Findlay S, Howland WC, Mitchell DQ, Woehler T. Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. *Ann Allergy Asthma Immunol.* 1996 Apr;76(4):363-8. PubMed PMID: 8612120.

350: Celenza A, Fothergill J, Kupek E, Shaw RJ. Thunderstorm associated asthma: a detailed analysis of environmental factors. *BMJ.* 1996 Mar 9;312(7031):604-7. PubMed PMID: 8595333; PubMed Central PMCID: PMC2350378.

351: Guerra F, Daza JC, Miguel R, Moreno C, Galán C, Domínguez E, Sánchez Guijo P. Sensitivity to Cupressus: allergenic significance in Córdoba (Spain). *J Investig Allergol Clin Immunol.* 1996 Mar-Apr;6(2):117-20. PubMed PMID: 8727269.

352: Bernstein DI, Creticos PS, Busse WW, Cohen R, Graft DF, Howland WC, Lumry WR, Pedinoff AJ, Ratner PH, Lim J, Stokes A, McNally C. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. *J Allergy Clin Immunol.* 1996 Mar;97(3):749-55. PubMed PMID: 8613630.

353: Prieto JL, Gutiérrez V, Bertó JM, Camps B. Sensitivity and maximal response to methacholine in perennial and seasonal allergic rhinitis. *Clin Exp Allergy.*

1996 Jan;26(1):61-7. PubMed PMID: 8789544.

354: Osterberger M. [Ragweed alert from the Drôme physicians]. *Allerg Immunol (Paris)*. 1995 Nov;27(9):343-4. French. PubMed PMID: 8590588.

355: Glassheim JW, Ledoux RA, Vaughan TR, Damiano MA, Goodman DL, Nelson HS, Weber RW. Analysis of meteorologic variables and seasonal aeroallergen pollen counts in Denver, Colorado. *Ann Allergy Asthma Immunol*. 1995 Aug;75(2):149-56. PubMed PMID: 7648379.

356: Subiza J, Jerez M, Jiménez JA, Narganes MJ, Cabrera M, Varela S, Subiza E. Allergenic pollen pollinosis in Madrid. *J Allergy Clin Immunol*. 1995 Jul;96(1):15-23. PubMed PMID: 7622759.

357: Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. *J Allergy Clin Immunol*. 1995 May;95(5 Pt 1):955-61. PubMed PMID: 7751516.

358: Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to *Parietaria officinalis* pollen. *J Investig Allergol Clin Immunol*. 1995 May-Jun;5(3):126-32. PubMed PMID: 7582157.

359: Bachert C, Wagenmann M, Hauser U. Proinflammatory cytokines: measurement in nasal secretion and induction of adhesion receptor expression. *Int Arch Allergy Immunol*. 1995 May-Jun;107(1-3):106-8. Review. PubMed PMID: 7542054.

360: Spielsma FT, Nikkels BH, Dijkman JH. Seasonal appearance of grass pollen allergen in natural, pauci-micronic aerosol of various size fractions. Relationship with airborne grass pollen concentration. *Clin Exp Allergy*. 1995 Mar;25(3):234-9. PubMed PMID: 7788570.

361: Antépara I, Fernández JC, Gamboa P, Jauregui I, Miguel F. Pollen allergy in the Bilbao area (European Atlantic seaboard climate): pollination forecasting methods. *Clin Exp Allergy*. 1995 Feb;25(2):133-40. PubMed PMID: 7750005.

362: Rinder J, Stjärne P, Lundberg JM. Capsaicin de-sensitization of the human nasal mucosa reduces pain and vascular effects of lactic acid and hypertonic saline. *Rhinology*. 1994 Dec;32(4):173-8. PubMed PMID: 7701224.

363: Fahlbusch B, Schlenvoigt G, Müller WD, Weber B, Jäger L. A two-site monoclonal antibody ELISA for the quantification of group V allergens in grass extracts. *Clin Exp Allergy*. 1994 Aug;24(8):752-7. PubMed PMID: 7982125.

364: Prieto L, López M, Bertó JM, Peris A. Modification of concentration-response curves to inhaled methacholine after the pollen season in subjects with pollen induced rhinitis. *Thorax*. 1994 Jul;49(7):711-3. PubMed PMID: 8066569; PubMed Central PMCID: PMC475064.

365: Ariano R, Panzani RC, Chiapella M, Augeri G. Pollinosis in a Mediterranean

area (Riviera Ligure, Italy): ten years of pollen counts, correlation with clinical sensitization and meteorological data. *J Investig Allergol Clin Immunol*. 1994 Mar-Apr;4(2):81-6. PubMed PMID: 7921331.

366: Pastorello EA, Riario-Sforza GG, Incorvaia C, Segala M, Fumagalli M, Gandini R. Comparison of rhinomanometry, symptom score, and inflammatory cell counts in assessing the nasal late-phase reaction to allergen challenge. *J Allergy Clin Immunol*. 1994 Jan;93(1 Pt 1):85-92. PubMed PMID: 8308185.

367: Emberlin J, Savage M, Jones S. Annual variations in grass pollen seasons in London 1961-1990: trends and forecast models. *Clin Exp Allergy*. 1993 Nov;23(11):911-8. PubMed PMID: 10779278.

368: Oppenheimer JJ, Nelson HS. Seasonal variation in immediate skin test reactions. *Ann Allergy*. 1993 Sep;71(3):227-9. PubMed PMID: 8372994.

369: Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. *Allergol Immunopathol (Madr)*. 1993 Sep-Oct;21(5):173-8. PubMed PMID: 8160561.

370: Aichane A, Campbell AM, Chanal I, Richard MC, Arnaud B, Michel FB, Bousquet J. Precision of conjunctival provocation tests in right and left eyes. *J Allergy Clin Immunol*. 1993 Jul;92(1 Pt 1):49-55. PubMed PMID: 8335854.

371: Søhoel P, Freng BA, Kramer J, Poppe S, Rebo R, Korsrud FR, Garud O, Woxen OJ, Olsen AK. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. *J Allergy Clin Immunol*. 1993 Jul;92(1 Pt 1):73-81. PubMed PMID: 8101534.

372: Dechamp C. Comparison of gramineae and ragweed pollen counts measured by Hirst's and Cour's traps. *Allerg Immunol (Paris)*. 1993 Apr;25(4):154-8. PubMed PMID: 8489697.

373: Rossi OV, Kinnula VL, Tienari J, Huhti E. Association of severe asthma attacks with weather, pollen, and air pollutants. *Thorax*. 1993 Mar;48(3):244-8. PubMed PMID: 8497823; PubMed Central PMCID: PMC464361.

374: Marzin C, Le Moullec Y, Ancelle T, Juhel J, Festy B, Pretet S. [Asthma, urban atmospheric pollution and the weather]. *Rev Mal Respir*. 1993;10(3):229-35. French. PubMed PMID: 8346367.

375: Batard T, Basuyaux B, Laroze A, Lambin P, Brémard-Oury C, Aucouturier P, Hamilton RG, David B, Peltre G. Isotypic analysis of grass-pollen-specific immunoglobulins in human plasma. 2. Quantification of the IgE, IgM, IgA class and the IgG subclass antibodies. *Int Arch Allergy Immunol*. 1993;102(3):279-87. PubMed PMID: 8219781.

376: Johnsen CR, Weeke ER, Nielsen J, Jensen J, Mosbech H, Frølund L, Madsen F, Poulsen LK. Aeroallergen analyses and their clinical relevance. II. Sampling by high-volume airsampler with immunochemical quantification versus Burkard pollen trap sampling with morphologic quantification. *Allergy*. 1992 Oct;47(5):510-6.

PubMed PMID: 1485654.

377: Subiza J, Masiello JM, Subiza JL, Jerez M, Hinojosa M, Subiza E. Prediction of annual variations in atmospheric concentrations of grass pollen. A method based on meteorological factors and grain crop estimates. *Clin Exp Allergy*. 1992 May;22(5):540-6. PubMed PMID: 1628252.

378: Banken R, Comtois P. [Concentration of ragweed pollen and prevalence of allergic rhinitis in 2 municipalities in the Laurentides]. *Allerg Immunol (Paris)*. 1992 Mar;24(3):91-4. French. PubMed PMID: 1599616.

379: Déchamp C, Déchamp J. [Ragweed pollen counts (P. Cour collection apparatus) from Lyon-Bron from 1982 to 1989: results, informing the public]. *Allerg Immunol (Paris)*. 1992 Jan;24(1):17-21. French. PubMed PMID: 1575897.

380: Carlson M, Håkansson L, Kämpe M, Stålenheim G, Peterson C, Venge P. Degranulation of eosinophils from pollen-atopic patients with asthma is increased during pollen season. *J Allergy Clin Immunol*. 1992 Jan;89(1 Pt 1):131-9. PubMed PMID: 1309840.

381: Rak S, Björnson A, Håkanson L, Sörenson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. *J Allergy Clin Immunol*. 1991 Dec;88(6):878-88. PubMed PMID: 1744358.

382: Ebner C, Birkner T, Valenta R, Rumpold H, Breitenbach M, Scheiner O, Kraft D. Common epitopes of birch pollen and apples--studies by western and northern blot. *J Allergy Clin Immunol*. 1991 Oct;88(4):588-94. PubMed PMID: 1717531.

383: Zwick H, Popp W, Jäger S, Wagner C, Reiser K, Horak F. Pollen sensitization and allergy in children depend on the pollen load. *Allergy*. 1991 Jul;46(5):362-6. PubMed PMID: 1928659.

384: Brunnée T, Nigam S, Kunkel G, Baumgarten CR. Nasal challenge studies with bradykinin: influence upon mediator generation. *Clin Exp Allergy*. 1991 Jul;21(4):425-31. PubMed PMID: 1913265.

385: Gamboa PM, Sanz ML, de la Cuesta CG, García BE, Castillo JG, Oehling A. Number of beta-receptors in rhinitic pollinic patients. *J Investig Allergol Clin Immunol*. 1991 Apr;1(2):113-21. PubMed PMID: 1727009.

386: Bousquet J, Hejjaoui A, Becker WM, Cour P, Chanal I, Lebel B, Dhivert H, Michel FB. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. *J Allergy Clin Immunol*. 1991 Mar;87(3):737-46. PubMed PMID: 2005328.

387: Jelks ML. Florida pollen review. *Allergy Proc*. 1990 Nov-Dec;11(6):273-80. Review. PubMed PMID: 2292374.

388: Grammer L, Wiggins C, Shaughnessy MA, Chmiel J. Absence of nasal priming as measured by rhinitis symptom scores of ragweed allergic patients during seasonal exposure to ragweed pollen. *Allergy Proc.* 1990 Sep-Oct;11(5):243-6. PubMed PMID: 2258045.

389: Zimmermann T, Beinder K, Mollet FE, Kroon AM. [Therapy of hayfever and pollen asthma in children with a new, modified allergen extract]. *Immun Infekt.* 1990 Aug;18(4):127-31. German. PubMed PMID: 2210795.

390: Banken R, Comtois P. [Concentration of ragweed pollen and prevalence of allergic rhinitis in 2 municipalities of the Laurentians]. *Union Med Can.* 1990 Jul-Aug;119(4):178-83. French. Erratum in: *Union Med Can* 1990 Sep-Oct;119(5):264. PubMed PMID: 2385869.

391: Svensson C, Andersson M, Persson CG, Venge P, Alkner U, Pipkorn U. Albumin, bradykinins, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. *J Allergy Clin Immunol.* 1990 May;85(5):828-33. Erratum in: *J Allergy Clin Immunol* 1991 Jan;87 (1 Pt 1):17. PubMed PMID: 2332562.

392: Fokkens WJ, Holm AF, Rijntjes E, Mulder PG, Vroom TM. Characterization and quantification of cellular infiltrates in nasal mucosa of patients with grass pollen allergy, non-allergic patients with nasal polyps and controls. *Int Arch Allergy Appl Immunol.* 1990;93(1):66-72. PubMed PMID: 1707857.

393: Lucas SK, Buckley CE 3rd. Quantitative studies of cutaneous hypersensitivity: the prevalence of epicutaneous flare reactions to allergenic pollen extracts. *J Allergy Clin Immunol.* 1989 Oct;84(4 Pt 1):465-74. PubMed PMID: 2794291.

394: Pipkorn U, Karlsson G, Enerbäck L. Nasal mucosal response to repeated challenges with pollen allergen. *Am Rev Respir Dis.* 1989 Sep;140(3):729-36. PubMed PMID: 2782744.

395: Barnetson RS, Wright AL, Benton EC. IgE-mediated allergy in adults with severe atopic eczema. *Clin Exp Allergy.* 1989 May;19(3):321-5. PubMed PMID: 2736432.

396: Tang RB, Wu KK. Total serum IgE, allergy skin testing, and the radioallergosorbent test for the diagnosis of allergy in asthmatic children. *Ann Allergy.* 1989 May;62(5):432-5. PubMed PMID: 2719352.

397: Håkansson L, Rak S, Dahl R, Venge P. The formation of eosinophil and neutrophil chemotactic activity during a pollen season and after allergen challenge. *J Allergy Clin Immunol.* 1989 May;83(5):933-9. PubMed PMID: 2654257.

398: Somville MA, Machiels J, Gilles JG, Saint-Remy JM. Seasonal variation in specific IgE antibodies of grass-pollen hypersensitive patients depends on the steady state IgE concentration and is not related to clinical symptoms. *J Allergy Clin Immunol.* 1989 Feb;83(2 Pt 1):486-94. PubMed PMID: 2918188.

399: Jensen J, Poulsen LK, Mygind K, Weeke ER, Weeke B. Immunochemical estimations of allergenic activities from outdoor aero-allergens, collected by a high-volume air sampler. *Allergy*. 1989 Jan;44(1):52-9. PubMed PMID: 2719177.

400: Pipkorn U, Karlsson G, Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure. *J Allergy Clin Immunol*. 1988 Dec;82(6):1046-54. PubMed PMID: 2462580.

401: Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. *J Allergy Clin Immunol*. 1988 Nov;82(5 Pt 1):869-77. PubMed PMID: 2461405.

402: Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. *Allergy*. 1988 Oct;43(7):523-9. PubMed PMID: 3148282.

403: Schumacher MJ, Griffith RD, O'Rourke MK. Recognition of pollen and other particulate aeroantigens by immunoblot microscopy. *J Allergy Clin Immunol*. 1988 Oct;82(4):608-16. PubMed PMID: 3049747.

404: Volovitz B, Osur SL, Bernstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. *J Allergy Clin Immunol*. 1988 Sep;82(3 Pt 1):414-8. PubMed PMID: 3170989.

405: Taudorf E, Moseholm L. Pollen count, symptom and medicine score in birch pollinosis. A mathematical approach. *Int Arch Allergy Appl Immunol*. 1988;86(2):225-33. PubMed PMID: 3391687.

406: Linder A. Symptom scores as measures of the severity of rhinitis. *Clin Allergy*. 1988 Jan;18(1):29-37. PubMed PMID: 3349590.

407: Pipkorn U, Karlsson G, Enerbäck L. Secretory activity of nasal mucosal mast cells and histamine release in hay fever. *Int Arch Allergy Appl Immunol*. 1988;87(4):349-60. PubMed PMID: 2466003.

408: Leng X, Ye ST. One year observation of immunotherapy for Artemisia hay fever in China: a clinical and immunological study. *Asian Pac J Allergy Immunol*. 1987 Dec;5(2):167-72. PubMed PMID: 2452642.

409: Freidhoff LR, Ehrlich-Kautzky E, Meyers DA, Marsh DG. A study of the human immune response to *Lolium perenne* (rye) pollen and its components, Lol p I and Lol p II (Rye I and Rye II). II. Longitudinal variation of antibody levels in relation to symptomatology and pollen exposure and correction of seasonally elevated antibody levels to basal values. *J Allergy Clin Immunol*. 1987 Nov;80(5):646-55. PubMed PMID: 3680810.

410: Bousquet J, Lebel B, Dhivert H, Bataille Y, Martinot B, Michel FB. Nasal challenge with pollen grains, skin-prick tests and specific IgE in patients with grass pollen allergy. *Clin Allergy*. 1987 Nov;17(6):529-36. PubMed PMID: 3436032.

411: Andersen NH, Jeppesen F, Schiøler T, Osterballe O. Treatment of hay fever with sodium cromoglycate, hyposensitization, or a combination. *Allergy*. 1987 Jul;42(5):343-51. PubMed PMID: 3115130.

412: Laursen LC, Faurschou P, Pals H, Svendsen UG, Weeke B. Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients. *Allergy*. 1987 Apr;42(3):168-72. PubMed PMID: 3592139.

413: Horak F, Watson K. A comparison of two grass pollen extracts in the treatment of hay fever. *Allergol Immunopathol (Madr)*. 1987 Mar-Apr;15(2):59-64. PubMed PMID: 3618442.

414: Johansen LV, Bjerrum P, Illum P. Treatment of seasonal allergic rhinitis--a double blind, group comparative study of terfenadine and dexchlorpheniramine. *Rhinology*. 1987 Mar;25(1):35-40. PubMed PMID: 2883715.

415: Barbato A, Pisetta F, Ragusa A, Marcer G, Zacchello F. Modification of bronchial hyperreactivity during pollen season in children allergic to grass. *Ann Allergy*. 1987 Feb;58(2):121-4. PubMed PMID: 3813128.

416: Souille B, Boissinot E, Terrisse M, Duguet-Gruau F, Varaigne F, Moline J. [Bronchial provocation tests in 59 asthmatic children. Comparison with skin tests and specific serum allergens]. *Rev Mal Respir*. 1987;4(5):225-30. French. PubMed PMID: 3432710.

417: Nardi G, Demasi O, Marchegiani A, Pierdomenico R, Mincigrucci G, Romano B, Frenguelli G, Bricchi E. A study on airborne allergenic pollen content in the atmosphere of Ascoli Piceno. *Ann Allergy*. 1986 Sep;57(3):193-7. PubMed PMID: 3752620.

418: Oei HD, Spijksma FT, Bruynzeel PL. Birch pollen asthma in The Netherlands. *Allergy*. 1986 Aug;41(6):435-41. PubMed PMID: 3789328.

419: Schumacher MJ, Cota KA, Taussig LM. Pulmonary response to nasal-challenge testing of atopic subjects with stable asthma. *J Allergy Clin Immunol*. 1986 Jul;78(1 Pt 1):30-5. PubMed PMID: 3722633.

420: Möller C, Dreborg S. Cross-reactivity between deciduous trees during immunotherapy. I. In vivo results. *Clin Allergy*. 1986 Mar;16(2):135-43. PubMed PMID: 3708791.

421: Barbato A, Pisetta F, Norbiato M, Ragusa A, Mesirca P, Pesenti P, Marcer G. Influence of aeroallergens on bronchial reactivity in children sensitized to grass pollens. *Ann Allergy*. 1986 Feb;56(2):138-41. PubMed PMID: 3946846.

422: De Montis G. [Risk indicators in reagin allergy. III. IgE specificities and family history. Description of a genetic index for sorting patients for studying constitutional markers]. *Ann Med Interne (Paris)*. 1986;137(7):579-83. French. PubMed PMID: 3468822.

423: Gómez Carrasco JA, Blanco Quirós A, Linares López P. [Clinical and biological impact of environmental pollen on children with pollinosis]. *Allergol Immunopathol (Madr)*. 1985 Nov-Dec;13(6):513-24. Spanish. PubMed PMID: 3832933.

424: Eisenbrey AB, Agarwal MK, Offord KP, Adolphson CR, Yunginger JW, Gleich GJ. Seasonal variation of in vitro lymphocyte proliferative response to ragweed antigen E. *J Allergy Clin Immunol*. 1985 Jan;75(1 Pt 1):84-90. PubMed PMID: 3968332.

425: Beswick KB, Kenyon GS, Cherry JR. A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. *Curr Med Res Opin*. 1985;9(8):560-7. PubMed PMID: 2863090.

426: Hurtado I, Riegles-Goihman M. Air sampling studies in tropical America (Venezuela). Frequency and periodicity of pollen and spores. *Allergol Immunopathol (Madr)*. 1984 Nov-Dec;12(6):449-54. PubMed PMID: 6528852.

427: Morrow-Brown H, Jackson FA, Pover GM. A comparison of beclomethasone dipropionate aqueous nasal spray and sodium cromoglycate nasal spray in the management of seasonal allergic rhinitis. *Allergol Immunopathol (Madr)*. 1984 Sep-Oct;12(5):355-61. PubMed PMID: 6441477.

428: Djurup R, Osterballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. *Allergy*. 1984 Aug;39(6):433-41. PubMed PMID: 6496881.

429: Baumgarten C, Kunkel G, Rudolph R. Grass pollen allergoid. A 4-year follow-up study. *Respiration*. 1984;46(1):97-104. PubMed PMID: 6494611.

430: Pipkorn U. Hay fever treatment with budesonide and beclomethasone dipropionate twice daily - a clinical comparison. *Rhinology*. 1983 Dec;21(4):335-40. PubMed PMID: 6364297.

431: Agarwal MK, Swanson MC, Reed CE, Yunginger JW. Immunochemical quantitation of airborne short ragweed, *Alternaria*, antigen E, and Alt-I allergens: a two-year prospective study. *J Allergy Clin Immunol*. 1983 Jul;72(1):40-5. PubMed PMID: 6682872.

432: Løwenstein H, Marsh DG. Antigens of *Ambrosia elatior* (short ragweed) pollen. III. Crossed radioimmuno-electrophoresis of ragweed-allergic patients' sera with special attention to quantification of IgE responses. *J Immunol*. 1983 Feb;130(2):727-31. PubMed PMID: 6217252.

433: Osterballe O. Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen. *Allergy*. 1982 Apr;37(3):169-77. PubMed PMID: 6814282.

434: Singh AB, Babu CR. Survey of atmospheric pollen allergens in Delhi: seasonal

periodicity. *Ann Allergy*. 1982 Feb;48(2):115-22. PubMed PMID: 7065467.

435: Brown HM, Engler C, English JR. A comparative trial of flunisolide and sodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. *Clin Allergy*. 1981 Mar;11(2):169-73. PubMed PMID: 6786796.

436: Reinert M. When is a positive nasal challenge test clinically relevant? *Respiration*. 1981;41(4):270-5. PubMed PMID: 7302390.

437: Klabuschnigg A, Götz M, Horak F, Jäger S, Machalek A, Popow C, Haschke F, Skoda-Türk R. Influence of aerobiology and weather on symptoms in children with asthma. *Respiration*. 1981;42(1):52-60. PubMed PMID: 7036304.

438: Merrett TG, Pantin CF, Dimond AH, Merrett J. Screening for IgE-mediated allergy. *Allergy*. 1980 Sep;35(6):491-501. PubMed PMID: 7468940.

439: Stevens WJ, Vermeire PA. Bronchial responsiveness to histamine and allergen in patients with asthma, rhinitis, cough. *Eur J Respir Dis*. 1980 Aug;61(4):203-12. PubMed PMID: 7202593.

440: Spieksma FT, Charpin H, Nolard N, Stix E. City spore concentrations in the European Economic Community (EEC). IV. Summer weed pollen (*Rumex*, *Plantago*, *Chenopodiaceae*, *Artemisia*), 1976 and 1977. *Clin Allergy*. 1980 May;10(3):319-29. PubMed PMID: 7418190.

441: Frostad AB, Grimmer O, Sandvik L, Aas K. Hyposensitization. Comparing a purified (refined) allergen preparation and a crude aqueous extract from timothy pollen. *Allergy*. 1980 Mar;35(2):81-95. PubMed PMID: 7386802.

442: Horak F, Hussarek M, Jäger S, Skoda-Türk R. [The determination of the aggressiveness of allergizing types of pollen (author's transl)]. *Wien Klin Wochenschr*. 1980 Feb 29;92(5):161-4. German. PubMed PMID: 6930759.

443: Skoda-Türk R, Horak F, Jäger S. [A modified therapy of hayfever with a depot-preparation (author's transl)]. *Wien Klin Wochenschr Suppl*. 1980;117:24-6. German. PubMed PMID: 6936978.

444: Schumacher MJ, Pain MC. Nasal challenge testing in grass pollen hay fever. *J Allergy Clin Immunol*. 1979 Sep;64(3):202-8. PubMed PMID: 469119.

445: Hill DJ, Smart IJ, Knox RB. Childhood asthma and grass pollen aerobiology in Melbourne. *Med J Aust*. 1979 May 19;1(10):426-9. PubMed PMID: 470669.

446: Viander M, Koivikko A. The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST. *Clin Allergy*. 1978 Jul;8(4):387-96. PubMed PMID: 709787.

447: Mullins J, Warnock DW, Powell J, Jones I, Harvey R. Grass pollen content of

the air in the Bristol Channel region in 1976. Clin Allergy. 1977 Jul;7(4):391-5. PubMed PMID: 589774.

448: Skov PS, Permin H, Malling HJ. Quantitative and qualitative estimations of IgE bound to basophil leukocytes from hay fever patients. Scand J Immunol. 1977;6(10):1021-8. PubMed PMID: 72406.

449: Hirsch SR, Kalbfleisch JH. Circulating basophils in normal subjects and in subjects with hay fever. J Allergy Clin Immunol. 1976 Dec;58(6):676-82. PubMed PMID: 993482.

450: Reinert M, Kiefer R. [Value of clinical history, skin testing and nasal allergen challenge in the diagnose of perennial rhinopathia]. Laryngol Rhinol Otol (Stuttg). 1976 Jun;55(6):482-6. German. PubMed PMID: 135177.

451: van der Giessen M, Homan WL, van Kernbeek G, Aalberse RC, Dieges PH. Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy. Int Arch Allergy Appl Immunol. 1976;50(5):625-40. PubMed PMID: 773842.

452: Frankland AW, Walker SR. A comparison of intranasal betamethasone valerate and sodium cromoglycate in seasonal allergic rhinitis. Clin Allergy. 1975 Sep;5(3):295-300. PubMed PMID: 810268.

453: Raynor GS, Ogden EC, Hayes JV. Spatial variability in airborne pollen concentrations. J Allergy Clin Immunol. 1975 Mar;55(3):195-202. PubMed PMID: 1112951.

454: LIPMAN WH, VILEN FI. Ragweed pollen counts and their correlation with symptoms. Wis Med J. 1962 Apr;61:223-8. PubMed PMID: 14465704.

Online table 1: PubMed hits of later addition

1: Caillaud DM, Martin S, Ségala C, Vidal P, Lecadet J, Pellier S, Rouzaire P, Tridon A, Evrard B. Airborne pollen levels and drug consumption for seasonal allergic rhinoconjunctivitis: a 10-year study in France. Allergy. 2015 Jan;70(1):99-106. doi: 10.1111/all.12522. Epub 2014 Nov 28. PubMed PMID: 25204990.

2: Quercia O, Bruno ME, Compalati E, Falagiani P, Mistrello G, Stefanini GF. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. Eur Ann Allergy Clin Immunol. 2011 Dec;43(6):176-83. PubMed PMID: 22360134.

3: Fuhrman C, Sarter H, Thibaudon M, Delmas MC, Zeghnoun A, Lecadet J, Caillaud D. Short-term effect of pollen exposure on antiallergic drug consumption. Ann Allergy Asthma Immunol. 2007 Sep;99(3):225-31. PubMed PMID: 17910325.

4: Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual

immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol. 2007 Apr;39(4):119-22. PubMed PMID: 17523385.

5: Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr). 1993 Sep-Oct;21(5):173-8. PubMed PMID: 8160561.

6: Baumgarten C, Kunkel G, Rudolph R. Grass pollen allergoid. A 4-year follow-up study. Respiration. 1984;46(1):97-104. PubMed PMID: 6494611.

Title: A systematic review of threshold values of pollen concentrations for symptoms of allergy

Journal: Aerobiologia

Authors:

Nadine Steckling-Muschack^{1,2}, Hanna Mertes¹, Isabella Mittermeier³, Paul Schutzmeier¹, Jana Becker^{1,4}, Karl-Christian Bergmann^{5,6}, Stephan Böse-O'Reilly^{1,2,7}, Jeroen Buters⁸, Athanasios Damialis⁹, Joachim Heinrich^{1,10,11}, Michael Kabesch^{7,12}, Dennis Nowak^{1,10}, Sandra Walser-Reichenbach³, Alisa Weinberger³, Mihai Zamfir³, Caroline Herr^{1,3}, Susanne Kutzora³, Stefanie Heinze^{1,3}

Affiliations:

¹ Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany

² Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-Private University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center I, Hall in Tyrol 6060, Austria

³ Department for occupational and environmental medicine, Bavarian State Office for Health and Food Safety, Pfarrstr. 3, 80538 Munich, Germany

⁴ Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

⁵ Allergy-Center Charité, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Luisenstr. 2, 10117 Berlin, Germany

⁶ German Pollen Information Foundation, Robert-Koch-Platz 7, 10115 Berlin, Germany

⁷ University Children's Hospital Regensburg (KUNO-Clinics), University of Regensburg, Clinic St. Hedwig, Steinmetzstr. 1-3, 93049 Regensburg, Germany.

⁸ ZAUM, Center of Allergy & Environment, Helmholtz Center Munich/Technische Universität München, Member of the German Center for Lung Research (DZL), Biedersteiner Str. 29, 80802 Munich, Germany

⁹ Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Neusässer Str. 47 86156 Augsburg, Germany

¹⁰ Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung Research, Max-Lebsche-Platz 31, 81377 Munich, Germany

¹¹ Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, 07 Bouverie St, Carlton VIC 3053 Melbourne, Australia

¹² Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Prüfeningerstr. 21, 93049 Regensburg, Germany

Corresponding Author:

Isabella Mittermeier
Bavarian Health and Food Safety Authority
Pfarrstr. 3
80538 Munich
09131- 6808- 4292
Isabella.Mittermeier@lgl.bayern.de

Electronic Supplementary Material 3: Risk of bias assessment of all studies included in the review, alphabetical order

Selected RoB tool: OHAT risk of bias tool (OHAT 2015) supplemented by a conflict of interest criteria

Online table 1: RoB assessment of Caillaud et al. (2014a)

Study: Caillaud et al. (2014a) Study design (reported): panel study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“Confounding variables, such as pollutants and weather variables were introduced into the model considering their own effect on both pollen levels and symptoms. They were chosen to avoid highly correlated variables. Maximum temperature, mean relative humidity, wind speed, O3, PM 10 were selected together with geographical area of the volunteers. Two time trend variables were introduced (trend in the data, weekend). Interactions between all explanatory variables were tested and included if significant.” “The average daily concentrations of NO2 and PM10 were used in the study as well as O3 concentrations.”
Detection bias: exposure characterization	++	“Average daily birch pollen concentrations were drawn from the National Aerobiological Network Survey. In each French city studies and from MeteoSwiss (Geneva). Measurements were made using Hirst type pollen traps, located in each study town, around 15m above ground level.”
Detection bias: outcome assessment	+	“Adult patients, sensitized to birch. All participants were asked to complete the diary from March 22 to May 16, 2010.”
Attrition bias	+	“71 adults with SAR were selected. Ten participants were excluded, either because they failed to provide the requested daily health records (n=8) or because they did not qualify for inclusion (n=2).”
Selective reporting bias	++	“They were asked to record, each evening, daily nasal, ocular, and bronchial symptoms, respiratory infections, and medication [...]. The severity of eye (itching and/or tear flow and/or conjunctival redness), nose (sneezing and/or runny nose and/or blocked nose) and bronchial (cough and/or wheezing and/or asthma) symptoms was reported on a 4-point scale (0, no symptoms; 1, mild symptoms; 2, moderate symptoms; 3, severe symptoms).” Symptoms were reported.
Conflict of interest	-	No information given.

Online table 2: RoB assessment of Caillaud et al. (2014b)

Study: Caillaud et al. (2014b) Study design (reported): panel study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“Average daily concentrations of NO2, PM10, O3 were measured. However, only PM10 and O3 were used for analysis.” “Confounding variables were chosen to avoid highly correlated variables.” “Maximum temperature, mean relative humidity, wind speed, O3, PM10, age. Two time trend variables were introduced: month and weekend.” → NO2 not considered in analysis
Detection bias: exposure characterization	++	“The panel study was carried out in 5 towns in France and 1 in Switzerland. Each town was equipped with at least 1 pollen trap. Daily ragweed pollen levels were drawn in each town from the National Aerobiological Network Survey and by Meteo Swiss for Geneva. Measurements were made using a Hirst-type pollen trap [...]. The pollen is then identified and quantified by a trained palynologist and related to the volume of air averaged over 24 hours.”

Detection bias: outcome assessment	+	“All patients were asked to complete a symptom diary [...].”
Attrition bias	++	“For the panel study, 31 adults with ragweed allergy were included. One patient was excluded because he failed to provide the requested daily health records during the month of August and additionally he experienced hay fever before the pollen season. “
Selective reporting bias	++	“They were asked to record, each evening, daily nasal, ocular, and bronchial symptoms, respiratory infections, and medication [...]. The severity of eye (itching and/or tear flow and/or conjunctival redness), nose (sneezing and/or runny nose and/or blocked nose) and bronchial (cough and/or wheezing and/or asthma) symptoms was reported on a 4-point scale (0, no symptoms; 1, mild symptoms; 2, moderate symptoms; 3, severe symptoms).” Symptoms were reported.
Conflict of interest	++	The authors declare that they have no conflicts of interest.

Online table 3: RoB assessment of Caillaud et al. (2015)

Study: Caillaud et al. (2015)		
Study design (reported): /		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“The construction of the model began with the introduction of the long-term trend and seasonal variations [...]. Dummy variables of public holidays, school holidays, and the days of the week were then introduced. As for the trend, weather and pollution factors were introduced [...]. In the final model, the greatest temperature, humidity, ozone and particulate matter were introduced for each pollen with a lag. NO2 was introduced without lag.” → wind speed not introduced
Detection bias: exposure characterization	++	“Average daily pollen concentrations [...] using a Hirst pollen trap located in Clermont-Ferrand, 30 metres above ground level.”
Detection bias: outcome assessment	+	“The health indicator, referred to as SAR case, was defined as the association between an oral antihistamine drug and a local (nasal or ocular) anti-allergic drug on the same medical prescription. For each year of the study, all patients who received at least one reimbursement for anti-allergic treatment were selected via the health insurance database.”
Attrition bias	N.A.	The basic health insurance system [...] supplied the data”
Selective reporting bias	++	Secondary data were chosen after a predefined health outcome.
Conflict of interest	++	“The authors declare that they have no conflict s of interest.”

Online table 4: RoB assessment of Cakmak et al. (2002)

Study: Cakmak et al. (2002)		
Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“To account for the effect of potentially confounding long-term trends such as could be caused by viral epidemics or unknown factors, we applied [...].” “We also accounted for weekly and daily changes in meteorological and air-pollution variables.” Measured: O3, NO2, SO2, coefficient of haze, daily sulphates; temperature, relative humidity, barometric pressure 2

		→ day of the week not mentioned, wind speed not mentioned, coefficient of haze one of the earliest measures of PM
Detection bias: exposure characterization	++	“We measured the concentration of allergens in the air with rotational-impaction sampling located 2.4 m above the ground within 8.1-16.1km from the children’s hospital. [...] to test the correlation between changes in daily emergency visit rates and changes in daily concentrations or airborne allergens.”
Detection bias: outcome assessment	+	“We included all patients who presented with a main diagnosis of conjunctivitis or rhinitis to the emergency department from Mai 1, 1993 to Sept 30, 1997.” Daily → all visits to hospital → ICD or other medical code not mentioned
Attrition bias	++	“We included all patients who presented with a diagnosis of [...]”.
Selective reporting bias	++	Data for rhinitis and conjunctivitis were used and reported.
Conflict of interest	++	“None declared.”

Online table 5: RoB assessment of Dales et al. (2008)

Study: Dales et al. (2008)		
Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“Each time-series model included indicator variables for day of the week, and were adjusted for temporal trends [...].” “Day of the week and daily changes in meteorological variables were also accounted for [...]”. “To further exclude the possibility of confounding, each tree pollen was adjusted for the effects of the other tree pollens, for grasses and deuteromycetes, and for the gaseous air pollutants, nitrogen dioxide, sulphur dioxide and ozone. → PM and wind speed are missing
Detection bias: exposure characterization	++	“Tree pollen grain concentrations have been collected using rotational impact sampling located in each city.” “Pollen has been collected in the same fashion in each city supervised by the same company.” “[...] day-to-day changes in tree pollen concentration [...]”
Detection bias: outcome assessment	++	“The study population included all emergency hospitalizations for asthma between April 1993, and March 31, 2000 in the cities [...].” “The International Classification of Diseases (9 th revision, code 493) identified asthma.” [...] day-to-day changes in hospitalization counts [...]”.
Attrition bias	N.A.	“Hospitalization data were provided by the Canadian Institute for Health information which collects information on virtually all asthma admissions in Canada, made possible by the fact that all acute care general medical hospitals in Canada are public funded.” “Cities in the Province of Quebec could not be included because their hospitalization data could not be included in the Canadian Institute for Health Information database we assessed.”
Selective reporting bias	++	Admissions for asthma were reported in the results section.
Conflict of interest	-	No information given.

Online table 6: RoB assessment of Darrow et al. (2012)

Study: Darrow et al. (2012)		
Study design (reported): time series, case-crossover study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)

Confounding bias	--	AMBROSIA “Effects of Ambrosia pollen on asthma exacerbations were difficult to assess in this large-scale temporal analysis due to possible confounding by the steep increase in circulating rhinoviruses every September.” “There is evidence to suggest that our results for Ambrosia were confounded.”
Detection bias: exposure characterization	+	“Airborne pollen concentrations were measured by the Atlanta and Asthma Clinic, a member of the National Allergy Bureau. The monitoring site was moved once; pollen was sampled from the same rooftop height at both locations and away from vegetation, air conditioner and building vents.” “[...] staff analysed air samples five days per week (Sunday-Thursday) using a Rotorod sampler. For our main epidemiologic analyses, the two days (Friday-Saturday) of missing pollen data each week were estimated using linear interpolation.”
Detection bias: outcome assessment	++	“We defined ED visits for asthma and wheeze as all visits with a primary or secondary ICD-9 code indicating asthma (493.0-493.9) or wheeze (786.09 before October 1, 1998; 786.07 beginning October 1, 1998), that did not also have a code for an external injury or poisoning (E800-E999).” “We identified ED visits for acute upper respiratory infections (URI; 460.0-466.0) without a concurrent ICD code for asthma or wheeze.”
Attrition bias	N.A.	“For each patient visit, hospitals provided the date of admission, International classification of Diseases 9 th Revision diagnostic codes, patient date of birth and residential ZIP code.”
	-	“We also created a control group for finger wounds (883) because these visits were unlikely to be causally related to pollen levels.” “Finally, models assessing relationships between pollen levels and ED visits for finger wounds, a control outcome group, did not suggest any systematic bias in the modelling approach; [...]” → no information about control group, e.g. age, gender
Selective reporting bias	++	Data for a specific health outcome were requested, they were reported.
Conflict of interest	-	No information given.

Online table 7: RoB assessment of Fuhrman et al. (2007)

Study: Fuhrman et al. (2007) Study design (reported): /		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“The core model included penalized cubic regression spline of time, dummy variables for days of the week and public holidays, [...] temperature and relative humidity [...] ozone concentration.” “When a significant association was found in the overall analysis (all ages combined), further analyses were performed distinguishing between age groups: [...]”
Detection bias: exposure characterization	++	“The concentration sin airborne pollen grains were obtained from the national aerobiological surveillance network [...]. 8[...] spore trap located in the town center [...]. The relation between daily changes in pollen concentrations [...]”
Detection bias: outcome assessment	+	“Data regarding reimbursements for antiallergic drugs were provided by the French national medical insurance. [...]. I refunds only drugs bought with a medical prescription and, until 2004, antiallergic drugs were not available over the counter.”

		“An episode of treated ARC was defined as the association of an oral antihistamine drug and of a local (nose or eye) antiallergic drug on the same medical prescription.”
Attrition bias	++	“This health insurance covers all active or retired employees and their dependents and is estimated to cover approximately 80% of the French urban population.” “[...] all the individuals living in the Clermont-Ferrand urban area who had benefited from at least 1 reimbursement for either an oral antihistamine or a local (nasal or ocular) antiallergic treatment were selected via the health insurance database.” “For technical reasons, data on drug reimbursements in 2002 could not be used.”
Selective reporting bias	++	Outcome was defined and reported.
Conflict of interest	++	“Authors have nothing to disclose.”

Online table 8: RoB assessment of Gleason et al. (2014)

Study: Gleason et al. (2014)		
Study design (reported): case-crossover		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“Multivariable conditional logistic regression controlling for holiday, school.in-session indicator, and a 3-day moving average for temperature and relative humidity was used to examine the associations.” “Stratification on gender, race, ethnicity and socioeconomic status was explored.” “This method avoids bias due to temporal trends since controls are selected at a time prior and following an event and selection by week avoids any effects of day of the week” “[...] can more effectively control for time-varying confounding [...].” “Multipollutant models were fit to assess how associations changed after adjusting for other exposures, using same day lag values for ozone and PM2.5 and 3-day moving average for each pollen type.”
Detection bias: exposure characterization	+	“Specific counts for various pollen types [...] are collected daily, except for weekends and some winter months, using volumetric sampling devices from a counting station located in Springfield, New Jersey.” “Data from this monitoring station, which is one of only two stations in the state New Jersey, served as representative for the whole state, as pollen season peaks are similar throughout the state.”
Detection bias: outcome assessment	++	“Data on daily ED visits were obtained [...] with a primary diagnosis of asthma (ICD-9 code 493.xx).”
Attrition bias	+	“After exclusions there were 21,854 visits to the ED for pediatric asthma (case days) that were matched with two control days from a total of 65,562 case and control days.”
	++	- Day of the week “[...] time stratification into 21-day strata was selected. This strata size was chosen for several reasons: first it is a multiple of seven therefore controls are selected on the same day of the week as the case, additionally 21 days is a wide enough period of time to allow for the selection of two control periods per case [...].” “Bi-directional control sampling was employed in which two control periods, one preceding and one proceeding is selected for each case day. This method avoids bias due to temporal trends since controls are selected at a time prior and following an event and selection by week avoids any effects of day of the week. Controls are only selected from weeks before or after that are within the 21-day stratum. If the control’s stratum did not match the case’s stratum a new control date was selected

		two weeks in the appropriate time direction such that case and controls would be from the same strata.”
Selective reporting bias	++	Data on asthma were requested and reported.
Conflict of interest	++	“The Authors declared that they have no competing interests.”

Online table 9: RoB assessment of Guilbert et al. (2016)

Study: Guilbert et al. (2016) Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	++	Analysed Confounders: PM ₁₀ , NO ₂ , SO ₂ , O ₃ and meteorological factors “Among air pollutants, PM ₁₀ , NO ₂ , SO ₂ and O ₃ were considered as potential confounders. [...]The influence of meteorological factors including daily minimal temperature and average relative humidity, was taken into account.”
Detection bias: exposure characterization	++	“Their daily concentrations were provided by the Mycology and Aerobiology service (www.airallergy.be) of the Belgian Scientific Institute of Public Health (WIV-ISP). The counts of pollen and fungal spores in the air were obtained using a Burkard_ volumetric spore sampler located on the top of the WIV-ISP building, in the centre of the study area. Measurements were carried out 7 days a week, from January to November included. For the month of December, zeros were imputed for all types.”
Detection bias: outcome assessment	+	“The health impact of pollen grains and fungal spores was assessed based on their association with reimbursable “Antihistamines for systemic use” sales (R06A category according to the World Health Organization Anatomical Therapeutic Chemical classification system [ATC]; detailed list available as supplemental material), referred to as “allergy medications” hereinafter. [...]This administrative system records, on a daily basis, data on any purchase of refundable drugs made by a patient affiliated to the social security, in one of the public Belgian pharmacies.”
Attrition bias	N.A.	
Selective reporting bias	++	All measured outcomes as described in the method section are reported in the results
Conflict of interest	++	“The authors declare that they have no competing interest.”

Online table 10: RoB assessment of Guilbert et al. (2018)

Study: Guilbert et al. (2018) Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	Adjusted for: • seasonal and long term trends • day of the week • public holidays • mean temperature • relative humidity Stratification by: • not stratified • age • PM_{2.5} • NO₂ • O₃ • Influenza epidemics

		• General respiratory infections → wind speed is missing
Detection bias: exposure characterization	++	• mean daily concentrations • First-type volumetric spore sampler [...] placed on the flat and unobstructed roof of a 16m high building, located in the centre of the study area.
Detection bias: outcome assessment	++	• daily number of hospital admissions • asthma (ICD 9: 493)
Attrition bias	++	See detection bias: outcome assessment “They [the health data] were derived from the Belgian Minimal Hospital Summary database: any Belgian general hospital is required to systematically generate a standardized summary of the medical record of every inpatient (with a few exceptions).”
Selective reporting bias	++	Asthma hospitalization data were requested and these results were reported.
Conflict of interest	++	“The authors declare that they have no competing interest.”

Online table 11: RoB assessment of Héguy et al. (2008)

Study: Héguy et al. (2008)		
Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“[...] models that were adjusted for temporal variations, daily weather conditions (temperature, atmospheric pressure), and gaseous air pollutants (ozone and nitrogen dioxide).”
Detection bias: exposure characterization	++	“Daily concentrations of pollen were obtained [...]. In Montréal, the sampler is located in the municipality of LaSalle, situated roughly 1km from the north shore of the Saint-Lawrence River [...].”
Detection bias: outcome assessment	++	“Asthma was defined according to the initial assessment of the attending emergency physician (diagnostic code 493 according to the 9 th revision [...])”
Attrition bias	N.A.	“The QHIP database allowed the identification of all visits to emergency departments for asthma among children under the age of 9 who were residents of Montreal between 1994 and 2004 (April 1-October 31) in all Montreal hospitals.”
Selective reporting bias	++	Requested were data about emergency department visits caused by asthma; reported in the results section.
Conflict of interest	-	No information given.

Online table 12: RoB assessment of Hofman et al. (1996)

Study: Hofman et al. (1996)		
Study design (reported): /		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	--	No consideration of confounder.
Detection bias: exposure characterization	+	weekly/all 5 days (Comment from the reviewer: Fig. 2 and 3 presents measurements all 5 days; unclear information in paper. Author request was not answered) “Pollenfall has been examined in the city centre by volumetric method using Burkard sampler and in north and south points of the city by gravimetric method using Durham sampler.” Patients came from city of Poznan, small towns in Poznan region or rural area of Poznan region.

Detection bias: outcome assessment	-	“[...] 1,459 patients with pollinosis from three main medical allergy centres in Poznan (Centre of Allergology, Regional Hospital for Lung Diseases, Regional Outpatients Clinic of Allergology) were examined. All patients had symptoms of allergic rhinitis and conjunctivitis. The occurrence of symptoms in affected patients allowed a correlation to be made with the intensity of pollenfall.” + SPT, IgE, in few cases also rhinomanometry “The results of allergy tests, patient’s history and symptoms have been correlated with local pollenfall to establish exactly the cause of the disease.”
Attrition bias	N.A.	No attrition of patients. “It was obvious that not all new cases were included, largely because these patients were treated in other outpatients departments, or they simply remain undiagnosed. To best of our knowledge, approximately three quarters of newly diagnosed patients in Poznan were included in our analysis.”
Selective reporting bias	-	„we noticed that this [... 6-12 grains m³/24h...] was enough for patients to develop clinically significant symptoms“ Information should be available but is missing <i>[Comment from the reviewer: it is not obvious, if no symptoms occurs below 6 grains.]</i>
Conflict of interest	-	No information given.

Online table 13: RoB assessment of Huynh et al. (2010)

Study: Huynh et al. (2010) Study design (reported): time-series		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	Considered confounders/variables adjusted for: asthma trend, seasonality, air pollution data (NO₂, PM₁₀, SO₂, O₃), meteorological variables (temperature, humidity), public holidays, influenza, all types of pollen. ➔ Wind speed is missing
Detection bias: exposure characterization	-	One pollen trap covering study area. Daily pollen counting. However: “Since the data on asthma attacks were measured on a weekly basis, the daily counts of pollen grains per m³ were averaged over each week.” ➔ Daily counting, but summarized in weekly counting.
Detection bias: outcome assessment	-	Weekly outcome counting. Outcome: “asthma attacks requiring a GP [general practitioner] consultation”. Standardized definition of asthma attacks. ➔ Not daily outcome counting
Attrition bias	--	257 GPs [general practitioners] were included, however “GPs participate on a volunteer basis [...]. [...] the sample of GPs providing the data on numbers of asthma exacerbations could have been biased.” “189 asthmatic patients were seen by the FSN GPs over the four-year study period, 177 of which were fully described in terms of socio-demographic and clinical variables.” ➔ It is not mentioned how many of the 257 GPs reported asthma attacks. The attrition/exclusion rate is unknown. The authors declare the bias.
Selective reporting bias	++	Asthma attacks ➔ One outcome was reported in methods and results section.
Conflict of interest	++	➔ “No conflict of interest.”

Online table 14: RoB assessment of Ito et al. (2015)

Study: Ito et al. (2015) (Ito et al. 2015) Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	Considered confounders: Day of the week, within seasonal trends, humidity, temperature, PM2.5, O3 → Wind speed, NO2, is missing
Detection bias: exposure characterization	+	“a Burkard volumetric spore trap [...] about 30 miles north of Manhattan. This station provides the closest long-term pollen record for the New York City (NYC) region.” “Daily pollen counts” → Daily counting. Pollen trap and population in different cities.
Detection bias: outcome assessment	++	Over-the counter allergy medication sales → Daily outcome counting
	++	Asthma syndrome emergency department visits. “[...] data from 52 hospitals (~95 % of annual ED visits in NYC).” “For asthma ED syndrome, the script searched for the word ”asthma”, “wheezing”, “COPD”, their common misspelled analogues and International Classification of Diseases 9th edition codes associated with asthma (because some hospitals report diagnosis codes)”. [...] “daily asthma syndrome ED visits” Daily outcome counting.
Attrition bias	NA	→ Secondary data
Selective reporting bias	++	Over-the counter allergy medication sales → One outcome was reported in methods and results section. <i>[decision of the assessor: it seems not necessary to present results of the single products included]</i>
	++	Asthma syndrome emergency department visits defined as the following: “For asthma ED syndrome, the script searched for the word ”asthma”, “wheezing”, “COPD”, their common misspelled analogues and International Classification of Diseases 9th edition codes associated with asthma (because some hospitals report diagnosis codes)”. [...] → <i>[comment of the assessor: the inclusion of Asthma, Wheezing and COPD in one definition “asthma syndrome” was discussed with an expert and as acceptable declared]</i>
Conflict of interest	++	“The authors declare that they have no competing interests.”

Online table 15: RoB assessment of Lewis et al. (2000)

Study: Lewis et al. (2000) Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	-	Adjusted for “long-term time trends, temperature, humidity, influenza epidemics, day of the week”. → Wind speed was not considered as confounder (although it was surveyed). Air pollutants were not considered.
Detection bias: exposure characterization	++	“daily aeroallergen counts”; Measurements were made using a pollen/spore trap (Burkard Manufacturing Co Ltd, Rickmansworth, UK) sited 10m above ground level in a Derby suburb 100m above sea level and approximately 4 km south-west of the city centre.”
Detection bias: outcome assessment	++	“Asthma morbidity was assessed in terms of daily A & E attendances for the 4-year period from January 1993 to December 1996. Daily admissions to either Hospital were available from April 94 to December 96”. “Cases were identified using the international coding for diseases (ICD-9493 til March 95 and then ICD-10 J45.9 & J46) and those with a main diagnosis of asthma were included.”
Attrition bias	NA	Hospital data
Selective reporting bias	-	The results of all outcomes are shown graphically in terms of “estimated log rate ratios”. Odds Ratios are presented occasionally in the text.
Conflict of interest	-	no information given

Online table 16: RoB assessment of Motreff et al. (2014)

Study: Motreff et al. (2014) Study design (reported): /		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	O3, NO2, PM10, day of the week, public holidays and vacation, temperature, humidity/ precipitations. “Ozone, NOx and PM10 concentrations were introduced into the initial model, but these factors were not significant and were not kept as confounding factors.” → Wind speed missing. Later exclusion of factors.
Detection bias: exposure characterization	++	“daily concentrations in airborne pollen grains”, “using two Hirst spore traps, each one located in the outskirts of town centres of Montpellier and Nîmes.”
Detection bias: outcome assessment	+	“database of the French medical insurance”, “The health indicator, further referred to as “ARC cases”, was defined as the association of an oral antihistamine drug and a local (nose or eye) antiallergic drug on the same medical prescription.” → Daily outcome data. Insurance data. ICD codes were not used
Attrition bias	NA	“database of the French medical insurance”,
Selective reporting bias	++	Allergic rhinitis and conjunctivitis (ARC) cases → One outcome was reported in methods and results section
Conflict of interest	-	Not reported

Online table 17: RoB assessment of Osborne et al. (2017)

Study: Osborne et al. (2017) Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“temperature, precipitation, humidity, day of week, and air pollutants” (PM ₁₀ , NO ₂ , O ₃ , SO ₂). Wind speed was not considered as confounder.
Detection bias: exposure characterization	++	“daily pollen counts”, “a single pollen monitoring site in Islington, central London, [...] using a Burkard 7-day volumetric trap in accordance with British Aerobiology Federation protocols. The drum was changed at 09:00 daily”
Detection bias: outcome assessment	++	“Counts of emergency in-patient admissions for asthma (ICD-10 J45 and J46) for all residents of Greater London (specifically those within the London Government Office Region) were derived for the observation days from Hospital Episode Statistics (HES) data for years 2005–2011 [...] HES captures all inpatient admissions to National Health Service hospitals in England”
Attrition bias	NA	
Selective reporting bias	++	“Hospital admissions for asthma”, just one outcome
Conflict of interest	-	No information given

Online table 18: RoB assessment of Ross et al. (2002a)

Study: Ross et al. (2002b) Study design (reported): panel study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	-	Considered confounder: ozone, temperature, cigarette smoker, environmental tobacco smoke, indoor bioaerosols, atopic status, air-conditioner use, subject variability, subject variability, routine medication use. PM, NO ₂ , humidity/precipitation and wind speed are missing
Detection bias: exposure characterization	++	3 Rotorod collection devices, 2 were installed near homes, the third was installed near the river; pollen were reported each day.
Detection bias: outcome assessment	+	“Frequencies of asthma medication use (beyond routine use) and asthma attack occurrence were recorded each evening.”
	-	“A symptom score (from 0 to 3) was also recorded each morning and evening”, “respiratory symptoms” → Details of the content of the symptoms score are not described (e.g. cough).
Attrition bias	-	Unacceptable large attrition or exclusion (>20%); reasons were documented, when subjects were removed from the study or excluded from analysis. “A group of 59 asthmatic residents [...] were recruited for participation in a panel study. [...] Two families withdrew early in the study period, and a number of participants either withdrew later in the study or failed to provide the requested daily health records. Thus, our analyses are based on data from 40 participants”
Selective reporting bias	--	Asthma attacks were surveyed but results were not presented.
Conflict of interest	-	No information given

Online table 19: RoB assessment of Tobías et al. (2003)

Study: Tobías et al. (2003)		
Study design (reported): time-series		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	Air pollutants (PM10, SO2 NO2, O3), meteorological data (temperature, humidity), acute respiratory infections, day of the week, public holidays, other pollen Wind was not considered as confounder.
Detection bias: exposure characterization	++	“Airborne pollen data were collected from the Madrid Regional Health Authority Palynology Network comprising 10 monitoring stations. Daily averages of all main pollen types with allergenic capacity in the Madrid area (Olea, Plantago, Poaceae, Urticaceae, Artemisia, Chenopodeaceae, Cupressaceae and Platanus) were collected.”
Detection bias: outcome assessment	++	Asthma hospital emergencies with the diagnoses asthma, asthmatic bronchitis, spastic bronchitis or bronchospasm
Attrition bias	NA	Not applicable
Selective reporting bias	++	“Because of the large number of pollens and lag tests, this paper emphasises the consistency of associations across lags and measures and discusses only the more highly significant findings ($p<0.01$).” → A selection of the best findings are presented
Conflict of interest	++	“Conflict of interest: none.”

Online table 20: RoB assessment of Villeneuve et al. (2006)

Study: Villeneuve et al. (2006)		
Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	Adjusted for temperature, humidity and influenza visits. Although air pollutants were surveyed, they were not considered as confounder in the pollen analysis.
Detection bias: exposure characterization	++	“rotational impaction sampling methods”, daily
Detection bias: outcome assessment	++	“Daily counts of physician visits for allergic rhinitis”
Attrition bias	NA	Not applicable
Selective reporting bias	++	physician visits for rhinitis; just one outcome
Conflict of interest	-	No information given

Online table 21: RoB assessment of Zeghnoun et al. (2005)

Study: Zeghnoun et al. (2005) Study design (reported): time series study		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	Trend and seasonal variation, weekdays, holidays, school holidays, temperature, humidity, precipitation, O ₃ . Further variables were collected but not used in the model: black smokes, sulphur dioxide, carbon monoxide, suspended particles, nitrogen dioxide, nitrogen monoxide. → Wind speed, PM, NO ₂ , were not included in the model.
Detection bias: exposure characterization	++	One pollen-measurement station in Clermont-Ferrand, daily count
Detection bias: outcome assessment	+	“Drug data are from ERASME database” Allergic rhinoconjunctivitis (ARC) cases, defined as “a person who, on a given day, had a prescription to obtain an oral antihistamine associated with treatment for allergic rhinitis or allergic conjunctivitis, or both”. Per day.
Attrition bias	N.A.	Insurance data
Selective reporting bias	++	Allergic rhinoconjunctivitis (ARC) cases, defined as “a person who, on a given day, had a prescription to obtain an oral antihistamine associated with treatment for allergic rhinitis or allergic conjunctivitis, or both”. → One outcome was reported in methods and results section.
Conflict of interest	-	No information given

Online table 22: RoB assessment of Zhong et al. (2006)

Study: Zhong et al. (2006) Study design (reported): /		
Criteria	Assessment	Justification of the assessment (quotation marks are used for direct quotes)
Confounding bias	+	“effects of season, day of the week, temperature, humidity, ozone and PM _{2.5} ” Wind and NO ₂ were not considered.
Detection bias: exposure characterization	++	“daily aeroallergen [...] data during the specified period were obtained from an outdoor monitoring station”
Detection bias: outcome assessment	++	“An “asthma visit” was defined as either an emergency room visit or an out-patient clinic visit for the diagnosis of asthma. Daily records [...] ICD9 codes 493–493.91”
Attrition bias	NA	Not applicable
Selective reporting bias	++	Asthma visits, just one outcome
Conflict of interest	-	Information not given

References

- Caillaud, D., Martin, S., Segala, C., Besancenot, J. P., Clot, B., & Thibaudon, M. (2014a). Effects of Airborne Birch Pollen Levels on Clinical Symptoms of Seasonal Allergic Rhinoconjunctivitis. *Int Arch Allergy Immunol*, 163(1), 43-50, doi:10.1159/000355630.
- Caillaud, D., Thibaudon, M., Martin, S., Segala, C., Besancenot, J. P., Clot, B., et al. (2014b). Short-term effects of airborne ragweed pollen on clinical symptoms of hay fever in a panel of 30 patients. *J Investig Allergol Clin Immunol*, 24(4), 249-256.
- Caillaud, D. M., Martin, S., Segala, C., Vidal, P., Lecadet, J., Pellier, S., et al. (2015). Airborne pollen levels and drug consumption for seasonal allergic rhinoconjunctivitis: a 10-year study in France. *Allergy*, 70(1), 99-106, doi:10.1111/all.12522.
- Cakmak, S., Dales, R. E., Burnett, R. T., Judek, S., Coates, F., & Brook, J. R. (2002). Effect of airborne allergens on emergency visits by children for conjunctivitis and rhinitis. *The Lancet*, 359, 947-948.
- Dales, R. E., Cakmak, S., Judek, S., & Coates, F. (2008). Tree pollen and hospitalization for asthma in urban Canada. *Int Arch Allergy Immunol*, 146(3), 241-247, doi:10.1159/000116360.
- Darrow, L. A., Hess, J., Rogers, C. A., Tolbert, P. E., Klein, M., & Sarnat, S. E. (2012). Ambient pollen concentrations and emergency department visits for asthma and wheeze. *J Allergy Clin Immunol*, 130(3), 630-638.e634, doi:10.1016/j.jaci.2012.06.020.
- Fuhrman, C., Sarter, H., Thibaudon, M., Delmas, M. C., Zeghnoun, A., Lecadet, J., et al. (2007). Short-term effect of pollen exposure on antiallergic drug consumption. *Ann Allergy Asthma Immunol*, 99(3), 225-231, doi:10.1016/s1081-1206(10)60657-6.
- Gleason, J. A., Bielory, L., & Fagliano, J. A. (2014). Associations between ozone, PM2.5, and four pollen types on emergency department pediatric asthma events during the warm season in New Jersey: A case-crossover study. *Environmental Research*, 132, 421-429.
- Guilbert, A., Cox, B., Bruffaerts, N., Hoebeke, L., Packeu, A., Hendrickx, M., et al. (2018). Relationships between aeroallergen levels and hospital admissions for asthma in the Brussels-Capital Region: a daily time series analysis. *Environ Health*, 17(1), 35, doi:10.1186/s12940-018-0378-x.
- Guilbert A, S. K., Hoebeke L, et al. (2016). Short-Term Effect of Pollen and Spore Exposure on Allergy Morbidity in the Brussels-Capital Region. *EcoHealth*, 303-315.
- Heguy, L., Garneau, M., Goldberg, M. S., Raphoz, M., Guay, F., & Valois, M. F. (2008). Associations between grass and weed pollen and emergency department visits for asthma among children in Montreal. *Environ Res*, 106, 203-211.
- Hofman, T., Wykretowicz, G., Stach, A., Springer, E., Kolasinska, B., & Ossowski, M. (1996). A multicentre analysis of a population of patients with newly-diagnosed pollinosis in Poznan, Poland, in the year 1995. *Annals of Agriculture and Environmental Medicine*, 3, 171-177.
- Huynh, B. T., Tual, S., Turbelin, C., Pelat, C., Cecchi, L., D'Amato, G., et al. (2010). Short-term effects of airborne pollens on asthma attacks as seen by general practitioners in the Greater Paris area, 2003-2007. *Prim Care Respir J*, 19(3), 254-259, doi:10.4104/pcrj.2010.00027.
- Ito, K., Weinberger, K. R., Robinson, G. S., Sheffield, P. E., Lall, R., Mathes, R., et al. (2015). The associations between daily spring pollen counts, over-the-counter allergy medication sales, and asthma syndrome emergency department visits in New York City, 2002-2012. *Environ Health*, 14, 71, doi:10.1186/s12940-015-0057-0.
- Lewis, S. A., Corden, J. M., Forster, G. E., & Newlands, M. (2000). Combined effects of aerobiological pollutants, chemical pollutants and meteorological conditions on asthma admissions and A & E attendances in Derbyshire UK, 1993-96. *Clin Exp Allergy*, 30(12), 1724-1732.
- Motreff, Y., Golliot, F., Calleja, M., Le Pape, A., Fuhrman, C., Farrera, I., et al. (2014). Short-term effect of pollen exposure on drug consumption for allergic rhinitis and conjunctivitis. *Aerobiologia (Bologna)*, 30, 35-44, doi:10.1007/s10453-013-9307-1. .
- OHAT (2015). Handbook for Conducting Systematic Reviews. Office of Health Assessment and Translation (OHAT), Division of the National Toxicology Program National Institute of Environmental Health Sciences.
- Osborne, N. J., Alcock, I., Wheeler, B. W., Hajat, S., Sarran, C., Clewlow, Y., et al. (2017). Pollen exposure and hospitalization due to asthma exacerbations: daily time series in a European city. *Int J Biometeorol*, 61(10), 1837-1848, doi:10.1007/s00484-017-1369-2.
- Ross, M. A., Persky, V. W., Scheff, P. A., Chung, J., Curtis, L., Ramakrishnan, V., et al. (2002a). Effect of ozone and aeroallergens on the respiratory health of asthmatics. *Archives of Environmental Health*, 57(6), 568-578.
- Ross, M. A., Persky, V. W., Scheff, P. A., Chung, J., Curtis, L., Ramakrishnan, V., et al. (2002b). Effect of ozone and aeroallergens on the respiratory health of asthmatics. *Arch Environ Health*, 57(6), 568-578, doi:10.1080/00039890209602090.

- Tobias, A., Galan, I., Banegas, J. R., & Aranguez, E. (2003). Short term effects of airborne pollen concentrations on asthma epidemic. *Thorax*, 58(8), 708-710, doi:10.1136/thorax.58.8.708.
- Villeneuve, J. P., Doiron, M. S., Stieb, D., Dales, R. E., Burnett, T. R., & Dugandzic, R. (2006). Is outdoor air pollution associated with physician visits for allergic rhinitis among the elderly in Toronto, Canada? *Allergy Asthma Clin Immunol*, 61, 750-758, doi:10.1111/j.1398-9995.2006.01070.x.
- Zeghnoun, A., Ravault, C., Fabres, B., Lecadet, J., Quenel, P., Thibaudon, M., et al. (2005). Short-term effects of airborne pollen on the risk of allergic rhinoconjunctivitis. *Arch Environ Occup Health*, 60(3), 170-176, doi:10.3200/aeoh.60.3.170-176.
- Zhong, W., Levin, L., Reponen, T., Hershey, G. K., Adhikari, A., Shukla, R., et al. (2006). Analysis of short-term influences of ambient aeroallergens on pediatric asthma hospital visits. *Sci Total Environ*, 370(2-3), 330-336, doi:10.1016/j.scitotenv.2006.06.019.

Title: A systematic review of threshold values of pollen concentrations for symptoms of allergy

Journal: Aerobiologia

Authors:

Nadine Steckling-Muschack^{1,2}, Hanna Mertes¹, Isabella Mittermeier³, Paul Schutzmeier¹, Jana Becker^{1,4}, Karl-Christian Bergmann^{5,6}, Stephan Böse-O'Reilly^{1,2,7}, Jeroen Buters⁸, Athanasios Damialis⁹, Joachim Heinrich^{1,10,11}, Michael Kabesch^{7,12}, Dennis Nowak^{1,10}, Sandra Walser-Reichenbach³, Alisa Weinberger³, Mihai Zamfir³, Caroline Herr^{1,3}, Susanne Kutzora³, Stefanie Heinze^{1,3}

Affiliations:

¹ Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany

² Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-Private University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center I, Hall in Tyrol 6060, Austria

³ Department for occupational and environmental medicine, Bavarian State Office for Health and Food Safety, Pfarrstr. 3, 80538 Munich, Germany

⁴ Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

⁵ Allergy-Center Charité, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Luisenstr. 2, 10117 Berlin, Germany

⁶ German Pollen Information Foundation, Robert-Koch-Platz 7, 10115 Berlin, Germany

⁷ University Children's Hospital Regensburg (KUNO-Clinics), University of Regensburg, Clinic St. Hedwig, Steinmetzstr. 1-3, 93049 Regensburg, Germany.

⁸ ZAUM, Center of Allergy & Environment, Helmholtz Center Munich/Technische Universität München, Member of the German Center for Lung Research (DZL), Biedersteiner Str. 29, 80802 Munich, Germany

⁹ Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Neusässer Str. 47 86156 Augsburg, Germany

¹⁰ Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung Research, Max-Lebsche-Platz 31, 81377 Munich, Germany


¹¹ Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, 07 Bouverie St, Carlton VIC 3053 Melbourne, Australia

¹² Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Prüfeningerstr. 21, 93049 Regensburg, Germany

Corresponding Author:

Isabella Mittermeier
Bavarian Health and Food Safety Authority
Pfarrstr. 3
80538 Munich
09131- 6808- 4292
Isabella.Mittermeier@lgl.bayern.de

Electronic Supplementary Material 4: Visualization of Relative Risk estimates by kind of pollen and studies about drug consumption, including information about the 65lag between exposure and outcome measurement as well as height of interquartile range increase in grains/m³



Legend:

Explanation of information regarding lag days

Lag 0: Outcome and exposure measurements from the same day were compared.

Lag 1: Outcome measurements were compared with exposure measurements from the day before.

Lag 2: Outcome measurements were compared with exposure measurements from two days before.

Lag 0-1 (averaged): Outcome measurements were compared with the average of the exposure measurements from the same day and the day before.

Lag 2-3 (averaged): Outcome measurements were compared with the average of the exposure measurements from two days earlier and three days earlier.

Lag 0-3 (cumulated): Outcome measurements were compared with the cumulated exposure measurements from the same day, the day before, two days earlier, and three days earlier.